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Abstract 
 
Introduction 
The incidence of oesophageal adenocarcinoma is increasing.  Although 
improvements have been seen, the overall 5 year survival rate remains poor, at 
15.1%.  As with other cancers, the survival rate is highest when the disease is 
confined to the oesophagus.   
Barrett’s oesophagus is an acquired condition, characterised by the 
replacement of the normal distal squamous epithelial lining of the oesophagus 
with columnar epithelium.  Oesophageal adenocarcinoma develops, in most 
instances, along a pathway of increasing dysplasia in the sections of Barrett’s 
oesophagus.  If dysplasia can be diagnosed accurately, then this would permit 
treatment prior to the development of adenocarcinoma. 
 
Methods 
Samples of Barrett’s oesophagus with varying degrees of dysplasia and 
adenocarcinoma were measured with Raman point and mapping spectroscopy.  
Analysis was performed using Matlab®.   
 
Results 
Samples of squamous epithelia, Barrett’s oesophagus without dysplasia, with 
low-grade dysplasia, with high-grade dysplasia and oesophageal 
adenocarcinoma were measured and analysed.  2078 point spectra 
measurements and 117 map regions were analysed. 
Raman point spectra measurements and Raman mapping differentiated 
samples without dysplasia from those with dysplasia, and differentiated 
samples of low-grade dysplasia from those of high-grade dysplasia and 
adenocarcinoma.  The specificity and sensitivity were, however, low.   
 
Conclusion 
This research has illustrated the ability of Raman spectroscopy to discern 
samples of Barrett’s oesophagus with low-grade dysplasia from those with 
higher grades of dysplasia.  This capability could be utilised clinically with in-
vivo measurements to identify the areas requiring detailed surveillance and 
biopsies. 
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The majority of patients with Barrett’s oesophagus and low-grade dysplasia will 
never progress to adenocarcinoma.  There is currently no means, either via 
histopathology or via a biomarker, to identify the minority who will develop high-
grade dysplasia or adenocarcinoma. Raman spectroscopy may have the ability 
to do this and I believe this is the path that this technology should pursue. 
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Section A: Literature Review 
Chapter 1: Barrett’s Oesophagus 
1.1:  Definition 
Barrett’s oesophagus, originally described in 1950 by the thoracic surgeon, 
Norman ‘Pasty’ Barrett (Barrett, 1950), is an acquired condition, characterised 
by replacement of the normal distal squamous epithelial lining of the 
oesophagus with columnar epithelium which is clearly visible above the gastro-
oesophageal junction (Fitzgerald et al 2013).  The importance of this change is 
the risk of its subsequent degeneration to adenocarcinoma.  
Intestinal metaplasia may be present and, if so, is usually incomplete, 
comprising of the presence of mucus or goblet cells.  Complete intestinal 
metaplasia can occur and is characterised by the additional presence of 
absorptive cells (Rothery et al 1986, Gottfried et al 1989).  Intestinal metaplasia 
is thought to be an adaptive response to the increased cell loss that results from 
chronic inflammation.  Inflammation is believed to induce tumour suppressor 
genes in the submucosal oesophageal gland ducts leading to clonal expansion 
of tissue that has an increased ability to survive in the acid-rich environments 
(Leedham et al 2008).   
 
 
Figure 1.1: Haematoxylin and Eosin Stained Histopathological Section of Barrett’s Oesophagus 
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Substantial controversy exists in the definition of and diagnostic criteria for 
Barrett’s oesophagus.  The UK (Fitzgerald et al 2013) and Japanese (Takubo et 
al 2009) definitions do not require the presence of intestinal metaplasia, 
whereas, in the USA, the AGA clearly states that intestinal metaplasia is 
required for diagnosis as it is the only type of columnar epithelium that 
unmistakably predisposes to malignancy (Spechler et al 2011).  As well as 
studies which dispute this statement (DeMeester et al 2002, Chaves et al 2007, 
Kelty et al 2007, Liu et al 2009, Riddell and Odze 2009, Takabo et al 2009), 
difficulties also arise as the incidence of intestinal metaplasia may be 
underestimated due to sampling errors (Harrison et al 2007, Gatenby et al 
2008), thereby, wrongly assigning patients as non-Barrett’s and eliminating 
them from ongoing surveillance.   
 
1.2:  Epidemiology of Oesophageal Adenocarcinoma 
The incidence of oesophageal adenocarcinoma has, since the 1970’s, 
increased at an alarming rate.  There are now 43% more cases than in the 
1970’s (Figure 1.2), encompassing 2% of all cancer cases (Cancer Research 
Stats, 2013).  The highest incidence occurs in the older age range with 57% of 
cases diagnosed in those aged 70 and over (Figure 1.3) (Cancer Research 
Stats 2013).       
 
Figure 1.2: Oesophageal adenocarcinoma rate from 1970 to 2013 (Cancer Research UK, 2013) 
 
	22	
The overall 5 year survival for oesophageal adenocarcinoma is 15.1% (Cancer 
Research Stats 2013), which although demonstrates a significant increase from 
the survival rates of the 1970’s (4%), still means that this is the 5th leading 
cause of cancer related death in men.  Survival rates are higher if disease is 
confined to the oesophagus at the time of diagnosis, making curative treatment 
in the form of surgical resection or chemoradiotherapy a possibility.  
Unfortunately, the majority of patients present at a time when the disease has 
spread beyond the confines of the oesophagus.   
  
Figure 1.3: Oesophageal adenocarcinoma rate according to patient age (Cancer Research UK, 
2013) 
The striking increase in the incidence of oesophageal adenocarcinoma is 
thought to have been preceded by a similar, inconspicuous increase in the 
incidence of Barrett’s oesophagus. 
 
1.3:  Epidemiology of Barrett’s Oesophagus 
The prevalence of Barrett’s oesophagus in the population remains largely 
uncertain.  Initial estimates were based on patients undergoing endoscopy for 
symptomatic diagnosis and these patients may represent a cohort of patients 
who differ from the general population, although the presence and extent of 
Barrett’s oesophagus does not appear to correlate with the presence and 
severity of reflux symptoms.  Three population studies have, nevertheless, 
looked at the prevalence in the general population with estimates of 1.3 % 
(Zagair et al 2008), 1.6% (Ronkainen et al 2005) and 1.9% (Zou et al 2011). 
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Methodological dilemmas in the identification of patients with Barrett’s 
oesophagus has rendered the documentation of changes in incidence and 
prevalence problematic as increases may be related, in some part, to increased 
use of endoscopy and heightened awareness of and recognition of Barrett’s 
oesophagus.  Information from the Northern Ireland Barrett’s Oesophagus 
Registry from 1993 to 2005 indicates an increase of 93% in the incidence 
(Coleman et al 2011), even when the total number of endoscopies performed is 
taken into account. 
There are two main theories to explain the momentous increase in the 
incidence of Barrett’s oesophagus.  There has been an equally significant 
decrease in the incidence of Helicobacter pylori bacterial infection during the 
same time period.  H. pylori infection causes gastric atrophy, resulting in a 
decrease in the production of gastric acid.  It is the constant reflux of this acid 
into the oesophagus that results in the metaplasia of the lining epithelium and, 
thus, with less acid it is presumed that there will be less metaplasia.  This theory 
of decreasing H. pylori incidence as the cause of increasing Barrett’s 
oesophagus would not, however, explain the differing incident rates and age lag 
that exists between men and women. 
The alternative hypothesis is that the increase in obesity, specifically that of 
abdominal obesity, has fuelled the increasing incidence.  Abdominal obesity 
leads to an increase in intra-abdominal pressure.  This increase in pressure 
causes reflux of acidic contents into the lower oesophagus, leading to 
metaplasia of the epithelial lining.  It is also postulated that obesity causes a 
systemic pro-tumourigenic inflammatory state (Ryan et al 2008) and this leads 
to an increased incidence of Barrett’s oesophagus in the face of ongoing acid 
reflux. 
Barrett’s oesophagus is more common in males with an overall male:female 
ratio of 2:1.  There is an age shift in prevalence with men developing Barrett’s 
oesophagus approximately 17-20 years before females (van Blankenstein et al 
2005).  This is consistent with the delay in age at which females develop 
oesophageal adenocarcinoma and may be accounted for by the protective 
mechanism of oestrogen which women have prior to the development of the 
menopause.  In both sexes, nevertheless, the prevalence of Barrett’s 
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oesophagus increases with age with a 7% increase added for each year of life 
(van Blankenstein et al 2005).    
Marked ethnic differences in the epidemiology of Barrett’s oesophagus exist 
with higher rates in white Caucasians (Devesa et al 1998; Brown et al 2008) 
and lower rates in black Americans and Asians (Ford et al 2005).  The 
prevalence in the Hispanic community remains contradictory with some studies 
reporting similar (Bersantes et al 1998), and some lower, rates than in 
Caucasians (Abrams et al 2008; Corley et al 2009). 
 
1.4:   Risk Factors for Barrett’s oesophagus 
The main established risk factors for Barrett’s oesophagus are male gender, 
age greater than 50 years and a history of reflux symptoms (Eloubeidi et al 
2001, Avidan et al 2002, Smith et al 2005, Cook et al 2005, Edelstein et al 
2009).  More recently, obesity in the form of an increased abdominal 
circumference (high waist:hip ratio) has been shown to lead to an increased risk 
of Barrett’s oesophagus (Corley et al 2007, Edelstein et al 2009).  Although 
traditionally believed to be solely an acquired condition, there is some evidence 
of familial clustering (Chak et al 2002).  In these family groups, two loci (6p21 
and 16q24) have been identified as being associated with this condition (Su et 
al 2012).   
 
1.5:   Dysplasia in Barrett’s oesophagus 
Oesophageal adenocarcinoma develops, in most instances, along an 
established pathway of worsening dysplasia in a segment of Barrett’s 
oesophagus and this is regarded as the best marker for malignant 
transformation.   
Dysplasia is a morphological term, defined by Riddell et al (1983) as an 
unequivocal neoplastic epithelium strictly confined within the basement 
membrane of the gland from which it arises.  It is a continuous spectrum, 
distinguished from regenerative non-neoplastic modifications, known as atypia, 
at one end, and from invasive cancer at the other extreme.   
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The diagnosis of dysplasia is based on architectural and cytological 
abnormalities (described in more detail in section 1.8.2).  The degree of the 
abnormalities present determines the severity of the dysplasia.  The majority of 
pathologists use a two-tiered system that distinguishes between low- and high-
grade dysplasia.  
A panel of International pathologists devised an alternative system, the Vienna 
Classification System, in 2000 (Schlemper et al) to minimise disagreement in 
classification.  It is a five-tiered system, but as yet is still to be tested 
prospectively in a large series of patients.   
 
1.6:  Natural History of Barrett’s Oesophagus 
Barrett’s oesophagus is now recognised as the precursor to oesophageal 
adenocarcinoma, however, it is only a minority of patients, rather than the vast 
majority, who progress to adenocarcinoma.  The metaplastic change to 
columnar epithelium is a response to the increased cell loss that is a result of 
chronic inflammation, typically as a result of gastro-oesophageal reflux.  The 
annual conversion rate of Barrett’s oesophagus to oesophageal 
adenocarcinoma, based on the seven published systematic reviews, varies 
from 0.3% to 0.6% (Shaheen et al 2000, Chang et al 2007, Thomas et al 2007, 
Yousef et al 2008, Wani et al 2009, Sikkema et al 2010, Desai et al 2012) and 
increases to 0.9 -1.0% if high-grade dysplasia is included alongside 
adenocarcinoma.   
Two population based studies from Northern Ireland (Hvid-Jenson et al 2011) 
and Denmark (Bhat et al 2011) have shown a lower incidence of progression of 
0.22% and 0.26% per year respectively.  The most recent meta-analysis 
calculated the risk of progression as 0.33% per year (Desai et al 2012).  This 
seems like a very small number of patients, however, this leads to a 
standardised incidence ratio of 11.3 which equates to an excess of >1000% 
more deaths in this cohort when compared to the general population.  
Despite evidence from surveillance cohorts indicating an increased risk of 
cancer in the population diagnosed with Barrett’s oesophagus, it remains 
problematic and extremely difficult to predict the risk for an individual patient.  
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Currently the only tool available is the presence of and grade of dysplasia within 
the Barrett’s segment.   
High-grade dysplasia is the nearest precursor to adenocarcinoma as 
exemplified by its presence in surgical resection specimens surrounding 
adenocarcinoma (Fléjou 2005) indicating that the cancer developed from an 
area of high-grade dysplasia.  Although published studies are dominated by 
small samples from tertiary referral centres, the evidence indicates that 25% of 
patients with high-grade dysplasia will develop adenocarcinoma after an 
average of 2.5 years (Schnell et al 2001).  
The step from high-grade dysplasia to adenocarcinoma is a much sturdier step 
than that of low-grade to high-grade dysplasia.  Recent studies have challenged 
the traditional view that low-grade dysplasia progresses towards high-grade 
dysplasia and has suggested that low-grade dysplasia has the ability to regress.  
The phenomenon of regression may, however, be the result of misdiagnosis of 
low-grade dysplasia at initial biopsy rather than true regression (Jagadesham 
and Kelty 2014). 
Recent studies have shown a rate of progression from low-grade to high-grade 
dysplasia or to adenocarcinoma of 30% (Montgomery et al 2001) and 28% 
(Skacel et al 2000) respectively.  The most recent evidence places the annual 
risk of progression at 9% (Duits et al 2015).  Of most interest, nevertheless, is 
that when three pathologists agreed on the diagnosis of low-grade dysplasia, 
80% of patients disease progressed, whereas, when there was no agreement, 
0% of patients progressed (Skacel et al 2000), suggesting that more developed 
low-grade dysplasia which is more easily identified is more likely to continue to 
high-grade dysplasia.   
The diagnosis of low-grade dysplasia may in fact be a watershed moment in the 
natural history of Barrett’s oesophagus and distinguishes a cohort of patients 
who are more likely to progress to significant disease.  It is, therefore, 
imperative to identify this cohort to enable appropriate surveillance, accurate 
diagnosis of progression and timely intervention.  
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1.7:   Risk factors for malignant progression 
The presence and grade of dysplasia is the only tool that we currently have at 
our disposal to classify the risk of progression to adenocarcinoma and to 
identify those who would benefit from treatment or continuing surveillance.  
Evidence has highlighted the existence of other factors which predispose to 
malignant progression. 
The most striking discriminator is the length of the segment of Barrett’s 
oesophagus.  The annual adenocarcinoma transition rate for long segment 
Barrett’s oesophagus (defined as a segment >3cm) is 0.22% per year (Pohl et 
al 2015) which is significantly higher than the rate for short segment (1-3cm) 
and ultra-short (<1cm) which is documented as 0.03 and 0.01% per year 
respectively (Pohl et al 2015).  For patients with high-grade dysplasia in a long 
segment of Barrett’s oesophagus, the rate of progression to adenocarcinoma 
may be as high as 25% per year (Kastelein et al 2015).   
Multifocal, as opposed to localised areas, of dysplasia have a higher risk of 
progression (Weston et al 2000, Buttar et al 2001) as does the presence of 
visible nodules or ulcers (Thurberg et al 1999, Weston et al 2000).  An ulcer 
that fails to heal following intensive proton-pump inhibitor therapy is a 
particularly suspicious feature (Pech et al 2008). 
The presence of intestinal metaplasia signifies an epithelium with a greater 
biological instability.  There is a significant volume of evidence which indicates 
that intestinal metaplasia has the greatest risk of adenocarcinoma progression 
from dysplasia when compared to columnar epithelium without the presence of 
intestinal metaplasia (Skinner et al 1983, Smith et al 1984, Bhat et al 2011) 
which explains the rationale behind the definition of Barrett’s oesophagus used 
in the AGA guidelines.  
Certain genetic traits may result in a cohort of patients with a greater risk of 
malignant progression.  These are summarised in Table 1.1.  Aberrant p53, p53 
mutation or p53 loss has been shown to increase the risk of developing 
dysplasia (Chatelain and Flejou 2003) and p53 overexpression has been shown 
to be an excellent predictor of dysplastic progression (Weston et al 2001).  The 
British Society of Gastroenterology (Fitzgerald et al 2013) suggest using p53 
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immuno-staining as an adjunct to histopathology to aid diagnosis in uncertain 
cases. 
 
Molecular Event Change Evoked 
Increased Proliferation Ki67 expression in HGD 
Cell Cycle Regulation 
E.g.: Cyclins D1 and E 
 
Increased expression in cancer 
Growth Factors and Growth Factor 
Receptors 
Increased expression in cancer 
P53 Frequent mutations in HGD and 
cancer 
Cell Adhesion 
E.g.: E Cadherin 
 
Decreased expression in cancer 
Telomerase Increased expression parallel to 
dysplasia 
 
Table 1.1: Molecular events involved in the neoplastic transformation of Barrett’s mucosa 
(adapted from Flejou, 2005) 
 
Additional molecules are being investigated to determine their ability to predict 
patients at greater risk of malignant progression.  Hypermethylation of p16 is an 
early predictor of progression, particularly in low-grade dysplasia (Wang et al 
2009).  Survivin, an apoptotic inhibitor, is overexpressed in oesophageal cancer 
and, to a lesser extent, in dysplastic tissue (Vallböhmer et al 2005).  At present 
there are no markers in routine clinical practise to aid the identification of at-risk 
individuals. 
 
1.8:  Diagnosis of Barrett’s oesophagus and dysplasia 
The diagnosis of Barrett’s oesophagus is made at endoscopy.  There is no 
screening programme in the United Kingdom, however, guidelines exist to 
identify which patients should be referred for endoscopy based on the likelihood 
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of the presence of an underlying cancer (Nice Guidelines NG12, 2014).  These 
include, but are not restricted to, patients with dysphagia (difficulty in 
swallowing), age greater than 55 years with weight loss, upper abdominal pain 
and new-onset or treatment resistant dyspepsia. 
The diagnosis of Barrett’s oesophagus and the presence of dysplasia is 
confirmed by histopathology following biopsy, although this is not always as 
uncomplicated as it would seem. 
1.8.1:  Endoscopic Assessment 
Barrett’s oesophagus has a classical appearance at endoscopy.  There is 
proximal displacement of the squamo-columnar junction with the salmon pink 
columnar epithelium of Barrett’s being seen as tongues of epithelium emerging 
into the distal oesophagus (Figure 1.4). 
 
Figure 1.4: Endoscopic appearance of Barrett’s oesophagus (Courtesy of Digestive Health 
Associates: South West Endoscopy Centre (www.digestivehealth.net)) 
 
The reporting of endoscopic findings is via the Prague classification which 
records the circumferential extent, the maximal length and any additional visible 
islands of columnar-lined oesophagus.   
Dysplasia in Barrett’s oesophagus is difficult to identify at endoscopy as it 
appears macroscopically identical to non-dysplastic Barrett’s oesophagus.  The 
current protocol is, thus, to take random biopsies from each quadrant of the 
oesophagus at 1-2cm intervals in areas of macroscopically visible Barrett’s 
oesophagus, known as the Seattle protocol.  This protocol, even if rigorously 
adhered to, samples less than 5% of the mucosa and may miss up to 57% of 
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cases of dysplasia (Vieth et al 2004, Singh et al 2007).  34% of early stage 
oesophageal cancers (both squamous and adenocarcinoma) failed to be 
recognised in preceding endoscopies (Chadwick et al 2014).      
 
1.8.2:  Histopathology 
Barrett’s oesophagus is confirmed by the presence of columnar lined 
epithelium, with or without the presence of goblet cells, signifying intestinal 
metaplasia.  The important question is, nevertheless, whether there is any 
evidence of dysplasia. 
The diagnosis of dysplasia is based on morphological changes that are seen at 
microscopy (Table 1.2).  Low-grade dysplasia is characterised by crypts with 
no, or minimal, architectural abnormalities combined with mild to moderate 
nuclear atypia (Figure 1.5).  High-grade dysplasia is characterised by further 
abnormalities, with architecturally distorted crypts combined with a higher 
degree of cytological atypia (Figure 1.6).  This typically includes complete loss 
of cell polarity, increased nuclear stratification, large ovoid-shaped nuclei and 
apoptotic debris within the crypt lumen. 
 
 
Figure 1.5: Barrett’s Oesophagus with Low-Grade Dysplasia 
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Figure 1.6: Barrett’s Oesophagus with High-Grade Dysplasia 
 
 Low-Grade Dysplasia High-Grade Dysplasia 
Nuclei Enlarged, Crowded 
Hyperchromatic, Ovoid 
Enlarged, usually 
Spheroidal 
Nuclear pleomorphism 
Mitotic Activity Substantial 
Atypical Mitoses + 
Stratification 
Substantial 
Atypical Mitoses ++ 
Cellular Disorganisation 
Architectural Change Loss of basal-luminal 
differentiation axis 
Villosity may be present 
Loss of basal-luminal 
differentiation axis 
Villosity often present 
Glandular budding and 
complex glandular 
structures are often 
present 
 
Table 1.2: Morphological Features associated with Low and High-Grade dysplasia (Adapted 
from Fléjou and Svrcek 2007) 
 
Neoplastic cells are typified by enlarged and hyperchromatic ovoid-shaped or 
elongated nuclei with membrane irregularity, nuclear pseudostratification and 
increased mitotic activity (Figure 1.7).  The carcinoma is deemed intra-mucosal 
if there is no breach through the lamina propria.  If there is penetration of this 
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layer, there is a risk of spread to the lymphatics and localised treatment may, 
therefore, be insufficient. 
 
Figure 1.7: Oesophageal Biopsy sample showing Adenocarcinoma 
 
At the other end of the spectrum, a degree of atypia that is more than that 
expected for regenerative changes, yet less than that expected for low-grade 
dysplasia can be seen.  These samples are classified as indefinite for dysplasia 
and may simply be the result of inflammation which can make the interpretation 
of cellular changes challenging.  Inadequate laboratory processing, such as 
poor staining, can add to this difficulty.    
With the complex array of changes that occur along this spectrum, it is hardly 
surprising that a high degree of intra- and inter-observer variability exists 
(Kerkhof et al 2007, Lee et al 2010, Gaddam et al 2011).  Given this and the 
implications of a diagnosis of dysplasia, it is recommended that all cases of 
suspected dysplasia, including indefinite for dysplasia (Fitzgerald et al 2013) 
are reviewed by a second GI pathologist.  
 
1.8.3:  Additional Tools 
Parallel to the morphological changes seen, genetic alterations occur which 
affect gene expression and ultimately the regulation of the cell cycle.  As 
discussed, certain genetic changes confer a greater risk of malignant 
progression and their identification, by immunohistochemistry, may, in the 
future, be used alongside histopathology to aid the diagnosis of dysplasia.  It 
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may also find a role in risk stratification, determining which patients require 
intensive surveillance and/or early treatment.   
Due to the complexity of the cell cycle and its control mechanism, a number of 
genetic alterations are likely to occur.  The changes may well be unique to each 
individual and, thus, it may not be appropriate for these changes to be used at a 
population level. 
 
1.9:  Active Surveillance and Screening 
The aim of endoscopic surveillance is to detect cancerous, or ideally 
precancerous, changes at a stage, prior to invasive cancer, where treatment is 
able to be curative.  These changes would preferably be detected when 
treatment is not only curative, but also able to be less radical.  There is, at this 
time, no evidence to demonstrate its efficacy in this aim, despite the widespread 
practise in Europe and North America.   
The benefit for surveillance for non-dysplastic Barrett’s oesophagus is, in 
particular, unclear, both in terms of detecting malignant progression and in cost 
effectiveness.  The BOSS (Barrett’s Oesophagus Surveillance versus 
endoscopy at need Study) trial, currently in its follow up phase, aims to address 
the question of the usefulness of endoscopic surveillance.    
The published literature does suggest that cancers which are detected during 
surveillance are of an earlier stage and, hence, associated with improved 
survival (Streitz et al 1993, Peters et al 1994, Van Sindick et al 1998, Corley et 
al 2002, Cooper et al 2002, Fountoulakis et al 2004, Rubenstein et al 2008, 
Cooper et al 2009).  The current surveillance recommendations are based on 
the presence or absence of dysplasia, the grade of dysplasia and the length of 
the Barrett’s segment.  At an individual level, the presence of significant 
comorbidities are taken into account to determine whether further endoscopies 
are in the best interest of the patient.  Other factors that may influence the 
likelihood of malignant progression are not, however, factored into the 
surveillance strategy. 
The incidence of oesophageal adenocarcinoma resulting from Barrett’s 
oesophagus is too low to warrant broad population-based screening (Watson et 
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al 2005, Wang et al 2008).  The cost effectiveness of endoscopic screening, 
even when restricted to patients with gastro-oesophageal reflux, is highly 
controversial with wide divergences in estimates of benefit (Inadomi et al 2003, 
Nietert et al 2003, Gerson et al 2004, Gupta et al 2011). 
Non endoscopic devices could prove to be more cost effective.  The 
Cytosponge, essentially a capsule attached to a string device which is 
swallowed and subsequently removed by pulling on the string, removing at the 
same time cells that line the oesophagus, has been shown to be more cost 
effective than endoscopy.  Its diagnostic accuracy is currently being assessed 
in the Barrett’s oEsophagus Screening Trial (BEST2) to determine its possible 
use as a screening modality. 
 
1.10:  Management of Barrett’s oesophagus 
The management algorithm for Barrett’s oesophagus, based on the evidence 
currently available and expert consensus, is dependent, primarily, on the 
presence and grade of dysplasia and, to a lesser extent, on the length of the 
segment of Barrett’s oesophagus. 
1.10.1:   Barrett’s oesophagus without dysplasia     
For patients in whom Barrett’s oesophagus is confirmed by histopathology, but 
where there is no evidence of dysplasia, the management strategy is for 
ongoing surveillance via oesophago-gastro-duodenoscopy (OGD).  The 
frequency of surveillance is dependent on the length of the Barrett’s segment as 
a longer segment confers a higher risk of malignant progression (Figure 1.8). 
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Figure 1.8: Management Algorithm for the Management of Barrett’s oesophagus without 
dysplasia, from the British Society of Gastroenterology Guidelines (Fitzgerald et al 2013) 
 
In patients with short segment or ultra short segment of Barrett’s oesophagus 
and no evidence of intestinal metaplasia, the risk of malignant progression is 
felt to be so small that the patient can be discharged from surveillance.  In a 
patient with additional risk factors, however, such as older age, obesity and 
ongoing reflux symptoms, a second endoscopy should be considered.   
In patients with intestinal metaplasia, the current recommendation is for 
endoscopic surveillance.  The frequency of this is dependent on the length of 
the segment of Barrett’s oesophagus and should also reflect the presence of 
additional risk factors, such as male gender and older age.  In a small cohort of 
patients, with significant comorbidities, surveillance may be inappropriate and 
they can be discharged from the surveillance programme. 
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1.10.2:  Indeterminate for dysplasia  
There is scant evidence detailing the management for patients with this 
diagnosis.  This is likely to be, to a large extent, due to the difficultly surrounding 
this diagnosis with high inter-observer variability, thus, making it difficult to make 
consensus decisions regarding this potentially diverse group.  It should be 
viewed as an interim diagnosis, not as the final conclusion. 
In some cases, the cellular atypia present is a result of inflammation and 
improving this by commencing or optimising anti-reflux medical therapy may 
result in regression of the cellular atypia.  All patients should, thus, receive high 
dose acid suppression to ensure control of inflammation.  A repeat endoscopy 
in 6 months is recommended to clarify whether dysplasia is present (Figure 
1.9), and if so, the patient is then managed according to the grade of dysplasia 
on repeat endoscopy.  There is no current consensus on how to manage 
patients with repeated indefinite dysplasia. 
1.10.3:  Low-Grade Dysplasia 
The management strategy for patients with low-grade dysplasia is currently 
surrounded by uncertainty which reflects the underlying uncertainty of its’ 
natural history.  Low-grade dysplasia does confer a greater risk of malignant 
progression as discussed above, yet it is unclear whether this risk warrants 
intense surveillance or even therapeutic intervention and the associated threat 
of complications. 
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Figure 1.9: Management Algorithm for the Management of Barrett’s oesophagus with dysplasia, 
from the British Society of Gastroenterology Guidelines (Fitzgerald et al 2013) 
 
There is, at present, no data regarding the appropriate surveillance strategy for 
these patients.  The overall consensus, based on expert opinion, appears to be 
that, following a first biopsy with low-grade dysplasia, patients should have a 
second endoscopy within a 6 – 12 month time interval (Figure 1.9).   
A repeat endoscopy within a relatively short time period enables one to 
determine if the dysplasia is persistent or progressive, or even if there has been 
any regression.  For a diagnosis that is plagued, at times, with significant levels 
of uncertainty due to the difficulty of diagnosis, a second set of biopsies may 
provide clarity and help to prevent the over-diagnosis of low-grade dysplasia.  In 
a recent Dutch study (Duitz et al 2015), 73% of cases initially diagnosed as low-
grade dysplasia were subsequently diagnosed as non-dysplastic or indefinite 
for dysplasia. 
Recent evidence from the ‘SURF’ Study (SUrveillance versus RadioFrequency 
ablation) (Phoa et al 2014), a multi-centre randomised clinical trial, found that 
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ablation in patients with low-grade dysplasia reduced the risk of progression to 
high-grade dysplasia or adenocarcinoma by 25%.  Treatment related adverse 
events were recorded in 19.1%, predominantly that of mild oesophageal 
stricturing.   
In patients with persistent low-grade dysplasia (i.e.: low-grade dysplasia on two 
consecutive endoscopies), or with other risk factors, such as long segment 
Barrett’s or multifocal areas of low-grade dysplasia, the evidence would suggest 
that ablative therapy be recommended at this time.  The British Society of 
Gastroenterology guidelines suggest endoscopic assessment plus biopsies in 6 
month intervals until either regression or progression (Fitzgerald et al 2013), 
however, these recommendations were published before the results of the 
SURF Study.       
If the development of low-grade dysplasia is in fact a defining moment in the 
natural history of Barrett’s oesophagus, then ablative therapy at this early stage 
would appear to be a sensible approach.  Further research is, however, needed 
to delineate the appropriate management for this diverse group. 
 
1.10.4:  High-Grade Dysplasia and Early Adenocarcinoma 
In patients in whom biopsies have shown high-grade dysplasia or early 
adenocarcinoma that is confined to the mucosa, endoscopic intervention is the 
preferred treatment modality.  Early adenocarcinoma, designated as T1, 
indicates cancerous cells have spread into the lining of the oesophagus, up to 
but not including the muscularis propria.  T1 cancers are divided into two 
groups: T1a where invasion is into the lamina propria, and T1b where invasion 
is into the submucosa (Table 1.3). 
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Table 1.3: Tumour Classification of Oesophageal Adenocarcinoma, from the TNM Classification 
 
 
 
Figure 1.10: Layers of the Oesophageal Mucosa (Courtesy of www.cancer.org) 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
TIS Carcinoma in situ / High-Grade Dysplasia 
T1  
T1a Tumour invades lamina propria or muscularis mucosae 
T1b Tumour invades submucosa 
T2 Tumour invades muscularis propria 
T3 Tumour invades adventitia 
T4  
T4a Tumour invades adjacent structures: pleura, pericardium or 
diaphragm 
T4b Tumour invades other adjacent structures: aorta, vertebral 
body or trachea 
	40	
 
Figure 1.11: Management Algorithm for the Management of Barrett’s oesophagus with high-
grade dysplasia or adenocarcinoma, from the British Society of Gastroenterology Guidelines 
(Fitzgerald et al 2013) 
 
High-grade dysplasia and T1a cancers are associated with a low rate of lymph 
node metastases with evidence indicating rates of 0% and 0-10% respectively 
(Buskens et al 2004, Liu et al 2005, Stein et al 2005, Westerterp et al 2005, 
Abraham et al 2007, Prasad et al 2009, Alvarez et al 2010, Barbour et al 2010, 
Sepesi et al 2010).  T1b cancers, on the other hand, carry a risk of up to 46%.  
This is also reflected in the 5 year recurrence free and overall survival rates of 
100% and 91% in patients with T1a cancer, compared to 60% and 58% in 
patients with T1b cancer.  Patients with T1b cancer, therefore, are not suitable 
for endoscopic intervention, whereas, for those with high-grade dysplasia or 
T1a cancer, endoscopic intervention is the preferred approach Figure 1.11). 
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For patients with visible lesions of high-grade dysplasia or T1a cancer, 
endoscopic resection is the preferred modality as, not only does this remove the 
lesion, but it enables histopathological review to confirm the diagnosis and 
grade (Figure 1.12).  If the grade is found to be greater than T1a with 
submucosal invasion, then patients should be considered for subsequent 
surgical intervention in the form of oesophagectomy.   
 
Figure 1.12: Endoscopic Mucosal Resection of a visible lesion in the Oesophagus (Courtesy of 
Gastrointestinal Tract Endoscopic and Tissue Processing Techniques and Normal Histology 
(Adler et al 2015)) 
 
Greater than 20% of patients who are treated by endoscopic resection for high-
grade dysplasia or T1a cancer develop a metachronus lesion within 2 years 
and, thus, as well as resection of the visible lesion, the remaining Barrett’s 
oesophagus requires treatment.  This should occur even if there is no evidence 
of dysplasia in the remaining Barrett’s oesophagus.  
For flat areas of high-grade dysplasia, ablation is the recommended treatment.  
Radiofrequency has the best safety and side-effect profile with efficacy equal to 
that of other ablative techniques (Fitzgerald et al 2013), although there is a 
paucity of data comparing techniques. 
Despite evidence that endoscopic resection and ablation results in long-lasting 
elimination of dysplasia, there remains a risk of both recurrence and of ‘buried’ 
dysplasia occurring in the crypts of the glands.  Endoscopic follow up is, 
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therefore, recommended at 3 monthly intervals for the initial 12 months 
following treatment and then for at 12 monthly intervals.   
For patients with T1b cancer, surgical resection is the treatment of choice, due 
to the significant risk of lymph node metastases.  Oesophagectomy has a 
mortality rate of 2% when performed in specialised centres, yet has a significant 
short term morbidity of 6-37% (Sujendran et al 2005, Williams et al 2007).  
Surgical follow up studies report the recurrence of Barrett’s oesophagus 
following curative surgery and although the risk of developing dysplasia or 
malignancy is unknown, the presence of goblet cells has been seen in 
‘neosquamous’ epithelium in the oesophageal conduit.  In view of this, patients 
who have undergone curative surgery also require endoscopic follow up.  The 
current recommendation is for this to occur at 2, 5 and 10 years. 
1.10.5:  Strategies for chemoprevention 
Chemoprevention, defined as the use of pharmacological agents or other 
strategies to prevent the development of cancer has been sought to prevent the 
progression towards malignancy that occurs in Barrett’s oesophagus.  Different 
agents have been studied in this setting, including non-steroidal anti-
inflammatories and statins, however, the majority of evidence has been for 
proton-pump inhibitors (PPIs). 
Evidence from cohort studies with patients using PPIs for symptom control have 
shown a significantly reduced odds ratio for the development of dysplasia 
compared to those not taking PPIs (El-Serag et al 2004), although this could, in 
some way be explained by the severity of the reflux symptoms.  There is 
insufficient evidence to recommend the use of PPIs solely as a 
chemopreventative agent to prevent the formation of Barrett’s oesophagus or 
malignant progression, despite the scientific plausibility that would indicate a 
benefit.  Their use for symptom control as required is advocated. 
Anti-reflux surgery in the form of fundoplication is offered to a cohort of patients 
with gastro-oesophageal reflux.  There is no evidence that this offers superior 
acid suppression for the prevention of neoplastic progression and, as such, 
should not be offered.  It should, however, still be recommended to suitable 
patients for symptom control and they will continue to require endoscopic 
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surveillance based on the presence and grade of dysplasia in the Barrett’s 
oesophagus. 
Aspirin has been shown in other cancers, including those of the GI tract, to 
improve outcome.  The Aspirin and Esomeprazole Trail (AspECT) (Jankowski et 
al) is currently in progress and should help to answer the question of their use 
in Barrett’s oesophagus. 
 
1.11:  Future Developments 
A considerable dilemma in managing Barrett’s oesophagus relates to the 
difficulty that exists in accurately identifying patients who are at risk of malignant 
progression and selecting those requiring treatment and/or surveillance.  Risk 
stratification biomarkers and optical techniques are being investigated for this 
role. 
1.11.1:  Risk Stratification Biomarkers 
Although risk factors for the likelihood of malignant progression are known, 
factors other than the presence and grade of dysplasia and, to a lesser extent, 
the length of the segment of Barrett’s oesophagus, are not used to stratify 
patients based on the likelihood of malignant progression.  If additional markers 
could be identified, this would enable surveillance and treatment to be 
selectively targeted. 
As discussed briefly in section 1.7, hypermethylation of p16 may be an early 
predictor of progression.  This information could be used alongside histology 
information to identify patients who are at greatest risk of progression.  The 
changes in p16 and p53 are, however, non-specific with mutations occurring in 
a multitude of cancers.  This non-specificity may make risk stratification difficult. 
An alternative would be to utilise immunophotodiagnostic technology, for 
example, by using monoclonal antibodies that are specific for tumour-related 
antigens.  Cell surface lectins are carbohydrate binding structures that are 
displayed on the surface of cells to serve as cell-cell binding sites.  In the 
progression from non-dysplastic Barrett’s oesophagus to adenocarcinoma, 
changes in the binding patterns of lectins have been identified (Bird-Lieberman 
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et al 2012).  The specific changes can be located at endoscopy using 
monoclonal antibodies, thus, guiding, the identification of areas that should be 
biopsied. 
1.11.2:  Advanced Imaging Tools 
One of the major difficulties in the management of Barrett’s oesophagus is the 
identification of and accurate diagnosis of dysplasia.  Endoscopy enables the 
visualisation of Barrett’s oesophagus, however, the presence of dysplasia is not 
macroscopically distinguishable and the diagnosis often relies on sampling by 
random quadrant biopsies.  These biopsies, due to sampling error, may miss 
areas of dysplasia, thus, underestimating the risk of malignant progression for 
that individual. 
A number of optical techniques have been developed and investigated to 
ascertain their role in solving this significant problem.  
1.11.2.1: High Resolution Endoscopy 
Traditional endoscopy generates an image of 300,000 pixels.  High resolution 
endoscopes, in contrast, generate images of >1,000,000 pixels.  This 
substantial increase in resolution enables improved detection of areas of 
Barrett’s mucosa (Kara et al 2005, Kara et al 2005a) and greater detection of 
visible lesions and nodules.  Areas of nodularity or visible abnormalities are 
more likely to harbour high-grade dysplasia or early adenocarcinoma. 
High resolution endoscopy is by no means perfect, however, with only 79% of 
dysplasia detected (Kara et al 2005) and with a substantial inter-observer 
variability (Kara et al 2005, Curvers et al 2008).  The performance of and 
experience of the endoscopist has a significant impact, regardless of the 
instrument used, with the mean inspection time per cm of oesophagus having, 
perhaps, the greatest influence on the detection of both Barrett’s mucosa and 
additional abnormalities (Gupta et al 2011).  Techniques, which ultimately rely 
on the operator, will need to take this into account when assessing their 
reliability. 
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1.11.2.2: Chromoendoscopy 
Chromoendoscopy describes the use of exogenous dyes to aid the detection of 
abnormalities.  The dyes are sprayed onto the mucosal surface at the time of 
endoscopy via a specially designed catheter.   
Lugol’s solution, one of the dyes used, interacts with glycogen present in the 
normal squamous epithelium resulting in a brown/black discoloration.  It does 
not, however, have the same effect on columnar epithelium which distinguishes 
Barrett’s oesophagus, thus, enabling effective differentiation between the two. 
 
Figure 1.13: Chromoendoscopy using indigo carmine staining of Barrett’s Oesophagus  
with High-Grade Dysplasia (Courtesy of gastrohep.com) 
Methylene blue and indigo carmine are alternative stains that can highlight 
areas of intestinal metaplasia.  They do not, however, aid the identification of 
areas of dysplasia within the intestinal metaplasia.  Acetic acid enhances the 
surface topography allowing heightened feature enhancement.  In some 
studies, it has been shown to be superior in the identification of dysplastic 
regions when compared to white light endoscopy (Longcroft-Wheaton et al 
2011). 
1.11.2.3: Narrow Band Imaging 
Narrow band imaging uses electronically activated filters to limit the wavelength 
spectrum of blue and green light and to remove the spectrum of red light.  This 
preserves the wavelengths which are absorbed by haemoglobin, resulting in 
attenuated delineation of the mucosal architecture based on the underlying 
vascular pattern.  This pattern is altered in disease. 
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Studies using narrow band imaging revealed a high sensitivity for distinguishing 
gastric mucosa from intestinal metaplasia (Curvers et al 2009) and, using high 
magnification, for identifying high-grade dysplasia (Curvers et al 2009).  Narrow 
band imaging is the most commonly used advanced imaging technique, 
excluding high resolution endoscopy, although only 14% of endoscopists 
referring patients to a tertiary centre had used this modality (Bennett et al 
2015).   
1.11.2.4: Autofluorescence 
All tissues produce autofluorescence when illuminated by ultraviolet (<400nm) 
or short visible (400 – 550nm) light.  Naturally occurring molecules in the tissue, 
termed fluorophores, become excited, emitting a longer wavelength of 
fluorescent light.  The number, concentration and distribution of these 
fluorophores in different tissue states produce distinct autofluorescent patterns 
(Kara et al 2004). 
1.11.2.5: Confocal Fluorescence Microendoscopy 
This imaging technique is an extension of autofluorescence and, by imaging 
endogenous and exogenous fluorophores within the cells of the tissue sections, 
a histological image of the tissue can be produced (Kara et al 2007).  High-
grade dysplasia was able to be differentiated from non-dysplastic Barrett’s in ex 
vivo samples using this method due to the alterations in the mucosal 
autofluorescent picture that occurs with dysplasia (Kara et al 2006).   
1.11.2.6: Optical Coherence Tomography 
Optical coherence tomography is an imaging system that is, in some ways, akin 
to ultrasonography.  It utilises electromagnetic waves to produce images based 
on the detection of reflected light as opposed to the detection of reflected sound 
(Filip et al 2011).  The resolution of the system allows identification of villi, 
glands and capillaries (DaCosta et al 2003). 
In vivo studies have shown that this modality can distinguish between 
squamous epithelium, columnar epithelium of Barrett’s oesophagus and 
adenocarcinoma (Li et al 2000, Poneros et al 2001, Zuccaro et al 2001, Evans 
et al 2005, Evans et al 2006), yet the ability to differentiate between grades of 
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dysplasia was lower with a specificity of 75% for distinguishing high-grade 
dysplasia from adenocarcinoma (Evans et al 2006).   
 
Figure 1.14: Cross-sectional optical coherence tomography images and corresponding histology 
showing buried glands (red arrowheads) from a patient in vivo (Courtesy of Tsai et al 2014) 
A supplementary benefit of this modality is its ability to provide cross-sectional 
imaging which allows assessment of the depth of invasion as well as the 
presence of buried glands in a previously treated oesophagus (Figure 1.14).  
Developments in these fields are occurring with incorporation into capsule 
endoscopy for screening to detect Barrett’s oesophagus. 
1.11.2.7: Spectroscopy 
Spectroscopy utilises information that is obtained from the detection of changes 
in energy level in the molecules and bonds of a tissue that occur when the 
sample is excited by light. 
Light scattering spectroscopy, also referred to as elastic scattering 
spectroscopy, uses the reflectance of scattered white light to provide 
microstructural information regarding the tissue.  For example, nuclear 
enlargement and crowding can be detected and this information can be used to 
differentiate dysplasia with sensitivities and specificities of >90% (Wallace et al 
2000).      
The two other main forms of spectroscopy, Raman and Infra-red, will be 
discussed in greater detail in the next chapter. 
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Section A: Literature Review 
Chapter 2: Vibrational Spectroscopy 
2.1:  Fundamental Principles 
2.1.1:  Electromagnetic Radiation 
Electromagnetic radiation is a form of energy that exists all around us, taking 
many forms, including radio waves, gamma rays and visible light.  It consists of 
electromagnetic waves which are synchronised oscillations of electric and 
magnetic fields which are created when an atomic particle is accelerated by an 
electric field.   
The behaviour of electromagnetic radiation depends on its frequency and 
wavelength.  Higher frequencies, such as gamma rays, have shorter 
wavelengths, whereas, lower frequencies at the other end of the spectrum, 
such as radiowaves, have longer wavelengths (Figure 2.1). 
 
 
Figure 2.1: Electromagnetic Radiation Spectrum (Courtesy of LiveScience 
(www.livescience.com/38169-electromagnetism.html)) 
 
Visible light is electromagnetic radiation that occurs in the wavelength range of 
400-700nm, sandwiched between ultra-violet and infrared rays.  In this region, 
the electromagnetic radiation consists of photons that are capable of causing 
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excitation that can lead to changes in molecular bonding or chemistry.  At the 
lower end of this spectrum, in the infrared region, there is no visible light as the 
photons do not have enough individual energy to cause a lasting change in the 
conformation of the visible molecule.   
2.1.2:  Biospectroscopy 
When light interacts with a material, the result is a number of different 
processes, including reflectance, transmission, scattering, absorption and 
vibration.  These processes occur when the incident radiation induces changes 
in the energy level of the tissue.  The change in energy state of the tissue is 
detected and has the ability to provide detailed biochemical information 
regarding the molecular composition and structure of the tissue. 
Vibrational spectroscopy, namely infra-red (IR) and Raman spectroscopy, 
interrogate tissues in a non-destructive manner, producing spectra based on 
the interaction of light with the tissue.  The spectrum is, in essence, an intrinsic 
molecular fingerprint, providing information regarding DNA, carbohydrate, 
protein and lipid content. 
 
2.2:   Raman Spectroscopy 
2.2.1:   Underlying Principles 
Molecules consist of atoms which are held together by chemical bonds, each of 
which has a characteristic vibrational energy.  When illuminated by 
electromagnetic radiation, the bonds vibrate as the molecule enters a virtual 
energy state.  A photon, from the light source itself, is absorbed by the material, 
exciting an electron into a higher, albeit unstable, virtual energy level.  As the 
electron decays back to a lower energy level, it emits this energy as a scattered 
photon.  If the scattered radiation has the same wavelength as the 
electromagnetic radiation, this is termed elastic, or Rayleigh, scattering (Figure 
2.2).  
When the incident photon interacts with the electric dipole of the molecule, the 
excited electron decays back to a different energy level from that of its starting 
position due to interactions between the incident electromagnetic waves and 
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the vibrational energy levels of the molecules in the sample.  This occurs in 
approximately 1/106-108 photons and is termed inelastic scattering.  The 
difference in energy level between the incident (non-scattered) photons and the 
scattered photons corresponds to the energy of the molecular vibration and is 
termed the Raman shift or scatter. 
Two forms of Raman scattering exist.  If the final energy level is higher than the 
original state, the inelastically scattered photon will be shifted to a lower 
frequency.  This shift is known as a Stokes shift.  If, however, the final 
vibrational state is less energetic, the photon will be shifted to a higher 
frequency, known as an anti-Stokes shift (Figure 2.3).   
 
 
Figure 2.2: Stokes and Anti-Stokes Shift Pattern (Courtesy of SoITPoMS, University of 
Cambridge (www.doitpoms.ac.uk/tlplib/raman/printall.php)) 
 
By detecting the scattered photons and their energy level, a unique spectrum is 
created.  The Raman shift, measured in wavenumbers, is plotted on the x-axis 
against the intensity of the scattered light on the y-axis, as exampled in figure 
2.3.  The unique spectrum of Raman peaks based on the bonds present 
provides an abundance of information regarding the chemical bonds associated 
with DNA, RNA, proteins, lipids, carbohydrates and other biomolecules.  The 
intensity of the scatter is directly proportional to the concentration of molecules 
within the specimen and, hence, quantitative information can also be attained.   
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Figure 2.3: Example of a Raman Spectrum (Courtesy of Eckenrode et al 2001) 
 
2.2.2: Challenges and Advantages to Raman Spectroscopy of Biological 
Samples 
The main difficulty faced with Raman spectroscopy is its inherently weak signal.  
Raman spectroscopy detects inelastically scattered photons, however, only a 
fraction, 1/106-109, of photons undergo this form of scattering (Kendall et al 
2009).  The weak signal is further compounded by ambient light.  This needs to 
be removed to avoid distracting and confusing spectral contributions.  Raman 
spectrometers must, therefore, aim to exclude all confounding signals. 
 
 
Figure 2.4: Schematic Representation of a Raman Spectrometer (Courtesy of Biswas et al 
2010) 
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In a Raman spectrometer, the monochromatic light from the laser is focused 
onto the sample.  Scattered light is reflected and filtered through a series of 
steps to eliminate any light that is elastically scattered, thereby, enhancing the 
signal (Figure 2.4).  Diffraction grating splits the beam, based on its 
wavenumber, prior to its reflection onto the charge-coupled detector (CCD).  
The CCD registers the number of photons at each region and translates this 
into a specific spectral map of the sample. 
A number of advanced Raman-based technologies which are able to produce a 
stronger signal have been developed and are currently being investigated in the 
research domain.  Coherent anti-Stokes Raman spectroscopy (CARS), for 
example, employs multiple photons, whereas, surface enhanced Raman 
spectroscopy (SERS) uses specially prepared metal surfaces or nanoparticles 
to enhance the signal.  Other examples of advanced techniques that utilise and 
adjust the energy from the incoming laser source are resonance Raman and 
resonance hyper Raman spectroscopy.  
A further disadvantage of Raman is that it is only able to penetrate a few 
hundred microns into a tissue sample (Matousek and Stone, 2009).  This is 
particularly relevant when considering the use of this technology in-vivo.  
Spatially offset Raman spectroscopy (SORS) uses the principle that photons 
migrate and measure spectra from surface areas at distances from the 
excitation point.  A scaled subtraction of the spectra from spatially offset points 
enables the production of pure spectra from the individual layers of the sample 
(Matousek 2009), enabling the determination of the depth of dysplastic 
changes.   
The Raman signals from the –OH bonds present in water molecules are very 
weak, resulting in an insignificant contribution of water molecules to the 
resultant spectra (Kong et al 2015).  This is extremely advantageous as it 
allows the examination of fresh tissue without prior preparation.  This, therefore, 
allows this technology to be utilised for real time in vivo sampling and analysis.  
This is in contrast to FTIR Spectroscopy where the influence of water remains a 
significant dilemma. 
Spectroscopic analysis, including both Raman and FTIR, is a tremendously 
attractive diagnostic tool.  It is able to provide information on the biochemical 
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constituents of tissue and, thus, could detect biochemical and molecular 
changes that predate morphological alterations, allowing identification of at risk 
individuals, and enabling early, less invasive treatment.  It may assist with the 
significant subjectivity and, therefore, inter and intra observer variability that can 
exist when analysing and assigning pathological classification based on 
morphological changes alone.      
Automated classification systems could be developed for use in the laboratory 
in conjunction with histopathology to enable earlier and less subjective 
detection of cancerous and precancerous changes.  This system would, in 
addition, free up valuable histopathologist time to analyse certain pathological 
samples rather than the reams of biopsies from endoscopic surveillance.  This 
would be an economically attractive option.   
The development of fibre-optic probes, in addition, has paved the way for in 
vivo measurements with the added benefits of real time diagnosis, thus, helping 
to identify potentially abnormal areas at the time of imaging and highlighting 
areas of the oesophagus requiring further examination. 
 
2.2.3:  Clinical Applications of Raman Spectroscopy in the Oesophagus 
Raman spectroscopy has long been shown to be able to discriminate between 
different pathological states in the oesophagus.  In an analysis of snap-frozen 
biopsy samples, this technology accurately discriminated between 8 pathology 
groups, including different subtypes of Barrett’s oesophagus such as the 
presence of intestinal metaplasia (Kendall et al 2000).   
The biochemical changes underlying the spectral differences seen in the 
different pathological states have been determined (Shetty et al 2006).  Higher 
levels of DNA, actin and oleic acid, for example, are present in dysplastic 
glandular tissue and cancerous tissue, likely signifying the abnormal DNA 
content and hyperchromatic state of neoplastic cells (Bergholt et al 2011).  In 
contrast, higher levels of glycogen are seen in normal squamous tissue 
representing the normal metabolism of glucose that occurs in non-neoplastic 
tissue (Bergholt et al 2011).   
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This technology has not yet made its move into routine clinical practise.  One 
area where it could be utilised is that of real time diagnosis.  From the turn of 
the century, a number of research groups have trialled in vivo Raman probes.  
Work in 2011 demonstrated that the identification of cancer in the oesophagus 
could occur with a sensitivity of 91% and a specificity of 94% and, importantly, 
with an acquisition time of 0.4-0.5 seconds (Bergholt et al 2011).  Dysplastic 
change was, however, not differentiated in this study.  Earlier studies had 
shown that with a variety of probes, predominantly in ex vivo samples, different 
grades of dysplasia were able to be determined with a range of sensitivities and 
acquisition times (Shim et al 2000, Wong et al 2005, Wong et al 2005a, Almond 
et al 2012, Almond et al 2014). 
The technological development of Raman probes will help to advance the use 
of this technology and studies are currently being planned and in progress.  The 
use of a real time probe may reduce the need for multiple biopsies and their 
associated small complication risk.  A major limitation, nevertheless, is the 
ability of the Raman probe to interrogate only a small volume of mucosa at one 
time.  This will undoubtedly prevent its use as a wide field scanning modality, 
however, it will still be an ideal adjunct to the clinical diagnostic arsenal for point 
measurements to aid diagnosis and to determine margins following endoscopic 
resection. 
An alternative place for this technology is in the laboratory as an adjunct to 
histopathology in ex vivo samples.  It has been shown that 2mm diameter 
sections can be mapped over a time period of 30-90 minutes which enables the 
accurate discrimination of pathology (Hutchings et al 2010).  This tool could be 
utilised in samples where histopathology has not reached a consensus 
regarding the diagnosis and, thus, act as a third expert.        
 
2.3:  Fourier-Transform Infra-Red Spectroscopy 
2.3.1:  Underlying Principles 
William Herschel initially discovered infrared radiation (IR) in 1800.  Many 
decades later, in the 1970s, commercially driven IR spectrometers led to the 
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broad application of IR spectroscopy and its position as one of the most 
important analytical methods in science. 
When infrared radiation is beamed onto a tissue sample, the chemical bonds 
present in the molecule vibrate.  The vibrations consist of symmetrical 
stretching, asymmetrical stretching, scissoring, rocking, wagging and twisting 
(Figure 2.5).  If the frequency of the vibration of the chemical bond equals that 
of the infrared radiation, the result is a temporary alteration in the dipole 
moment of the molecule.   
 
 
Figure 2.5: Schematic Diagram of some of the vibrations that molecular bonds undergo when 
excited (skcchemistry.wikispaces.com) 
 
The change in the dipole moment results in the formation of light.  By 
measuring this transmitted light, the energy absorbed at each wavelength is 
determined.  An absorbance spectrum, as exemplified in figure 2.6, is 
produced. 
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Figure 2.6: Infrared Spectrum of Ethanol (CH3CH2OH) (chemguide.co.uk) 
 
The first commercial Fourier Transform Infrared (FTIR) spectrometer was 
pioneered by Digilab in 1969.  In this spectrometer, an interferometer is used to 
guide the infrared beam through the sample (Figure 2.7).  A moving mirror 
allows information from multiple wavelength frequencies to be collected 
simultaneously and subsequently distributed.  This results in a higher signal-to-
noise ratio for a given scan time, known as Fellgett’s advantage, leading to 
superior results when compared to a scanning (dispersive) spectrometer.   
 
Figure 2.7: Schematic Representation of FTIR Spectroscopy (courtesy of Jasco, UK) 
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2.3.2: Challenges and Advantages to FTIR Spectroscopy of Biological 
Samples 
The advantages of FTIR include the ability to gain information in a non-
destructive manner from a small amount of tissue and to gain this information in 
a short amount of time. 
Water is highly absorbent in the mid infrared range of 400 – 4000 cm-1.  This is 
the range at which most other vibrations occur and, thus, masks the vibrations 
from the tissue sample itself.  As the majority of biological tissue has high water 
content, the ability of FTIR to gain meaningful data from in vivo measurements 
is limited. 
There is, however, an intense drive to be able to produce real time, in vivo 
measurements.  Fibre-optic evanescent wave spectroscopy (FEWS)-FTIR with 
endoscope compatible fibre-optic silver halide probes have been shown, in the 
research setting, to be feasible (Mackanos et al 2010), and allow in vivo 
measurements. 
FTIR is ideal for use with paraffin-embedded tissue samples as, although 
paraffin is visible in the fingerprint region, this can be overcome with spectral 
subtraction and, hence, not affect interpretation of the tissue.  These 
preparations are routinely used in histopathology for Haematoxylin and Eosin 
(H&E) staining and immunohistochemistry and, thus, the technique of FTIR 
could be used as an adjunct in the laboratory without additional sample 
preparation and the associated costs that would entail.   
 
2.3.3:  Clinical Applications of FTIR in the Oesophagus 
The development of adenocarcinoma follows an established pathway, 
commencing prior to the establishment of any visible morphological changes.  
DNA, protein, glycoprotein and glycogen produce peaks in the wavelength 
range of 950 – 1800 cm-1 and differences in these peaks are seen in low-grade 
dysplasia.  Studies have shown that these changes are able to identify and 
classify dysplasia in fresh oesophageal samples with a high sensitivity of 92% 
and a specificity of 80% (Wang et al 2007). 
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The ability of FTIR to distinguish pathologies in paraffin embedded samples has 
also been demonstrated.  Glycoproteins from goblet cells, the characteristic 
feature of intestinal metaplasia, were identified based on their spectral changes 
(Quaroni and Casson 2009). 
 
2.4:   Autofluorescence 
2.4.1:  Underlying Principles 
Some tissues produce fluorescence when they are illuminated.  Fluorophores, 
the constituent biomolecules of the tissue, absorb a photon of high energy when 
illuminated.  This results in the excitation of an electron into a vibrational state 
of higher energy.  As the electron relaxes into its ground state, a photon of 
lower energy is released, causing the emission of light (Figure 2.8).  Unlike in 
Raman spectroscopy, however, the resultant fluorescence is dependent on the 
frequency of incident light. 
 
 
Figure 2.8: Schematic Representation of Autofluorescence  
(Image courtesy of Thermo Fisher Scientific) 
 
Most fluorophores are found in the submucosa, with collagen and elastin 
contributing highly green fluorescent signals.  Epithelium and lamina propria in 
the mucosa provide a weaker contribution (Figure 2.9).  Disease processes 
result in different autofluorescent patterns due to alterations in the type, 
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concentration and microdistribution of fluorophores that accompany the 
changes in the mucosa that are part of the disease process. 
 
Figure 2.9: Autofluorescent image of the intestine of a mouse (en.wikepedia.org) 
 
Confocal Fluorescence Microscopy (CFM) permits high resolution imaging of ex 
vivo tissue samples, yielding a wealth of information of the intrinsic cellular and 
extracellular autofluorescence as well as the microstructure of the tissue.   
2.4.2: Challenges and Advantages to Autofluorescence of Biological 
Samples 
A significant advantage of autofluorescence is its ability to sample wide areas of 
the mucosal surface in a short space of time, meaning that the entire 
oesophagus can be sampled in a single endoscopy.  This is in comparison to 
the spectroscopy techniques described above which can only sample a small 
area at one time.   
The major disadvantage seen in all studies involving autofluorescence, not only 
those involving the oesophagus, is the non-specificity of these changes.  Acute 
inflammation results in changes in the vascularity of the tissue.  Changes in the 
vasculature also occur in dysplasia and it is impossible to detect the underlying 
cause of the changes using autofluorescence. 
2.4.3:  Clinical Applications of Autofluorescence in the Oesophagus 
Imaging of tissue autofluorescence is undertaken in real time, enabling 
interrogation of the entire mucosal lining.  The first fluorescence endoscopic 
imaging system had varying results.  Initial studies suggested that, in 
comparison to white light endoscopy alone, this system improved the detection 
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of early neoplasia (Haringsma et al 2001, Niepsuj et al 2003).  Subsequent 
studies, however, found that the technique added no additional diagnostic value 
(Kara et al 2005). 
The next generation system, which utilised green autofluorescence in addition 
to red, improved the sensitivity in the detection of severe neoplasms 
(Haringsma et al 2005).  The newest development that has followed is a video-
endoscopic system with the ability for white light and autofluorescent imaging.  
Normal squamous and non-dysplastic Barrett’s oesophagus appear as a green 
discolouration, whereas, areas of high-grade dysplasia or oesophageal 
carcinoma have a blue to purple discolouration which improved the ability to 
detect these areas. 
High-grade dysplasia was distinguishable by the increase in nuclear-to-
cytoplasm ratio, causing a reduction in the amount of autofluorescent light, 
which is then detected by a change in the autofluorescent signal (Kara et al 
2005).  In addition, thickening of the mucosal layer occurs in early neoplastic 
lesions and leads to the attenuation of autofluorescence in this layer.  Tissue 
haemoglobin absorbs light and as the vascularity and, hence, haemoglobin 
concentration changes, so too does the fluorescent signal.   
The changes are, nevertheless, subtle and there was found to be an overall 
comparable red-green autofluorescent intensity ratio between Barrett’s 
oesophagus with and without dysplasia suggesting that these changes alone 
are inadequate to detect areas of dysplasia.  The obvious advantage of wide 
field viewing of autofluorescence would make it an ideal adjunct to a 
technology, such as Raman spectroscopy, that has higher sensitivity and 
specificity.  Autofluorescence could identifiy the areas of mucosa of greatest 
interest which spectroscopy could then analyse to determine the presence of 
dysplasia.  This combination, to date, has not been tested in research or clinical 
trials.     
Additional work investigating autofluorescence in the colon has shown the 
presence of high numbers of autofluorescent lysosomal granules in dysplastic 
epithelial cells which could be diagnostic for dysplasia (DaCosta et al 2005).  
The lysosomal granules contain lipofuscin and may represent dysregulated 
‘waste disposal’ in these cells, and/or are linked to high rates of cell apoptosis, 
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both of which are possible processes occurring in dysplastic change.  If 
lipofuscin, or the lysosomes containing lipofuscin, or a similar molecule, is 
shown to be a reliable marker of dysplasia, and is shown to have a signature 
autofluorescent pattern, then this would enable the accurate detection of 
dysplasia.  Currently, however, no such marker has been identified. 
 
2.5:  Point Spectra versus Imaging Mapping 
Spectroscopy techniques can be utilised in two ways.  Point measurements, 
where a single point of the sample, is measured; or mapping where a larger 
section of the sample is measured.  The benefit of point spectra is the speed of 
acquisition of the measurement, however, as changes in tissue are not uniform, 
there is a risk that vital information is missed.  For example, if the changes that 
depict dysplasia are not in the point sampled, then the diagnosis cannot be 
made.  This can, however, be overcome by taking multiple point measurements 
for each sample. 
Image mapping, on the other hand, generates a detailed chemical image of the 
sample.  A complete spectrum is acquired at each and every pixel of the image, 
and then interrogated to generate false colour images based on the molecular 
composition and structure.  The sacrifice for this volume of information is the 
time required to map the sample, often being multiple hours, and occasionally 
extending into days.  This makes mapping impossible to perform in real time, in 
vivo measurements as it would be unfeasible to maintain tissue contact with a 
peristalsing GI tract for the length of time required, not to mention the effect on 
the patient. 
 
2.6:  Chemometrics 
Analysis of biological samples is inherently complex due to the quantity of 
constituents within them.  Chemometric analysis, when applied to the measured 
spectra, interprets the wealth of information obtained, to detect any qualitative 
or quantitative biochemical changes existing between samples.  Statistical 
analysis can then be applied to identify and quantify the differences that may 
exist between samples. 
	62	
Principal Component Analysis (PCA) and Linear Discriminant Analysis (LDA) 
are techniques that are frequently applied to the database of measured spectra.  
These techniques are able to extract biochemical information and to convert the 
information into a predicted diagnosis. 
Pre-processing steps can also be included to improve the performance of 
pattern recognition.  Extended Multiplicative Scatter Correlation (EMSC), for 
example, is used to reduce the influence of confounders, such as paraffin, on 
the resultant spectrum. 
2.6.1:  Principle Component Analysis (PCA) 
PCA is an orthogonal linear transformation technique which transforms 
correlated variables into linearly uncorrelated variables, called principle 
components.  The first principle component comes to lie on the first coordinate 
and contains the largest degree of variance which exists in the data set.  The 
second principle component, which occupies the second coordinate, accounts 
for the next highest amount of variability and so on.  Analysis of variance 
(ANOVA) can be applied to the principle components to identify which have the 
greatest variance and, hence, which should be used to build the resultant 
classification models. 
2.6.2:  Linear Discriminant Analysis (LDA) 
LDA is a similar statistical method which expresses one dependent variable as 
a linear combination of other features or measurements.  LDA takes into 
account information from the group that the data originated from and, hence, is 
known as a ‘supervised’ technique.  This is in contrast to PCA which assumes 
no prior knowledge or information and is, thus, termed an ‘unsupervised’ 
method.  By taking into account information from the group, LDA maximises the 
differences between groups, whilst minimising the differences that exist within 
the group. 
2.6.3: Training Models and Leave One Sample Out Cross Validation 
(LOSOCV) 
The analysis techniques described above are used to produce a classification 
model.  This model can then be tested to see how the results will generalise to 
an independent data set.  If this test is done using the training dataset, a falsely 
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optimistic performance can be inferred as the data being tested is contained 
within the dataset. 
The use of a separate dataset where the data being tested was not used to, or 
contained within the classification model is a preferable situation and prevents 
to possibility of overfitting.  This, however, requires a larger dataset which is 
often not feasible or practical.  Removal of the sample being tested from the 
dataset without the need for a separate database is a compromise which 
prevents overfitting without unduly affecting the number of samples required.  
This testing technique is known as leave one sample out cross validation 
(LOSOCV). 
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Chapter 3: Aims and Objectives 
3.1: Introduction and Aims 
 
There are areas in the understanding of and management of Barrett’s 
oesophagus that require further research in order to transform the care of 
patients and to reduce the incidence of oesophageal adenocarcinoma.  The 
British Society of Gastroenterology (BSG) guidelines express, in their 
recommendations, 11 areas that require investment and development.  The use 
of advanced imaging modalities to improve the detection of dysplasia and the 
cost effectiveness of this endeavour as well as more studies on the natural 
history of Barrett’s oesophagus, especially in the context of LGD are just 2 of 
the themes. 
Oesophageal adenocarcinoma is preceded by the development of dysplasia in 
a segment of Barrett’s oesophagus.  With the current endoscopic diagnosis and 
surveillance, it is difficult to visualise areas of dysplasia and, once biopsied, to 
ascertain definitively the presence and grade of dysplasia.  Years of research 
have looked at a variety of imaging modalities that could aid the identification of 
dysplasia. 
The vibrational spectroscopy techniques of Raman and FTIR, as well as tissue 
autofluorescence, offer a number of potential advantages as tools for clinical 
diagnosis.  As well as a less subjective identification of dysplasia and the 
capacity for real-time diagnosis, these technologies may also be able to identify 
changes that occur prior to any morphological changes.  There may be changes 
that occur that help to differentiate, for example degrees of low-grade dysplasia, 
that have previously been classified together and may enable risk stratification 
for these patients.   
This research aims to further the understanding of these advanced imaging 
modalities, predominantly their ability to predict and understand biochemical 
changes that exist between the different pathological states. 
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3.2: Objectives 
 
The objectives for this thesis are: 
 
1) To develop classification models based on Raman point-based and 
Raman map-based measurements; 
a. that classify Barrett’s oesophagus without dysplasia from Barrett’s 
oesophagus with dysplasia. 
b. that classify Barrett’s oesophagus with low-grade dysplasia from 
Barrett’s oesophagus with high-grade dysplasia and 
adenocarcinoma. 
 
2) To compare the results obtained from point and map-based 
measurements to determine if the classification model developed 
from the point-based measurements is able to predict the pathology 
classification of data from the map-based data. 
 
3) To analyse potential biochemical peak assignments from the point-
based measurements to ascertain the biochemical changes that are 
seen in the different pathology states. 
 
4) To see if we can determine where low-grade dysplasia fits on the 
spectrum of Barrett’s oesophagus without dysplasia through to 
oesophageal adenocarcinoma and if there are any features that 
indicate the risk of progression for these patients. 
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Section B 
Chapter 4: Methodology 
4.1:   Ethical Approval 
Ethical approval for the project was granted by the Gloucestershire Local Ethics 
Committee as a non-substantial amendment of the SMART project.  The 
SMART (Stratified Medicine through advanced Raman Technologies) project 
was granted ethical approval in 2015.  Archived tissue samples, identified from 
hospital pathology databases, were used.  No fresh tissue samples were 
collected for the study and, therefore, patient consent for tissue use was not 
required, nor obtained. 
4.2:  Sample Collection 
4.2.1:  Identifying Samples 
Samples were identified from a hospital database which had been created by 
the pathology lab manager.  The database recorded all oesophageal biopsy 
and oesophagectomy samples from June 2013 to December 2015.  The 
samples had been coded as Barrett’s oesophagus (+/- dysplasia) or 
oesophageal adenocarcinoma based on the pathology review completed at the 
time of sample acquisition for clinical purposes.  Each sample was recorded 
with a unique code and, thus, pseudo-anonymised with the researcher not 
seeing any patient identification details.    
For some samples, a second pathologist opinion had been sought as part of the 
clinical diagnostic process.  This was according to the protocol in practise at the 
time of sample acquisition.  BSG guidelines from 2013 (Fitzgerald et al) state 
that all cases of suspected dysplasia are reviewed by a second GI pathologist, 
with review in a cancer centre if intervention is being considered.  
Specimens of Barrett’s oesophagus without dysplasia, Barrett’s oesophagus 
with low-grade dysplasia, Barrett’s oesophagus with high-grade dysplasia and 
adenocarcinoma were selected based on their original histopathology report.  
10 specimens from each group were selected.  An additional 10 samples from 
normal squamous lined oesophageal biopsies were selected as the control 
group. 
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Once the cases had been identified, the samples were located from the 
pathology laboratory based at Cheltenham General Hospital.  The archived 
samples had been routinely processed at the time of their acquisition and kept 
in paraffin embedded tissue blocks in ideal conditions according to the local 
departmental protocols. 
50 samples in total were chosen for analysis (10 from each group of; normal 
squamous, Barrett’s oesophagus without dysplasia, Barrett’s oesophagus with 
low-grade dysplasia, Barrett’s oesophagus with high-grade dysplasia and 
adenocarcinoma).  The samples had been acquired during the time period of 
November 2014 to February 2016.   
4.2.2:  Processing of Samples 
Acquisition of samples took place in the histopathology laboratory at 
Cheltenham General Hospital in July and August 2016.  Once the paraffin-
embedded tissue blocks had been located and sourced from the storage 
department, contiguous sections of 7 µm thickness were prepared on calcium 
fluoride slides.  Contiguous samples are used so that each section closely 
resembles the other sections, thus, ensuring correlation between histology and 
spectroscopic measurements. 
Calcium fluoride slides were selected as calcium fluoride produces only 1 
significant Raman peak which is not only distinct, but occurs at a wavelength 
(323 cm-1) outside that of the wavelength range in which tissue produce spectra 
(400 – 1800 cm-1) and, thus, can be eliminated from data analysis.  In addition, 
calcium fluoride produces a low background intensity. 
The calcium fluoride slides, once prepared, were placed in plastic coin cases to 
prevent scratching and other forms of physical damage and to reduce the 
likelihood of dust and other micro-particles affecting the sample.  Each coin 
case was labelled with the unique code assigned from the histology database.  
The coin cases were stored in the Biophotonics Research Unit at 
Gloucestershire Royal Hospital. 
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4.2.3:  Confirmation of Histology 
The samples used for analysis were selected based on their histological 
diagnosis, given at the time of sample acquisition.  This diagnosis was 
produced from an experienced histopathologist employed at Gloucestershire 
Hospitals NHS Foundation Trust.  In some instances, two opinions had been 
sought to confirm the diagnosis.   
The areas of the section that were felt to strongly represent the overall 
pathology were identified according to the microscopic features (for example, 
appearance of glandular tissue) by a post-doctoral research fellow in the 
Biophotonics lab.  This was to ensure that spectral measurements would be 
taken from the appropriate area, and from the same area for the differing 
technologies.  This was important as sections may show a heterogeneous mix 
of pathologies. 
4.3:  Sample Measurement 
4.3.1:  Pre-measurement Preparation  
For each sample, the H&E section was scanned, in high resolution, onto 
computer software (Microsoft PowerPoint 2016).  This allowed the regions that 
best reflect the overall diagnosis to be highlighted and labelled.  On average, 
four regions were selected for each sample.  Selection of regions also ensured 
that the same area was used for measurement on each modality.   
Archived tissue blocks are embedded in paraffin wax as this provides support 
for the tissue and ensures durability for long term storage without deterioration 
of the tissue sample.  Paraffin wax, nevertheless, produces a significant Raman 
signal (Figure 4.1) with distinctive peaks (at 888cm-1, 1061cm-1, 1131cm-1, 
1171cm-1, 1294cm-1, 1417cm-1, 1440cm-1 and 1462cm-1).  These peaks are in 
the fingerprint region and would, therefore, render the interpretation of tissue 
spectra impossible.  The sections were, therefore, deparaffinised according to 
local protocol (Appendix I) using Hexane (C6H14) prior to commencing Raman 
measurements.  The samples were deparaffinised in batches which were 
selected at random and contained a mixture of pathologies.   
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Figure 4.1: Raman Spectral Measurement of Paraffin Wax (Mian et al 2014) 
For all samples, Raman point spectra were taken initially, followed by Raman 
mapping at a later date, although the time interval between the two modalities 
varied.  The samples were stored in plastic coin cases between measurements 
to avoid contamination.  In general, samples were not measured in group order 
to ensure that any variables such as temperature and humidity did not affect 
one pathology group to a greater extent.  The exception to this was, however, 
the normal squamous epithelium samples which were obtained at a later date 
and, thus, measured as a cohort in the latter days of measurement. 
Autofluorescence measurements are unaffected by paraffin and, thus, these 
measurements were taken from a contiguous slide which had not been 
deparaffinised on a different date.  As these measurements were not the main 
focus of the research, only 10 samples were used. 
 
4.3.2:  Raman Point Spectra Measurements of Oesophageal Tissue 
Raman point spectra were measured using the Renishaw System 1000 at the 
Biophotonics Research Unit at Gloucestershire Royal Hospital (Figure 4.2) 
using 830 nm NIR excitation from a diode laser source.  Calibration was carried 
out by the user on each occasion that measurements took place.  Silicon is 
used to calibrate the Raman shift wavenumber value as it has a single sharp 
peak at 520.4 cm-1 which is then used as a reference point.  Manual entry of the 
required wavenumber offset is entered as required. 
A standard sample of green glass is measured to detect spectrometer detector 
sensitivity.  Green glass has a smooth fluorescent spectral signal with four 
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Raman peaks across a broad wavenumber range.  An energy transfer function 
correction can be applied to correct for variations in detector sensitivity.  
Cyclohexane is used in the calibration process to detect changes in laser 
wavelength.  The distinctive peaks of cyclohexane which appear at 801, 1027, 
1264 and 1441 cm-1 enable the recognition of any wavenumber drift.   
 
 
Figure 4.2: Renishaw System 1000 at the Biophotonics Research Unit 
 
The deparaffinised samples on calcium fluoride slides were measured with an 
acquisition time of 30 seconds using a Leica x50 magnification.  Signal to noise 
ratio is proportional to the square of the intensity of incident light multiplied by 
the acquisition time.  An acquisition time of 30 seconds was, therefore, selected 
as this provides an appropriate sampling time without compromising on spectral 
information. 
Each of the 50 samples had an average of 4 regions (range 1 – 4 regions) 
which had been preselected as described.  An average of 15 point spectra were 
measured in succession from random points, selected manually, within each 
region.  Once measured, the samples were stored in plastic coin cases to await 
Raman mapping.   
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4.3.3:  Raman Mapping of Oesophageal Tissue 
Raman maps were measured using the Renishaw RA800 Series bench top 
Raman system at the Biophotonics Research Unit in Gloucestershire Royal 
Hospital (Figure 4.3).  This system uses an excitation wavelength of 785 nm, a 
long working distance (50x) Leica objective lens to focus the laser beam and a 
motorised xyz stage to move the sample under the linear laser beam. 
 
 
Figure 4.3: Renishaw RA800 Series at the Biophotonics Unit 
 
Prior to any sample measurements, the instrument was calibrated.  On this 
system, an automated process, known as Performance Qualification, optimised 
system alignment and made wavenumber adjustments based on known 
reference standards of green glass, silicon and polymer readings. 
Raman streamline mapping is performed by moving the sample on the 
motorised stage under the laser beam.  Streamline mapping generates high 
definition 2D chemical images of very large sample areas rapidly by illuminating 
with a line of laser light.  This prevents laser induced sample damage and 
ensures that a high quality image is produced.  The size and area of the section 
to be mapped was based on the regions selected on the high resolution H&E 
stain.  This ensured that the same area that had been analysed with point 
spectra was captured for mapping.  The size of the section was selected to 
ensure capturing within the selected area with an appropriate timeframe. 
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On average, two regions from each sample were mapped (range 1 – 4 regions) 
with a diverse range of size area depending on the size of the area of interest 
and the time. The larger maps were typically from samples of adenocarcinoma 
which had a single larger section of interest as compared to the other 
pathologies which had multiple smaller areas of interest.  
4.3.4:   Autofluorescent Imaging of Oesophageal Tissue 
Autofluorescence was measured using the Leica TCS SP5 Confocal System 
(Figure 4.4) at the University of Exeter.  Ten specimens, two from each 
pathology set (Normal squamous epithelium, Barrett’s oesophagus without 
dysplasia, Barrett’s oesophagus with low-grade dysplasia, Barrett’s oesophagus 
with high-grade dysplasia and Adenocarcinoma), were measured on the same 
day at three different wavelengths (476, 488 and 496nm). 
 
 
Figure 4.4: Confocal Fluorescence Microscopy System at the University of Exeter 
 
Paraffin embedded specimens mounted on calcium fluoride slides were used.  
These samples were not the same as those used for the Raman 
measurements, but were adjacent cuts from the same specimen block.  Paraffin 
does not produce an autofluorescent signal at these wavelengths and, thus, 
deparaffinisation was not undertaken prior to sample measurement. 
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The same area that was used to measure both Raman point spectra and 
Raman maps was selected for autofluorescent measurement.  Measurements 
from each wavelength were taken sequentially. 
 
4.4:  Data pre-processing and Analysis 
In-house software programs written in Matlab® R2016a (Mathworks, USA) were 
developed for the pre-processing and date analysis of Raman point spectra and 
Raman mapping data.  Data was analysed by PCA (principle component 
analysis), LDA (linear discriminant analysis) and LOSOCV (leave one sample 
out cross validation). 
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Section C: Summary of Measurements, Results and Analysis 
Chapter 5: Summary of Measurements 
5.1:  Raman Point Spectra of Oesophageal Tissue 
10 samples of each pathology type (Normal squamous, Barrett’s oesophagus 
without dysplasia, Barrett’s oesophagus with low-grade dysplasia, Barrett’s 
oesophagus with high-grade dysplasia and oesophageal adenocarcinoma) 
were selected.  1 sample, initially classified as Barrett’s oesophagus with high-
grade dysplasia, was reclassified based on histopathological review to low-
grade dysplasia. 
Pathology Number of Samples Number of Regions 
Normal Squamous 10 32 
Barrett’s oesophagus without dysplasia 10 33 
Barrett’s oesophagus with low-grade 
dysplasia 
11 37 
Barrett’s oesophagus with high-grade 
dysplasia 
9 30 
Oesophageal adenocarcinoma 10 29 
Table 5.1: Number of Samples and Regions per pathology 
1 to 4 regions from each sample were used for point spectra measurements, 
resulting in a range of 29 to 37 regions depending on pathology (Table 5.1).  
The regions had selected based on the quality of that area for defining the 
pathology of the sample as a whole.  They were identified and highlighted on 
scanned H&E sections as described in the methods section.  The scanned 
images were used to identify the correct area at the time of measurement (as 
depicted in Figure 5.1). 
 
Figure 5.1: H&E Stained Sample indicating the areas to be used for measurements 
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From each region, approximately 15 point spectra were measured.  Following 
measurements, each spectrum was analysed and compared to the mean of the 
sample.  Spectra which contained cosmic rays or which were significantly 
abnormal compared to the other spectra from that sample were eliminated prior 
to analysis.  The number of spectra measured and the number eliminated is 
shown in Table 5.2.  
Overall 16% of the measured spectra were eliminated from the final analysis.  
Of note, the highest percentage of eliminated spectra was from the normal 
squamous specimens.  These samples were measured separately over a 
period of 2 days in September at the end of the study period due to delayed 
procurement of these samples.  Samples from the other 4 groups were 
measured in a random order over the course of 12 days in August.  It may be 
that the conditions on the days on which the normal squamous samples were 
measured were subtly different resulting in a higher proportion of abnormal 
spectra. 
Pathology Number of Point 
Spectra Measured 
Number of Point 
Spectra eliminated 
Number of Point 
Spectra for Analysis 
Normal Squamous 
 
467 107 (23%) 360 
Barrett’s oesophagus 
without dysplasia 
470 61 (13%) 409 
Barrett’s oesophagus 
with LGD 
588 86 (15%) 502 
Barrett’s oesophagus 
with HGD 
490 87 (18%) 403 
Oesophageal 
adenocarcinoma 
465 61 (13%) 404 
Total 2480 402 (16%) 2078 
Table 5.2: Summary of Measured and Eliminated Point Spectra 
 
In total 2480 spectra were measured on 14 days in a 2 month period.  After 
elimination, 2078 point spectra remained for analysis.  Appendix II details all 
samples measured.  
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5.2:  Raman Mapping of Oesophageal Tissue 
The same samples that were used for point spectra measurements were then 
used for Raman Map Measurements.  Between measurements, the samples 
were stored at room temperature out of the light in protective plastic coin cases, 
nevertheless, three slides were damaged and were unable to be used for 
mapping measurements.  The time between measurements on the two systems 
ranged from 6 hours to 37 days, although the vast majority were completed 
within 7 days.  8 samples had a delay of greater than 7 days from point 
measurement to mapping due to availability of the Raman mapping machine 
which was also being utilised for other research projects as well as availability 
of the researcher.  During this research project, clinical on-calls were continued.  
These occurred in a 3 week block every 9 weeks and meant that 
measurements had to be suspended during this time.  
 
Figure 5.2: White light image of tissue sample produced and area selected for mapping 
 
The number of regions selected for each sample was based on the size of the 
region and, thus, fewer areas were utilised for mapping when compared to the 
point spectra measurements. The complete sample was scanned, as indicated 
in Figure 5.2, and the region selected by comparison with the H&E stain.  The 
number of specimens and regions are shown in Table 5.3. 
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Pathology Number of Samples Number of Regions 
Mapped 
Normal Squamous 9 18 
Barrett’s oesophagus without dysplasia 10 27 
Barrett’s oesophagus with LGD 10 27 
Barrett’s oesophagus with HGD 9 24 
Oesophageal adenocarcinoma 9 21 
Total 47 117 
Table 5.3:  Summary of Samples and Regions measured using Raman Mapping 
In total 117 regions were mapped.  The number of points measured in each 
map was dependent on the size of the region selected and ranged from 238 to 
108350 points.  The total number of points measured in each pathology is 
shown in Table 5.4 and the average number in Table 5.5.  Measurements were 
undertaken on 20 days in a 2 month period.   
Pathology Number of Points 
Mapped 
Time Taken (mins)  
Normal Squamous 68712 867 
Barrett’s oesophagus without dysplasia 91251 1172 
Barrett’s oesophagus with LGD 112898 1445 
Barrett’s oesophagus with HGD 218442 1504 
Oesophageal adenocarcinoma 179001 2179 
Total 670304 7167 
Table 5.4: Summary of Raman Map Measurements 
 
Pathology Average Number of 
Points Mapped / 
Region 
Average Time (mins) 
/ Region  
Normal Squamous 3817 48 
Barrett’s oesophagus without dysplasia 3380 43 
Barrett’s oesophagus with LGD 4181 54 
Barrett’s oesophagus with HGD 9102 63 
Oesophageal adenocarcinoma 8524 104 
Total 5729 61 
Table 5.5: Averages of Raman Map Measurements 
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5.3:  Autofluorescence of Oesophageal Tissue 
Ten samples, two from each pathology group, were selected for autofluorescent 
measurements.  The one region that most accurately depicted the underlying 
pathology was measured.  The area was measured with three wavelengths, 
476, 488 and 496nm, sequentially.  All ten samples were measured on a single 
day. 
5.4:  Data Analysis 
Principle component analysis was used to identify variance between the 
measured spectra.  Analysis of variance, with a 0.95 confidence threshold for 
inclusion, was subsequently utilised for each comparison to identify which 
components provided the variance between the data sets, as exemplified in 
figure 5.3. 
 
Figure 5.3: ANOVA for comparison of LGD versus HGD and Adenocarcinoma 
Linear Discriminant Analysis was performed using the principal components 
identified from the training dataset (i.e.: all measured spectra).  The 
classification model was then tested on the test dataset using LOSOCV (i.e.: all 
data excluding the sample currently being tested).  This enabled the sensitivity 
and specificity of the dataset to be calculated and assessed.   
 
Section C: Summary of Measurements, Results and Analysis 
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Chapter 6: Results and Analysis 
6.1:  Classification Models 
6.1.1: Determining the presence of dysplasia: Barrett’s oesophagus 
without dysplasia versus Barrett’s oesophagus with dysplasia 
One of the aims of this project was the development of classification models for 
diagnosing dysplasia in Barrett’s oesophagus. The diagnosis of dysplasia is 
clinically important as the management differs for patients without dysplasia as 
they have an extremely low risk of malignant progression.  For patients whose 
biopsies indicate the presence of dysplasia, the management ranges from 
repeat endoscopy (for low-grade dysplasia) to either endoscopic resection or 
even oesophagectomy (for high-grade dysplasia and adenocarcinoma).   
Raman spectroscopy needs to be able to differentiate, with high specificity and 
sensitivity, between the presence and absence of dysplasia for it to be a viable 
modality.  Previous studies have shown that Raman spectroscopy is able to 
achieve this in the GI tract (Kendall et al 2003).  Ideally it will also be able to 
determine the grade of dysplasia and be able to classify samples that are 
indeterminate for dysplasia as with dysplastic or inflammatory.  This study has 
used both point spectra and map data to determine if Raman spectroscopy can 
identify dysplasia and if low-grade dysplasia can be differentiated from high-
grade dysplasia and adenocarcinoma. 
To determine if Raman spectroscopy is able to effectively distinguish samples 
with dysplasia from those without, the samples were spilt into two groups: 
Barrett’s without dysplasia as one group, and Barrett’s with dysplasia as the 
other group.  The Barrett’s with dysplasia group was formed from Barrett’s 
oesophagus with low-grade dysplasia, Barrett’s oesophagus with high-grade 
dysplasia and oesophageal adenocarcinoma. 
 
6.1.1.1: Raman Point Spectra 
When all the samples obtained using point spectra measurements were 
analysed, the most striking difference appears in the samples of oesophageal 
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adenocarcinoma (Figure 6.1).  The other histology types are more closely 
aligned to each other. 
 
Figure 6.1: Scatterplot of Raman Point Spectra Measurements  
When the samples were analysed based on their segregation into a group 
without dysplasia and a group with dysplasia (as described above), using 
principals component analysis (Training Set), the results indicate that the two 
groups are able to be differentiated with a sensitivity of 0.69 and a specificity of 
0.68 (Table 6.1).   
Barrett’s Oesophagus without Dysplasia versus Barrett’s oesophagus with Dysplasia: Point 
Spectra  
 Sensitivity Specificity AUC 
Training Set 0.69 0.68 0.76 
Test Set 0.46 0.59 0.53 
Table 6.1: Analysis Results: Raman Point Spectra (No Dysplasia versus Dysplasia) 
 
When plotted on a Receiver Operating Characteristic (ROC) curve, the Area 
under the Curve (AUC), which indicates how well the diagnostic groups can be 
differentiated, is 0.76.  An AUC of 1 is a perfect classification model, whereas, 
0.5 indicates that that the differentiation is no better than chance alone.  This 
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indicates that the ability to differentiate samples with dysplasia from those 
without is possible, although the accuracy is limited. 
The results for the test set, performed using LOSOCV, are unsurprisingly poorer 
with an AUC of 0.53 (Figure 6.2) which is only marginally better than chance.  In 
particular, the sensitivity was low at 0.46, meaning that a significant number of 
samples with dysplasia were incorrectly classified as not having dysplasia using 
this classification model. 
 
Figure 6.2: ROC Curve for Dysplasia versus Non-Dysplasia: LOSOCV: Point Spectra 
 
6.1.1.2: Raman Mapping 
Using Raman mapping data, it was also possible to differentiate between 
samples with and without dysplasia.  The training set results predict an AUC of 
0.84 (as exemplified in Figure 6.3) which indicates that Raman mapping is 
significantly better than chance alone for differentiating the two pathologies.   
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Figure 6.3: ROC Curve for Dysplasia versus Non-Dysplasia on CaF2 Slides: PCA. 
The test set, however, demonstrated poor results (see Table 6.2), with a 
sensitivity of only 0.26 and a specificity of 0.84.  These results are poorer than 
expected based on previous research results and indicate an inadequate ability 
to correctly identify dysplasia when present.  The training set, which does not 
remove a sample to test the results, also has a poor sensitivity of 0.52. 
 
Barrett’s Oesophagus without Dysplasia versus Barrett’s oesophagus with Dysplasia: Raman 
Mapping (Calcium Fluoride Slides) 
 Sensitivity Specificity AUC 
Training Set 0.52 0.93 0.84 
Test Set 0.26 0.84 0.35 
Table 6.2: Analysis Results: Raman Mapping (No Dysplasia versus Dysplasia) on CaF2 
The reasons for this are likely to include the small sample numbers, particularly 
in the Barrett’s oesophagus without dysplasia group.  In addition, the group with 
dysplasia included a range of grades of dysplasia from low-grade to 
adenocarcinoma which may have affected the sensitivity.  The pathway from 
low-grade dysplasia to adenocarcinoma encompasses a variety of 
morphological and biochemical changes.  Not only are these changes variable 
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along the pathway, they are also variable in, for example, two patients who both 
have low-grade dysplasia.  This means that in a group that contains samples 
from both ends of the spectrum (low-grade dysplasia to adenocarcinoma), there 
will be significant differences between the samples.  These differences may be 
greater than the difference between Barrett’s oesophagus without dysplasia and 
low-grade dysplasia, resulting in the poor results seen when comparing these 
two cohorts of samples. 
All data from the Raman maps was included in the analysis.  Although the area 
that best represents the underlying pathology was selected for mapping, there 
undoubtedly were areas surrounding that was normal oesophageal tissue.  This 
means that in, for example, a sample of low grade dysplasia, there will be areas 
that contain none of the features of low grade dysplasia and are normal 
oesophageal tissue.  These areas will lower the sensitivity and specificity of the 
analysis as identical areas will be present in samples of adenocarcinoma.  All 
spectra that was obtained was included in the analysis as this will reflect the 
likely situation in clinical practise to minimise the necessary pre-preparation of 
samples and, hence time and money required for this technology.   
Lastly, the samples were affected by residual paraffin which remained despite 
following the standard and thorough protocol for de-paraffinisation.  Different 
tissue pathologies have been shown to hold onto residual paraffin to a varying 
degree (Nallala et al 2015), which is a likely result of the different biochemical 
make-up of the tissues.  This would have resulted in differences between the 
groups and within the group containing the wide range of degrees of dysplasia.  
The residual paraffin is further discussed in Section 6.2.   
In addition to de-paraffinisation, chemical bleaching of pathology during oven 
and clearing agent chemical treatment may affect the underlying sample and 
may do this to a different degree dependent on the biochemical make-up of the 
underlying tissue.  Whether this occurs and the degree to which it does is 
unknown.    
The same comparison between Barrett’s oesophagus without dysplasia and 
Barrett’s oesophagus with dysplasia was undertaken using Raman mapping 
data from samples on stainless steel slides.  These samples, which were 
obtained from the same archived tissue blocks as the samples on calcium 
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fluoride slides, were prepared and measured during a similar time frame for the 
SMART project (Stratified Medicine through Advanced Raman Technologies 
Project) in collaboration with Gloucestershire Royal Hospital, Renishaw, 
University College London and the University of Exeter.   
Barrett’s Oesophagus without Dysplasia versus Barrett’s oesophagus with Dysplasia: Raman 
Mapping (Stainless Steel Slides) 
 Sensitivity Specificity AUC 
Training Set 0.65 0.91 0.85 
Test Set 0.33 0.80 0.47 
Table 6.3: Analysis Results: Raman Mapping (No Dysplasia versus Dysplasia) on Stainless 
Steel Slides 
The results obtained from the stainless steel slides (see Table 6.3) show results 
that are similar to the calcium fluoride slides for the training set with an AUC of 
0.85 (see Figure 6.4).  The test set results were marginally better with a 
sensitivity of 0.33 and a specificity of 0.80.  Even when the effects of residual 
paraffin are excluded, the low number of samples used in the analysis and, 
perhaps most importantly, the grouping of all grades of dysplasia into one group 
has resulted in poorer than expected outcomes. 
 
Figure 6.4: ROC Curve for Dysplasia versus Non-Dysplasia on Stainless Steel Slides: LOSOCV 
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The range of differences that are seen as cells progress through dysplasia 
results in subtle differences in the Raman maps, particularly as a large area that 
may contain different and varying features is mapped.  The area of the sample 
that was selected to be mapped represented the grade of dysplasia, however, 
there would have been surrounding areas which would not have been 
representative of the underlying pathology.  In addition, there are a range of 
features which represent each grade of dysplasia.  The amassing of all grades 
of dysplasia in one group would have resulted in a broad range of changes 
which is likely to have affected the cross validation results as there would have 
been significant differences between, for example, the area adjacent to low-
grade dysplasia and the central of an area of adenocarcinoma. 
6.1.1.3: Comparison: Point Spectra to Mapping 
The point spectra measurements are from a single point of the sample that is 
mapped over a period of 30 seconds, whereas, Raman mapping samples a 
greater area over a significantly longer period.  It is hypothesised that the 
results obtained from the point spectra measurements will be inferior as less 
information is contained within each spectra.  In addition, it is possible that the 
small area measured will miss vital and, perhaps, diagnostic information. 
When comparing the classification models for point spectra and Raman 
mapping (on calcium fluoride slides) for Barrett’s oesophagus without dysplasia 
and Barrett’s oesophagus with dysplasia and adenocarcinoma, the overall 
results in terms of the AUC were similar; 0.76 versus 0.84.  The sensitivity and 
specificity results were, however, quite different (see Table 6.4). 
 
Barrett’s Oesophagus without Dysplasia versus Barrett’s Oesophagus with Dysplasia and 
Adenocarcinoma 
 Sensitivity Specificity AUC 
Point Spectra 0.69 0.68 0.76 
Map Spectra 0.52 0.93 0.84 
Table 6.4: Comparison Results: Point Spectra Training Set versus Map Spectra Training Set: 
No Dysplasia versus Dysplasia 
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The specificity, also known as the true negative rate, measures the proportion 
of negative results that are correctly identified as negative.  As mapping 
encompasses a larger area, it is likely that if any areas of dysplasia were 
present, they would be identified and this is reflected in the specificity of 0.93 
which is significantly better than 0.68 obtained with point spectra 
measurements.  
The sensitivity, on the other hand, measures the proportion of positive results 
that are correctly identified as positive.  Point measurements may miss the area 
of interest and, thus, not include the area of dysplasia which would result in a 
falsely negative result.  It was surprising, therefore, that the sensitivity was 
higher at 0.69 in the point spectra measurements when compared to 0.52 
obtained with Raman map measurements.  This may be due to changes in the 
area surrounding dysplasia which, if measured, are also diagnostic of the 
overall histology of the sample.    
 
6.1.2: Determining the grade of dysplasia: Low-Grade Dysplasia versus 
HGD/Adenocarcinoma 
Low-grade dysplasia, especially if persistent, may represent an important 
transition on the road towards malignancy.  The ability to accurately identify 
low-grade dysplasia is essential if it is indeed a transition point and has been 
difficult to do with histopathology alone due to the subtle morphological changes 
and, hence, high variability among assessors.  One of the aims of this study 
was to determine if low-grade dysplasia could be distinguished from that of 
high-grade dysplasia and adenocarcinoma. 
For this analysis, Barrett’s with low-grade dysplasia was compared to Barrett’s 
oesophagus with high-grade dysplasia and oesophageal adenocarcinoma.   
 
6.1.2.1: Raman Point Spectra 
These results have shown that point spectra measurements are able to 
differentiate low-grade dysplasia from that of high-grade dysplasia and 
adenocarcinoma.  The results are, however, far from ideal.  When testing the 
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classification model, the sensitivity and specificity results (Table 6.5) were 
poorer than they would need to be to be clinically applicable.  
Barrett’s Oesophagus with Low-Grade Dysplasia versus High-Grade Dysplasia: Raman Point 
Spectra 
 Sensitivity Specificity AUC 
Training Set 0.84 0.70 0.86 
Test Set 0.66 0.59 0.68 
Table 6.5: Analysis Results: Raman Mapping (Low-Grade Dysplasia versus High-Grade 
Dysplasia): Point Spectra 
The ROC curve (see Figure 6.5) shows an AUC of 0.68 on the test set.  These 
results are better than those of no dysplasia versus dysplasia.  This suggests 
that when the sample sets are closer to each other, rather than including a wide 
range of pathologies, the differences between groups are greater than the 
differences seen within groups and, thus, results in higher accuracy.  Including 
multiple grades of dysplasia within a single subgroup increases the number of 
samples, however, as each sample of dysplasia differs slightly anyway, 
combining multiple grades introduces a significant range of variance within the 
group.  Comparing each pathology individually to each other and creating a 
multi-point classification model may improve both the sensitivity and specificity 
and bring the accuracy to a level that is clinically applicable. 
 
Figure 6.5: ROC Curve for LGD versus HGD: LOSOCV: Point Spectra 
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6.1.2.2: Raman Mapping 
When using the results obtained from Raman mapping, the results were far 
from ideal (see Table 6.6).  The training set had a sensitivity of 0.88 for high 
grade dysplasia, meaning that there was a high likelihood of the true positive 
results being identified.  The specificity was, however, lower at 0.51, meaning 
that a proportion of low-grade dysplasia would be misidentified.  Overall the 
AUC was calculated at 0.80 (see Figure 6.6).  These poor results were 
exemplified in the test set which reported an extremely low specificity of 0.09. 
Barrett’s Oesophagus with Low-Grade Dysplasia versus High-Grade Dysplasia: Raman 
Mapping (Calcium Fluoride Slides) 
 Sensitivity Specificity AUC 
Training Set 0.88 0.51 0.80 
Test Set 0.73 0.09 0.43 
Table 6.6: Analysis Results: Raman Mapping (Low-Grade Dysplasia versus High-Grade 
Dysplasia) on CaF2 Slides 
 
Figure 6.6: ROC Curve for Low-Grade Dysplasia versus High-Grade Dysplasia on CaF2 Slides: 
LOSOCV 
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This extremely low specificity may be, in some part, due to the reduced amount 
of differences that exist between low-grade and high-grade dysplasia, thus, 
meaning that it is extremely difficult to differentiate between the two.  Only very 
small numbers of samples were used and, as discussed, not all areas of the 
sample mapped represent low-grade dysplasia to the same degree.  This is 
likely to have had a significant impact on the results obtained. 
The same analysis was also completed on the samples measured on stainless 
steel slides.  As with the earlier comparison, the results from these slides were 
better than those obtained from the calcium fluoride slides (see Table 6.7 and 
Figure 6.7), reflecting the influence that residual paraffin has on the results.  
The specificity, nevertheless, remained poor, especially on the cross validation 
analysis (test set). 
Barrett’s Oesophagus with Low-Grade Dysplasia versus High-Grade Dysplasia: Raman 
Mapping (Stainless Steel Slides) 
 Sensitivity Specificity AUC 
Training Set 0.94 0.72 0.92 
Test Set 0.83 0.33 0.32 
Table 6.7: Analysis Results: Raman Mapping (Low-Grade Dysplasia versus High-Grade 
Dysplasia) on Stainless Steel Slides 
 
Figure 6.7: ROC Curve for Low-Grade Dysplasia versus High-Grade Dysplasia on Stainless 
Steel Slides: LOSOCV 
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6.1.2.3: Comparison: Point Spectra to Mapping 
When differentiating Barrett’s oesophagus with low-grade dysplasia from 
Barrett’s oesophagus with high-grade dysplasia and adenocarcinoma, the 
results obtained from the point measurements and the map measurements 
were similar (see Table 6.8). 
Barrett’s Oesophagus with Low-Grade Dysplasia versus High-Grade Dysplasia and 
Adenocarcinoma 
 Sensitivity Specificity AUC 
Point Spectra 0.84 0.70 0.86 
Map Spectra 0.88 0.81 0.80 
Table 6.8: Comparison Results: Point Spectra Training Set versus Map Spectra Training Set: 
LGD versus HGD and adenocarcinoma 
The main difference was that the specificity was lower for the point spectra 
measurements, meaning that some samples would be classified as low-grade 
dysplasia when they were in fact high-grade and vice versa.  This is important 
as the differentiation between the grades is clinically relevant and needed.  The 
results may have been more similar in terms of sensitivity and specificity as 
each sample group contained a more narrowly specified collection of 
pathologies.  This would have meant that the samples in each group were more 
closely aligned to each other, whereas, in the previous comparison the 
dysplastic group had a wide range of pathologies, some of which may have 
been closer to the other group than to other samples within the same group. 
 
6.1.2.4 Can point spectra be used to form a robust classification model? 
Point spectra measurements have the obvious advantage over mapping 
measurements of permitting rapid data acquisition.  Multiple point spectra 
measurements can be acquired in a timeframe that is much shorter than that 
required for even a single map.  As well as cost implications, the greatest 
benefit of rapid data acquisition is the ability for this to be performed in vivo as 
contact between the probe and mucosa can be maintained for the duration of 
the measurement.  Even with multiple measurements, this could be completed 
within the realms of a standard diagnostic endoscopy. 
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Point spectra measurements with their rapid acquisition will, however, only be 
acceptable if the data obtained is good enough to differentiate the various 
pathologies.  Although the data from both point and map measurements in this 
research were poor compared to previous published work, the sensitivity and 
specificity for diagnosing the pathologies varied between point and map data.  
To further aid the understanding of whether point spectra data alone is 
adequate for diagnosis, the map data was projected onto the training set 
formed from the point spectra.   
Map data encompasses a larger tissue area and, thus, has a greater likelihood 
for including changes that are diagnostic and enable differentiation between 
pathologies in the spectra produced.  Point spectra, in contrast, has a smaller 
area and may, thus, not include any or enough changes that are discernible in 
the resultant spectra.  If this is the case, there is likely to be a higher risk of false 
negatives, or a lower sensitivity.  It would be important to see if the areas 
surrounding the predominant area of interest also contain enough changes to 
enable differentiation by their spectra.  This is likely to be especially pertinent in 
in vivo measurements where manoeuvring the endoscopic probe against the 
vertical wall of the oesophagus is extremely tricky and, thus, may result in the 
exact point of interest being slightly outside the measurement area.  This 
knowledge will inform the size of point spectra required and the protocol for the 
number and spacing of measurements required.     
If the point spectra data is ample for differentiation, then the diagnosis for each 
map sample should be attainable from this training set.  The two Raman 
systems used for point spectra measurement and map measurements are, 
however, different in terms of wavelength, filters and optics.  The models 
produced for each system, therefore, are different and are unable to 
compensate for the differences between the two systems.  It was, therefore, 
impossible to project the map data onto the point spectra training set.  
The differences in the systems and the need to compensate for these in the 
models produced exemplifies the importance of the data analysis.  Without 
advances in this area, spectroscopy will be unable to be used routinely as it will 
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be impossible to create a classification model that can be used and comparable 
in different settings.   
 
6.1.3:  Where does Low-Grade Dysplasia fit? 
The results obtained from this research show that Raman spectroscopy has the 
ability to differentiate Barrett’s oesophagus with low-grade dysplasia from that 
of high-grade dysplasia and adenocarcinoma, although the results are far from 
flawless.  Low-grade dysplasia provides some of the greatest difficulty in 
diagnosis by histopathological changes and is a huge challenge for all 
pathologists with increasing numbers of patients being diagnosed as indefinite 
for dysplasia and consensus on histopathological diagnosis being impossible.  
In addition, the exact meaning of a diagnosis of low-grade dysplasia for the 
patient is uncertain.  
The samples of low-grade dysplasia were analysed to see if they more closely 
resembled those of Barrett’s oesophagus without dysplasia or Barrett’s 
oesophagus with high-grade dysplasia as this may clarify the position that low-
grade dysplasia has on the spectrum towards malignancy.  When analysing the 
samples with cluster analysis and rank tests, it shows that the samples of low-
grade dysplasia are as similar to themselves as they are to everything else. 
This result is not surprising given the small number of samples of low-grade 
dysplasia.  It would be interesting to see if, with a higher number of samples, 
there is a closer resemblance to either Barrett’s oesophagus without dysplasia 
or to Barrett’s oesophagus with high-grade dysplasia.  There may be different 
subgroups of low-grade dysplasia; one that does not progress towards 
malignancy, and one which does.  It would be interesting to analyse the low-
grade dysplasia samples in different groups, based on the certainty of the 
histopathologist report (i.e.: when all pathologists agree on the diagnosis 
compared to when there is disagreement between pathologists), and based on 
the subsequent progression of the samples (i.e.: are those samples that do 
progress to high-grade dysplasia distinguishable at an earlier stage when 
analysed by Raman Spectroscopy).  This is further discussed in Section 7.1 
and 7.2.3.       
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6.2:   Paraffin 
6.2.1:  The impact of paraffin 
 
For this project, archived tissue samples and, hence, formalin fixed paraffin 
embedded (FFPE) tissue samples were used.  The formalin preserves the 
tissue for future analysis in a manner that enables easy storage and provides 
substantial support to the tissue to aid microtomy and tissue sectioning.  
Fixation in formalin, nevertheless, results in changes in the tissue.  The process 
of fixation results in the breakage of hydrogen bonds within large intracellular 
molecules leading to a loss of protein conformation (Srinivasan et al 2002).  
Dehydration of intracellular proteins through the formation of cross-links 
between amine residues (Srinivasan et al 2002, Murk et al 2003, Gazi et al 
2005) as well as the washing out of lipids also occurs (Masuda et al 1999).  
These changes have, however, been shown to produce spectral content that is 
closet to that seen in live cells and, by extension, formalin fixation is deemed to 
best preserve cellular integrity (Meade et al 2010).    
As previously discussed, paraffin produces a distinctive Raman spectrum which 
overwhelms and obscures the spectrum of the tissue.  De-paraffinisation of the 
samples took place prior to sample measurement, however, despite no visually 
apparent paraffin contamination, analysis of the samples revealed elements of 
retained paraffin. 
A spectrum of pure paraffin wax has significant peaks at 888cm-1, 1061cm-1, 
1131cm-1, 1171cm-1, 1294cm-1, 1417cm-1, 1440cm-1 and 1462cm-1 (see Figure 
6.8) which are the result of stretching of the C-C bond and deformities of CH2 
and CH3 (Faoláin et al 2005).  Figure 6.9, which depicts the average spectra of 
the maps of both normal squamous and oesophageal adenocarcinoma tissue, 
also shows dominant peaks at 1061cm-1, 1131cm-1, 1296cm-1, 1440cm-1 and 
1462cm-1 which correlate to those of paraffin. 
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Figure 6.8: Raman Spectrum of Pure Paraffin highlighting the predominant peaks 
produced (adapted from Mian et al 2014) 
 
Figure 6.9: Average spectra of each map of Normal Squamous and Oesophageal 
Adenocarcinoma tissue 
Raman spectroscopy is more sensitive to the incomplete removal of paraffin 
than infrared spectroscopy (Faoláin et al 2005), thus, the inability to remove 
paraffin completely raises important issues if this tool is to be clinically 
applicable and robust.  Previous studies (Fullwood et al 2014, Nallala et al 
2015) have compared a variety of agents used for de-paraffinisation.  Long 
Hexane incubation (~18 hours) was shown to be the most effective agent, 
however, even with this chemical, some residual paraffin remained in the 
tissues. 
The amount of paraffin remnants remaining in the tissue was not uniform, but 
varied depending on the underlying pathology with cancerous tissue retaining 
the most paraffin.  Figure 6.10 highlights the difference between normal 
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squamous tissue and oesophageal adenocarcinoma tissue with differences in 
intensity at the paraffin peaks, indicating a different amount of paraffin, as well 
as differences due to the underlying histology.  This difference in paraffin 
retention has been documented in previous studies (Nallala et al 2015), 
although the exact reasons are unclear. 
 
Figure 6.10: Mean Spectra of Normal Squamous and Oesophageal Adenocarcinoma Tissue 
 
Calcium fluoride slides were selected as, despite their cost, they display a 
single predominant peak that is outside that of the tissue range and background 
peaks of lower intensity (Kerr et al 2015), however, their average surface 
roughness is high at 4.76nm (Fullwood et al 2015).  This may affect the ability 
of deparaffinisation of samples on this slide, whereas, slides of a lower 
roughness, such as stainless steel, are better suited to the deparaffinisation 
process. 
6.2.2:  Comparison to Stainless Steel Slides 
As well as improved deparaffinisation, stainless steel has been shown to 
improve the Raman signal by reducing the background contribution of the slide 
by a factor of 6 (Lewis et al 2017).  The results presented in this thesis, despite 
their downfalls, are improved when using samples mapped on stainless steel as 
compared to calcium fluoride slides.   
The other advantages of stainless steel slides are reduced cost when compared 
to calcium fluoride slides.  Not only is the original outlay higher for calcium 
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fluoride slides, but their fragility will, in all likelihood, result in higher costs 
relating to damages and may also result in a loss of samples. 
 
An alternative approach to avoid the difficulties and implications that FFPE 
tissue brings is to use fresh or snap frozen samples.  Fresh samples would 
enable reduced tissue processing and, hence, avoid the possibility that the 
paraffin and chemical de-paraffinisation process change the tissue constituents.  
For in-vivo use, this would be essential, however, it would necessitate 
immediate measurement which would, outside of research facilities, be 
impossible in most situations.  Frozen tissue samples have their own difficulties 
with storage and thawing techniques, hence, it would seem improbable that this 
technology will be able to step away from FFPE tissue and, thus, choosing a 
suitable substrate slide is likely to be the preferential method to avoid the 
implications that residual paraffin brings. 
 
6.3:  Biochemical Peaks 
6.3.1:  Is there a purpose to biochemical assignment? 
The Raman spectrum that is produced when tissue is analysed is a direct 
function of the molecular composition of that tissue.  Biological tissues have a 
multitude of biomolecules, each of which has its own distinctive Raman 
signature and, hence, each peak produced during analysis can be traced to the 
exact molecule or bond creating the peak.  Significant overlap of the spectra, 
however, exists, creating broad signal envelopes (Pavićević et al 2012).  This, 
combined with overlap that is produced from endogenous fluorescence, means 
that the assignment of a peak to a single molecule may be overly optimistic and 
ultimately misleading.   
The spectrum reflects the underlying quantity and distribution of, predominantly, 
glycogen, DNA, lipids and proteins.  Initial work that looked to elucidate the 
underlying causes of the resultant peaks in oesophageal tissue and the 
differences between benign and dysplastic tissue found increased DNA, oleic 
acid, collagen I and actin in areas of high-grade dysplasia, whereas, increased 
glycogen was seen in areas of normal squamous tissue (Shetty et al 2006).   
	97	
Not only have subsequent studies (Bergholt et al 2011, Ishigaki et al 2016) 
corroborated these findings, but the biomolecular findings also reflect the 
changes that occur in neoplastic tissue.  Neoplastic tissue shows increased 
DNA and histones which emulates the abnormal DNA content that occurs in 
malignancy.  Furthermore, a well-established indicator of dysplasia and 
malignancy is an increase in the nuclear: cytoplasmic ratio which is reflected by 
a decrease in actin in the spectral peak.  A major change that occurs in the 
process of malignancy is the change and variation in protein configuration.  A 
higher concentration of β-pleated sheet conformation (Maziak et al 2007) and a 
lower concentration of extracellular collagen, possibly secondary to cleavage by 
matrix metalloproteinases, (Bergholt et al 2011) occurs in malignancy. 
Despite replication of studies identifying the likely cause of each of the Raman 
peaks, a body of researchers (including Diem, Gerwert and Wood, 2016) refute 
the need for biochemical assignment and the uncertainty of the allocations.  
The complexity of the spectra produced from a tissue sample as well as the 
large number of overlapping bands mean that a significant element of the 
biochemical assignment is based on guesswork.  Nevertheless, there is 
considerable similarity in peak assignment despite different methodology 
between studies which would indicate that the results are reproducible. 
Differences in spectral pattern without knowledge of the underlying biochemical 
change that results in the spectral shift would enable discrimination between 
pathologies without any advancement in the understanding of the malignant 
progression.  I would contend that it only by understanding the changes that 
occur, will the ability to manipulate and ideally prevent them be able to take 
place.  Furthermore, by analysing the order in which the changes occur, the 
fundamental change that pushes patients onto the malignant pathway may be 
realised and become the gold standard for identifying patients at risk of 
progression.  If, for example, this was an increase in a certain substance, a 
means of identifying this substance alone, could be utilised as a marker for risk 
stratification in patients.  Simply comparing peaks in different pathologies to the 
current gold standard of histopathology will not move our understanding 
forward. 
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6.3.2:  Peak Differences 
As discussed in the classification models, the predominant difference in spectra 
occurs in the normal squamous tissue.  The other tissue types (Barrett’s 
oesophagus without dysplasia, Barrett’s oesophagus with low-grade dysplasia, 
Barrett’s oesophagus with high-grade dysplasia and adenocarcinoma) have 
more closely aligned spectral patterns as depicted in Figure 6.11.   
 
Figure 6.11: Mean Spectra by pathology 
 
Normal squamous tissue samples show increased amplitude in peaks that 
have, in other studies, been shown to represent glycogen.  These peaks include 
852 cm-1, 934 cm-1, 1036 cm-1, 1048 cm-1 and 1467 cm-1 (Shetty et al 2006, 
Hutchings et al 2010).  In addition, normal squamous tissue shows decreased 
amplitude in peaks that represent nucleic acids (1173 cm-1), DNA (720 cm-1, 
748-755 cm-1, and 785 cm-1) and protein (820 cm-1), including amide III (1265 
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cm-1) (Shetty et al 2006, Hutchings et al 2010, Almond et al 2014, Bergholt et al 
2014, Chen et al 2014).  A comprehensive review of biochemical assignments 
is included in Appendix II.   
Differences in peaks were also observed at 888 cm-1, 1131 cm-1, 1171 cm-1, 
1294 cm-1 and 1440 cm-1.  These peaks have been shown to be due to paraffin.  
Previous studies (Nallala et al 2015) have indicated that different tissue types 
retain paraffin variably following the same deparaffinisation regimen with 
adenocarcinoma preserving paraffin to a greater extent.  My samples showed 
variation at these points, however, it was the normal squamous tissues that had 
the highest peaks.  If the normal squamous peaks are eliminated, then the 
retention of paraffin is next highest in the adenocarcinoma tissue, as predicted 
by previous work (Figure 6.12).  In my research, normal squamous tissue 
samples were obtained at a later date than the other samples and 
deparaffinised separately and, thus, may have a greater paraffin residue.  This 
may account for some of the differences when comparing to the other tissue 
types.    
 
Figure 6.12: Magnification of peak at 1440cm-1, which corresponds to paraffin 
Samples of Barrett’s oesophagus without dysplasia, with low-grade and high-
grade dysplasia and oesophageal adenocarcinoma show differences, albeit 
smaller.  For example, as shown in Figure 6.13, adenocarcinoma represented 
by the green line, is closer to normal squamous than the other pathologies.  
There is not a graduated change with, for example, the amount of glycogen 
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decreasing in a continuum that matches the continuum of malignant 
progression.  This may be because the greatest change is the transition to 
Barrett’s oesophagus and the progression along the continuum to malignancy is 
not as gradual as suspected, but rather a series of significant steps that affect 
the spectra at certain points.  
 
Figure 6.13: Magnified view of spectral peaks at 934cm-1, 1036cm-1, 1048cm-1. 
6.3.3:  Low-Grade Dysplasia 
As discussed, the ability to distinguish dysplasia, particularly low-grade 
dysplasia from high-grade dysplasia, is paramount to helping both diagnostic 
abilities as well as the understanding of the progression of dysplasia.  From 
analysing the peak differences, it is clear that there is not a change that occurs 
with the presence of dysplasia that is representative and diagnostic for the 
change, rather there are subtle differences in the concentrations of the tissue 
constituents.  This is expected as the change of dysplasia is a series of 
morphological changes which alter the composition of the tissue and do not add 
or remove a single distinctive substrate. 
This research only utilised ten samples of each grade of dysplasia.  It would be 
noteworthy to see if there are changes that are different between the samples 
of dysplasia that progress to malignancy and those that do not.  As discussed 
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earlier, the samples of low-grade dysplasia analysed did not show any 
alignment to either Barrett’s oesophagus without dysplasia or to Barrett’s 
oesophagus with high-grade dysplasia, however, it may be that there were not 
enough samples to identify this.  The low number of samples resulted in a low 
number of biochemical changes being able to be captured in the measurements 
and subsequent analysis.  It is not surprising, therefore, given the heterogeneity 
of changes of dysplasia that the classification model was unable to accurately 
differentiate the samples when it was built on a small selection of samples and, 
hence, a small selection of biochemical changes.       
In the future it would be interesting to measure many more samples of low-
grade dysplasia and see if certain samples of low-grade dysplasia were more 
aligned to high-grade dysplasia.  This could identify those patients at risk of 
progression and highlight the changes in tissue constituents that mark this 
progression.    
 
6.4:  Autofluorescence 
Raman spectroscopy has, for a long time, been shown to distinguish between 
benign, dysplastic and cancerous tissue.  The difference in spectra is a result of 
the biochemical changes.  Modalities that utilise autofluorescence, such as 
confocal fluorescence microendoscopy, are also able to see changes at the 
cellular level.  Research by DaCosta et al in 2005 found that dysplastic colonic 
cells had lower average green autofluorescence when compared to normal 
epithelial cells.  The average red fluorescence was increased leading to a 
higher red to green ratio.  A significant increase in the red fluorescence was in 
the apical regions of the cells due to a high presence of autofluorescent 
granules in this region.   
Many cellular constituents exhibit fluorescent features including aromatic amino 
acids, reduced pyridine nucleotides and endogenous porphyrins (DaCosta et al 
2005).  The red autofluorescence seen in dysplastic cells was shown to be due 
to lysosomes, or their contents.  Lysosomes are cellular organelles which 
contain hydrolytic enzymes and, thereby, acts as a ‘waste disposal’ system for 
the cell.  For example, apoptosis of epithelial cells results in cell fragments 
which, due to oxidisation and polymerisation, form lipofuscin within lysosomes.  
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Lipofuscin could be the focus of the fluorescence (DaCosta, personal 
communication).  Regardless of whether it is lipofuscin or another molecule that 
is the cause of fluorescence, if such a molecule exists, this molecule could be 
responsible for the differences seen in the spectroscopic signature between 
disease states. 
I undertook autofluorescence on a small selection of samples to ascertain if 
there are any visible differences.  Unsurprisingly given the small sample, there 
were no accountable difference seen (See Appendix II for a selection of the 
results).  Further work, focusing on the cellular constituents, may expose the 
changes indicated in previous research and provide focal areas for Raman 
mapping to identify the cellular constituents responsible for the change in 
autofluorescent signature. 
A biomarker that is identifiable by fluorescence and/or spectroscopy and is 
diagnostic of dysplasia is highly sought after.  If found, it could reduce the time 
required to obtain tissue samples and reduce the subsequent analysis time as 
identification of this marker would be enough to distinguish tissue that is 
dysplastic and tissue that is not.  Perhaps more importantly, if a marker were to 
be discovered that typified the transition to dysplasia, then this could aid the 
understanding of why some patients with Barrett’s oesophagus begin down the 
path to dysplasia and aid in identifying measures to prevent this.     
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Section D: Summative Discussion and Conclusions 
Chapter 7: Summative Discussion and Conclusions 
Dysplasia in Barrett’s oesophagus is currently the only marker that we have at 
our disposal to ascertain the likelihood that an individual will progress along the 
path to malignancy.  The diagnosis is, however, fraught with difficulty due to the 
subtle morphological changes which result in high variability amongst even 
specialist GI histopathologists.  This is most apparent in the changes that 
characterise low-grade dysplasia with a Cohen kappa coefficient of only 0.27 
(Kerkhof et al 2007).  The changes that represent indefinite for dysplasia also 
provide a significant problem.  This characterisation of dysplasia is important as 
patients are subjected to aggressive proton pump therapy and an earlier 
endoscopy.  The consequence of a diagnosis of high grade dysplasia is even 
more important as the management is, in some instances, an oesophagectomy.   
Improving the diagnosis of dysplasia will undoubtedly aid the management of 
individual patients.  In addition, further understanding of the biochemical and 
structural changes that result in dysplasia and identification of the features of 
patients who have a higher risk of progression will aid in management 
stratification and identify those who will benefit from intensive surveillance or 
early treatment.  Hopefully these strategies will result in a reduction in incidence 
of oesophageal adenocarcinoma and, hence, an improvement in survival. 
 
7.1:  The Dilemma of Low-Grade Dysplasia 
One of the controversies in the management of Barrett’s oesophagus is the 
clinical significance and implication of a diagnosis of low-grade dysplasia.  The 
most recent meta-analysis (Duits et al 2015) places the overall risk of 
progression of low-grade dysplasia to high-grade dysplasia at 9%.  A shortfall of 
many of these studies is, however, the difficulty in the accurate assignment of 
low-grade dysplasia due to the, often subtle, features seen on histopathology 
review and, thus, the actual figure may be different.     
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Interestingly, the risk of progression to high-grade dysplasia was greatest, 80%, 
when three pathologists agreed on the diagnosis of low-grade dysplasia, and 
the risk lowest, 0%, when no pathologists agreed on the diagnosis (Skacel et al 
2000).  The reasons for this are uncertain.  It may be that when a greater 
number of pathologists agree on the diagnosis of low-grade dysplasia, it is 
because the changes are more advanced and further along the continuum 
towards high-grade dysplasia and adenocarcinoma.  It, thus, seems likely that 
the further along the continuum the tissue is, the less likely that it will stall or 
regress.  Earlier in the pathway, when the changes are more subtle and, thus, 
more subjective, the tissue may well be unstable and be more likely to regress 
and lose the features of dysplasia. 
An alternative explanation is that the cohort of patients who are more likely to 
progress have a single distinctive change that is a cornerstone in the risk of 
progression and may also be a very distinctive marker for pathologists.  If there 
is a biomolecular change that signifies a watershed moment in the biology of 
low-grade dysplasia, and this is identifiable either by histology or by Raman 
spectroscopy, then this could separate the patients with low-grade dysplasia 
and aid in their risk stratification. 
 
7.2:  Building a Model from an imperfect Standard 
7.2.1:  The ‘Not so Gold’ Gold Standard 
The presence of the morphological changes of dysplasia in Barrett’s 
oesophagus is, at the present time, the best marker that we have to predict the 
development of adenocarcinoma.  These changes, a result of the accumulation 
of genetic and epigenetic changes that cause disruption at the cellular level, 
however, are difficult to identify as they are a subtle continuum, as opposed to 
abrupt differences.  There is also a marked overlap in the morphological 
changes of inflammation, regeneration and metaplasia with those of 
malignancy.   
A multitude of studies (Reid et al 1988, Sagan et al 1994, Alikhan et al 1999, 
Baak et al 2002) have, for some time, demonstrated inter-observer variability in 
identifying the presence of dysplasia, as well as assigning the grade of 
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dysplasia.  These findings were confirmed in a large, multicentre prospective 
study (Kerkhof et al 2007).  This study used Cohen’s kappa coefficient (κ) which 
measures inter-observer variability whilst also taking into account the possibility 
that agreement occurs by chance (Cohen 1960).  A score of ≤0 equates to no 
agreement with increasing agreement up to a score of 1.  Even between expert 
GI Histopathologists, when differentiating Barrett’s oesophagus without 
dysplasia versus low-grade dysplasia (including indefinite for dysplasia) versus 
high-grade dysplasia and adenocarcinoma, the kappa coefficient was 0.27 
(Kerkhof et al 2007).  This equates to a fair or minimal agreement, with 3 out of 
every 10 samples potentially being misdiagnosed.   
The majority of studies assessing inter-observer variability found that the main 
source of disagreement was in the differentiation of Barrett’s oesophagus 
without dysplasia and Barrett’s oesophagus with low-grade dysplasia or 
indefinite for dysplasia.  A more recent study, nevertheless, found that a 
considerable variability in the diagnosis of high-grade dysplasia.  40% of 
patients initially diagnosed as high-grade dysplasia were reclassified to low-
grade dysplasia, and in some cases as no dysplasia or not even the presence 
of Barrett’s oesophagus (Sangle et al 2015).  The current recommendation for 
patients with high-grade dysplasia is for, after review by a specialist 
histopathologist, endoscopic resection (Fitzgerald et al 2013).  If the results of 
this study are repeatable, it implies that 40% of patients may have undergone 
unnecessary intervention.  
This difficulty in diagnosis has fuelled the desire to find an improved detection 
method for Barrett’s oesophagus and, in particular, dysplasia.  Multiple research 
groups have looked into using enhanced imaging modalities to identify these 
changes as discussed in previous chapters.  When analysing their ability to 
differentiate changes and grades of dysplasia, they are compared to and 
analysed according to the current gold standard of histopathological review.  
This gold standard has, as discussed, been shown to be less than gold.  This 
makes it extremely difficult to ascertain how good and how meaningful the 
results of research utilising different modalities are.   
It may be, for example, that Raman spectroscopy is more sensitive than 
histopathology and, hence, actually appears to contradict the histopathology 
review when it is more accurate.  How are we to assess which is the more 
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accurate assessment when the standard is far from flawless?  Could we, for 
example, build a classification model from only the samples which have 
complete agreement from pathologists and use this to characterise the samples 
for which we are unsure?   
 
7.2.2:  Molecular Biomarkers to improve the Gold Standard 
Alongside research looking at enhanced imaging techniques, an alternative 
branch of research has been looking into biomarkers.  A biomarker is defined 
as a characteristic that is objectively measured and evaluated as an indicator of 
normal biological processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention (Atkinson et al 2001).   
p53, a tumour suppressor gene, is probably the most studied genetic marker in 
all cancer types.  Multiple studies have shown that for patients with Barrett’s 
oesophagus, aberrant p53 protein expression is associated with an increased 
risk of malignant progression (Kastelein et al 2013).  Interestingly, the 
combination of established low-grade dysplasia with aberrant p53 expression 
results in a much higher progression than that of low-grade dysplasia alone 
(Kaye et al 2009, Kastelein et al 2013).   
Flow cytometric analysis is able to detect changes in DNA content and 
chromosome number, known as aneuploidy.  Evidence is accumulating that 
aneuploidy places the patient at a higher cumulative risk for malignant 
progression (Reid et al 2000).  SOX2, a transcription factor, essential for 
maintaining self-renewal, has been shown to be overexpressed or upregulated 
in a number of cancers, including high Gleason grade prostate cancer and 
squamous cell lung cancer.  In patients with Barrett’s oesophagus, it has been 
shown that SOX2 expression is progressively lost as patient’s progress along 
the path to malignancy (van Olphen et al 2015).  
More recently, a panel of four genes, CDX2, p120 catenin, c-myc and Jagged1, 
was investigated to determine their ability, in combination, to aid histological 
assessment of Barrett’s oesophagus.  The four proteins, each from a different 
signalling pathway, showed the greatest change in expression between low-
grade and high-grade dysplasia, yet could also aid in distinguishing Barrett’s 
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without dysplasia from Barrett’s with low-grade dysplasia (Karamchandani et al 
2016). 
 
These studies demonstrate that the morphological changes that are detected as 
dysplasia are preceded and caused by an array of genetic and epigenetic 
changes.  Although these changes may occur to a different degree and in a 
different order in each individual, evidence has indicated that certain changes 
result in an increased risk of malignant progression, with the majority of 
changes occurring in the transition from low-grade to high-grade dysplasia.     
It is apparent that a cohort of patients with Barrett’s oesophagus will never 
progress along the path of malignant progression.  Once low-grade dysplasia 
has occurred, a proportion of these patients will also not progress further along 
the pathway.  The recommendation, however, for all these patients is 
surveillance endoscopy which is costly in terms of resources and finance and 
can be anxiety-inducing for the patient.  It may be that the molecular changes 
are what differentiate and divide the two cohorts and, if identified, could aid 
management decisions.  For example, patients with the beginnings of low-grade 
dysplasia without genetic changes may be in a state of flux and able to regress, 
whereas, once genetic changes have occurred, they may be unable to reverse 
the changes.    
The molecular changes may impact on the histological features of dysplasia 
that are too subtle to be detectable by histopathological review.  Raman 
spectroscopy has been shown to provide the greatest information regarding the 
molecular composition of the tissue.  It may be, therefore, that there are 
differences that Raman spectroscopy can detect between, for example, patients 
with low-grade dysplasia who will not progress to malignancy and patients who 
will.  Rather than comparing spectroscopic changes to the current gold standard 
of histopathology alone, it may be appropriate to compare to histopathological 
and molecular changes to see if this improves accuracy and detects a 
difference in the two cohorts of patients.   
The British Society of Gastroenterology Guidelines suggest that the addition of 
a p53 immunostain to the histopathological assessment may improve the 
diagnosis of dysplasia (Fitzgerald et al 2013).  It would be of interest to see if 
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patients with low-grade dysplasia and aberrant p53 expression have a different 
signature spectrum when compared to low-grade dysplasia and no aberrant 
p53 expression.  If a difference could be detected, Raman spectroscopy could 
then be utilised as both a diagnostic and prognostic tool, and identify patients 
who would benefit from intense surveillance or early treatment and those who 
would not.  If there were no barriers in terms of money and manpower, the next 
step in investigating Raman spectroscopy as a clinical diagnostic tool in 
Barrett’s oesophagus would be to measure a large volume of samples which 
are stratified by histopathology as well as genetic changes and, if possible, 
stratified according to their progression in subsequent biopsy samples.  
 
7.2.3:  The benefit of hindsight 
The ultimate aim of endoscopic surveillance and biopsy is to identify patients 
prior to their progression to invasive carcinoma.  The majority of patients in the 
surveillance programme will never reach this point.  Aside from the diagnosis of 
dysplasia, no identifiable feature has helped in the risk stratification of patients 
and it is only time that predicts which patients benefit from rigorous surveillance. 
Histopathological diagnosis cannot detect, aside from dysplasia, which patients 
have a greater risk of progression.  For example, there is not a specific feature 
that occurs in some patients with low-grade dysplasia and not in others, that 
distinguishes those with a greater risk of progression.  Raman spectroscopy 
may be able to detect features via their unique spectrum that may not be 
distinguishable microscopically, hence, improve upon rather than match the 
current Gold standard.   
One way of assessing this would be to identify patients in a retrospective study 
and separate the patients who progressed to high-grade dysplasia or 
adenocarcinoma from those that did not.  By reviewing their original biopsies 
and performing Raman spectra of these biopsies, any differences, if present at 
an earlier stage, could be identified.  If there are differences between the two 
groups, these could be representative of early biochemical changes that 
distinguish patients who will, or who are at a greater risk, of progression, thus, 
aiding management decisions.   
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7.3:  Where do we go from here? 
 
Raman spectroscopy and indeed other enhanced imaging modalities have been 
used in research settings for many years now.  There has, as yet, not been a 
major breakthrough in the management of Barrett’s oesophagus or a transition 
of any of these technologies into routine clinical practise.  There are many 
potential reasons for this.  One of them, however, is certainly not due to the 
need for advancements in the management of Barrett’s oesophagus.   
One of the primary reasons for the lack of transition to clinical practise is the 
difficulty in understanding where this technology would fit in the current clinical 
setting of the NHS.  The two main areas where this technology could fit is in ex-
vivo analysis and in-vivo diagnosis.  For either of these roles there has, as yet, 
been no large scale, multi-centre research studies indicating an improvement in 
diagnosis and subsequent patient outcomes when this technology is utilised.  
For this to occur, there not only needs to be a large volume of centres utilising 
Raman spectroscopy that can enrol patients into the study, but there would also 
need to be a significant follow-up period extending into years.  This is because 
the diagnosis of dysplasia is relevant in its likelihood to progress to high-grade 
dysplasia and adenocarcinoma, rather than simply the accuracy of the initial 
diagnosis. 
Other issues in the integration of any new technology is overcoming the outlay 
costs which, in this case, would be high and overcoming scepticism among 
clinicians.  The best way of removing scepticism is to show, with high quality 
research, how the new method can benefit patient care.  
 
7.3.1: Automated Histology: Reducing the burden on the Histopathology 
Department 
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Surveillance for patients with Barrett’s oesophagus places considerable 
demands on endoscopy and histopathology departments in terms of resource 
allocation and, of course, cost.  The benefits of enrolment onto a surveillance 
programme are actually unclear with a case control study indicating no 
substantial reduction in death from oesophageal cancer in those on the 
programme (Corley et al 2013).  A prospective multi-centre trial, Barrett’s 
Oesophagus Surveillance versus endoscopy at need Study (BOSS), is 
underway to answer the question as to the benefits of surveillance (Old et al 
2015).   
At the present time, the only method of risk stratification is dysplasia.  If no 
additional markers or refinement of features that can segregate those at most 
risk can be found, then it is likely that surveillance with random biopsies as per 
the Seattle regimen and histopathological review will continue.  In addition to 
the burden placed on endoscopy units, the preparation and review of the 
biopsies by the Histopathology department constitutes a substantial workload.  
It has been shown that 2mm diameter sections which were mapped over 30-90 
minutes, provided sufficient information to enable the discrimination of 
pathology (Hutchings et al 2010).   
An automated means of screening biopsy samples ascertained as part of the 
surveillance programme would significantly reduce the impact on 
Histopathologists.  Given the number of biopsy samples taken from a routine 
surveillance endoscopy, which equates to at least 4 biopsies for every 1-2 cm of 
Barrett’s oesophagus, a faster time frame than 30-90 minutes would be 
required.  Point spectra would be markedly swifter, however, in this research, 
the specificity for identifying dysplasia was only 0.59.  As discussed these 
results are poorer than expected, yet it may be that point spectra alone are 
inadequate and a higher volume of tissue with a reasonable time frame enables 
a high specificity which identifies the samples requiring further review by a 
histopathologist.  This system would be ideal, at least until in vivo, real time 
probes could reduce the need for biopsies in some, but certainly not all, 
situations.     
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7.3.2:  Real time, In-vivo Raman Spectroscopy  
 
Several fibre-optic Raman probes have been developed specifically for 
compatibility with endoscopes (Shim et al 1999, Day et al 2009, Huang et al 
2009).  The first in vivo probe (Shim et al 2000), which sampled mucosal and 
submucosal samples, failed to achieve the high diagnostic discrimination 
required, however, subsequent studies have had better results, both in term of 
higher specificities and sensitivities of diagnosis, and in reduced spectral 
acquisition times. 
An in vivo probe is a desired addition to the arsenal of clinical diagnosis.  It 
would allow real time diagnosis of dysplasia and, thus, guide further 
management at the time of endoscopy.  I would not envisage a time where 
high-grade dysplasia would be diagnosed and endoscopic resection completed 
in the same sitting although spectroscopy could be utilised to guide resection 
margins.  I would imagine, however, that in vivo findings would guide the need 
for biopsies.  For example, if no dysplasia is identified, biopsies would not be 
required.  If dysplasia, of any grade, is detected then these areas would need to 
be biopsied, resulting in additional biopsies from areas of concern or 
uncertainty.  For this to be clinically applicable, a high specificity would be 
required as the implications from missing any areas of dysplasia could be 
catastrophic, whereas, a biopsy of areas without dysplasia would be time-
consuming but not a disaster. 
The vast majority of research to date, even using Raman probes built 
specifically for use in a current endoscope, has been on ex vivo samples.  This 
eliminates the technical difficulties of maintaining contact with an oesophageal 
mucosa with constant peristaltic waves.  For this reason as well as the need for 
assessing multiple areas, acquisition time for each spectra must be rapid, whilst 
still maintaining a high specificity.   
Recent work using in vivo probes (Bergholt et al 2011, Bergholt et al 2014) has 
demonstrated high specificity (>90%) in identifying oesophageal 
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adenocarcinoma and areas of dysplasia with short acquisition times of 0.5 
seconds.  These studies focused on abnormal areas of the oesophagus and, 
thus, the next step to determine the full value of this technology would be 
screening of an oesophagus with Barrett’s oesophagus and no visible 
abnormalities to ascertain how many areas can be screened, how to ensure 
variable areas are assessed and what acquisition time provides an appropriate 
specificity.   
Overall a strategy of only taking a biopsy of areas that show dysplasia on in 
vivo Raman spectroscopy would reduce the resources on the Histopathology 
department in the processing of samples, and reduce the risk, albeit small, of 
complications from the biopsy procedure itself.  Of perhaps greatest 
importance, this strategy would ensure that more tissue is sampled from the 
areas of interest, improving the likelihood that, if present, dysplastic changes 
are identified.  These areas would then be reviewed by a Histopathologist 
whose skills and expertise compliment and add to the knowledge that the 
Raman spectroscopy analysis provides. 
 
7.3.3:  Enhanced Risk Stratification  
 
A considerable dilemma in the management of patients with Barrett’s 
oesophagus is the inability to determine at an early stage which patients are at 
risk of progression to malignancy, thus, at present, all patients are enrolled onto 
a surveillance programme.  Low-grade dysplasia appears to be an unstable, 
and possibly fluctuant, stage at which a cohort of patients set off on the path 
towards malignancy.  Knowing this subset would enable treatment in the form of 
ablation at this very early stage, preventing progression and also refining the 
need for surveillance for the remaining patients with Barrett’s oesophagus. 
I would suspect that there are changes or markers that occur in low-grade 
dysplasia that can determine which patients are likely to progress.  These 
markers could be related to cellular proliferation, apoptosis or migration, for 
example.  Raman spectroscopy, with the potential to detect biomolecular 
changes in tissue, may be able to detect these changes.  At present there have 
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been no studies in the oesophagus with potential biomarkers.  In the colon, an 
in vivo pilot study using a peptide that binds with the human tyrosine kinase c-
Met conjugated to a fluorescent cyanine dye enabled improved detection of 
colonic polyps, including polyps unidentifiable with white light endoscopy 
(Burggraaf et al 2015).  
The rate-limiting step in the oesophagus, nevertheless, is the determination of 
which changes these may be.  Improving the current gold standard with 
additional information from genetics or from longitudinal studies may identify 
which markers are significant.  Not only will improved risk stratification have the 
potential to treat patients at a very early stage, hopefully improving outcome, 
but it would also rationalise resources and improve patient anxiety.  
 
7.4:  Final Thoughts 
 
The greatest means of improving the survival from oesophageal 
adenocarcinoma is the identification of at risk individuals and the prevention of 
the development of carcinoma.  It has been well established that Barrett’s 
oesophagus places an individual at greater risk, yet within this group it is 
difficult to ascertain those at greatest risk. 
Spectroscopy has the ability to identify subtle changes in tissue that reflect the 
earliest changes that occur in the path to malignancy.  This body of research 
again supports this, however, in order for this technology to become a useful 
adjunct in the fight against cancer, further work needs to incorporate this with 
other risk factors to determine if there are changes that identify which 
individuals are at risk.  This will enable earlier treatment for those who will 
benefit as well as streamlining the surveillance workload which currently utilises 
a substantial amount of resources.   
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Appendix I 
Deparaffinisation protocol 
 
• Sections of FFPE tissue were cut and placed on calcium fluoride slides, 
stored in plastic coin cases and transferred from the Histopathology lab 
at Cheltenham General Hospital to the Biophotonics Research Unit at 
Gloucestershire Royal Hospital. 
 
• The calcium fluoride slides were soaked in Xylene solution for at least 12 
hours.  Safety precautions of personal protection wear were undertaken 
and the work was carried out under a fume extraction system. 
 
• After soaking in Xylene, each slide was rinsed alternatively with sterile 
water and methanol to rinse off the residual paraffin.  This cycle was 
completed at least twice for each slide. 
 
• The slides were left to air dry under the fume extraction hood.  Once dry, 
the slides were stored in plastic coin containers and kept at room 
temperature in dark conditions until needed for measurements. 
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Appendix II 
Details of Sample Measurements 
 
Sample	
Number	 Histology	
Point:	
Region	1	
Point:	
Region	2	
Point:	
Region	3	
Point:	
Region	4	 802	Map	 Region	1	 Region	2	 Region	3	 Region	4	
15.35188	 BE	
02/08/16	
+	
08/08/16	 02/08/16	 02/08/16	 02/08/16	 03/08/16	
RM1	(Section	1:	
Region	1):	2478	
points:	31.8	mins	
RM3	(Section	2:	
Region	2):	3420	
points:	48	mins	
RM4	(Section	2:	
Region	3):	2640	
points:	35.4	mins	
RM2	(Section	1:	
Region	4):	238	
points:	4.4	mins	
15.33592	 LGD	 03/08/16	 03/08/16	 03/08/16	 03/08/16	 04/08/16	
RM3	(Section	3:	
Region	1):	5483	
points:	65	mins	
RM2	(Section	1:	
Region	2):	7812	
points:	100	mins	
RM1	(Section	2:	
Region	3):	5950	
points:	75	mins	 X	
15.34297	 HGD	 04/08/16	 04/08/16	 04/08/16	 04/08/16	 04/08/16	
RM6	(Section	1:	
Region	1):	3477	
points:	45	mins	
RM5	(Section	5:	
Region	2):	1404	
points:	18	mins	
RM4	(Section	
4+2:	Region	3):	
11025	points:	130	
mins	 X	
15.20106	 AC	 18/08/16	 18/08/16	 18/08/16	 18/08/16	 25/08/16	
RM1	(Section2:	
Region	1):	6402	
points:	79	mins	
RM3	(Section	6:	
Region	2):	1927	
points:	26	mins	
RM2	(Section	5:	
Region	3):	7004	
points:	88	mins	 X	
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15.32635	 BE	 04/08/16	 04/08/16	 04/08/16	 04/08/16	 08/08/16	
RM1	(Section	2:	
Region	1):	2528	
points:	31	mins	
RM2	(Section	1:	
Region	2):	1505	
points:	21	mins	 X	
RM3	(Section	1:	
Region	4):	1540	
points:	19	mins	
15.30884	 LGD	 08/08/16	 08/08/16	 08/08/16	 08/08/16	 08/08/16	
RM1	(Section	3:	
Region	1):	1476	
points:	20	mins	
RM2	(Section	4:	
Region	2):	1485	
points:	19	mins	
RM3	(Section	1:	
Region	3):	8330	
points:	101	mins	 X	
15.32885
_2	 HGD	 17/08/16	 17/08/16	 17/08/16	 17/08/16	 22/08/16	
RM1	(Section	3:	
Region	1):	5504	
points:	70	mins	
RM2	(Section	4:	
Region	2):	2268	
points:	31	mins	
RM3	(Section	1:	
Region	3):	1740	
points:	25	mins	 X	
15.17409
_1	 AC	 08/08/16	 08/08/16	 08/08/16	 08/08/16	 15/08/16	
RM1	(Section	3:	
Region	1):	6083	
points:	75	mins	
RM3	(Section	1:	
Region	2):	9494	
points:	116	mins	
RM2	(Section	2:	
Region	3):	4473	
points:	57	mins	 X	
15.29335	 BE	 08/08/16	 08/08/16	 08/08/16	 08/08/16	 11/08/16	
RM4	(Section	4:	
Region	1):	11960	
points:	142	mins		
RM2	(Section	2:	
Region	2):	5859	
points:	75	mins		 X	
RM3	(Section	1:	
Region	4):	3132	
points:	40	mins	
15.30026	 LGD	 09/08/16	 09/08/16	 09/08/16	 09/08/16	 16/08/16	
RM1	(Section	1:	
Region	1):	9744	
points:	117	mins	
Section:	High	
fuscin	content	
RM2	(Section	2:	
Region3):	1386	
points:	20	mins	
RM3	(Section	3:	
Region	4):	1640	
points:	22	mins	
15.32885
_3	 HGD	 09/08/16	 09/08/16	 09/08/16	 X	 09/08/16	
RM1	(Section1:	
Region	1):	108350	
points:	131	mins	
RM3	(Section	3:	
Region	2):	1833	
points:	25	mins	
RM3	(Section	2:	
Region	3):	7797	
points:	98	mins	 X	
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15.17409
_2	 AC	 09/08/16	 09/08/16	 09/08/16	 09/08/16	 09/08/16	
RM1	(Section	3:	
Region	1):	2250	
points:	30	mins	
RM	2	(Section	2:	
Region	2):	2538	
points:	34	mins	 X	
RM3	(Section	2:	
Region	4):	675	
points:	10	mins	
15.25743
_1	 BE	 09/08/16	 09/08/16	 09/08/16	 09/08/16	 16/08/16	
RM1	(Section	3:	
Region	1):	1400	
points:	18	mins	
RM2	(Section	3:	
Region	2):	2356	
points:	30	mins	
RM3	(Section	4:	
Region	3):	943	
points:	13	mins	 X	
15.19302
_1	 LGD	 09/08/16	 09/08/16	 09/08/16	 09/08/16	 11/08/16	
RM1	(Section	1:	
Region	1):	5561	
points:	93	mins	 X	
RM2	(Section	1:	
Region	3):	1978	
points:	27	mins	
RM3	(Section	1:	
Region	4):	640	
points:	9	mins	
15.28130	 HGD	 18/08/16	 18/08/16	 18/08/16	 18/08/16	 26/08/16	 X	 X	
RM1	(Section	1:	
Region	3):	12420	
points:	147	mins	 X	
15.16592	 AC	 09/08/16	 09/08/16	 09/08/16	 09/08/16	 18/08/16	
RM1	(Section	1:	
Region	1):	3312	
pints:	42	mins	
RM3	(Section	2:	
Region	2):	7216	
points:	89	mins	
RM2	(Section	4:	
Region	3):	6000	
points:	74	mins	 X	
15.25743
_2	 BE	 11/08/16	 11/08/16	 11/08/16	 11/08/16	 17/08/16	
RM1	(Section	1:	
Region	1):	1608	
points:	20	mins	 X	
RM2	(Section	2:	
Region	3):	812	
points:	12	mins	
RM3	(Section	2:	
Region	4):	1887	
points:	25	mins	
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15.19302
_2	 LGD	 17/08/16	 17/08/16	 17/08/16	 17/08/16	 23/08/16	
RM2	(Section	2:	
Region	1):	4466	
points:	56	mins	
RM1	(Section	1:	
Region	2):	4350	
points:	53	mins	 X	
RM3	(Section	2:	
Region	4):	2480	
points:	32	mins	
15.26104	 HGD	 11/08/16	 11/08/16	 11/08/16	 11/08/16	 15/08/16	
RM3	(Section	3:	
Region	1):	924	
points:	13	mins	
RM1	(Section	7:	
Region	2):	3552	
points:	47	mins	
RM2	(Section	2:	
Region	3):	2112	
points:	30	mins	 X	
15.15313	 AC	 17/08/16	 17/08/16	 17/08/16	 17/08/16	 17/08/16	
RM1	(Section	2:	
Region	1):	11421	
points:	141	mins	
RM2	(Section	1:	
Region	2):	5609	
points:	70	mins	
RM3	(Section	4:	
Region	3):	1716	
points:	23	mins	 X	
15.25742
_1	 LGD	 19/08/16	 19/08/16	 19/08/16	 X	 22/08/16	
RM3	(Section	1:	
Region	1):	4355	
points:	55	mins	
RM2	(Section	2:	
Region	2):	2294	
points:	30	mins	
RM1	(Section	2:	
Region	3):	1590	
points:	23	mins	 X	
15.20664
_5G	 AC	 19/08/16	 19/08/16	 X	 X	 05/09/16	
RM1	(Section	1:	
Region	1):	27816	
points:	324	mins	 		 		 		
15.25742
_2	 LGD	
Not	
present	 23/08/16	
Section	3	
(?HGD):	
23/8/16	 		 05/09/16	 Not	present	
RM1	(Section	2:	
Region	2):	5546	
points:	71	mins	
RM2	(Section	4:	
Region	3):	12348	
points:	150	mins	 		
15.30026
_3	 LGD	 22/08/16	 22/08/16	 22/08/16	 22/08/16	 26/08/16	
RM1	(Section	1:	
Region	1):	2491	
points:	33	mins	
RM2	(Section	1:	
Region	2):	3626	
points:	45	mins	
RM3	(Section	2:	
Region	3):	900	
points:	13	mins	 X	
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15.17961	 AC	 23/08/16	 23/08/16	 23/08/16	 X	 26/08/16	
RM1	(Section	1:	
Region	1):	18120	
points:	217	mins	
RM2	(Section	1:	
Region	2):	8148	
points:	100	mins	 X	 X	
15.19041	
LGD	
(?HGD)	 22/08/16	 22/08/16	 22/08/16	 X	 28/09/16	
RM1	(Section	2:	
Region	1):	6161	
points:	74	mins	
RM2	(Section	1:	
Region	2):	2860	
points:	37	mins	 X	 X	
15.19299
_2	 BE	 19/08/16	 19/08/16	 19/08/16	 X	 23/08/16	
RM1	(Section	1:	
Region	1):	2068	
points:	27	mins	
RM2	(Section	2:	
Region	2):	2664	
points:	37	mins	
RM3	(Section	3:	
Region	3):	3825	
points:	48	mins	 X	
15.20664
_5C	 AC	 22/08/16	 X	 X	 X	 06/09/16	
RM1	(Section	1:	
Region	1):	27248	
points:	324	mins	 X	 X	 X	
15.25358	 BE	 22/08/16	 22/08/16	 22/08/16	 X	 25/08/16	
RM1	(Section	2:	
Region	1):	5742	
points:	71	mins	 X	
RM2	(Section	4:	
Region	3):	4554	
points:	61	mins	 X	
15.21320	 HGD	 22/08/16	 22/08/16	 22/08/16	 22/08/16	 25/08/16	
RM1	(Section	1:	
Region	1):	2325	
points:	29	mins	
RM2	(Section	8:	
Region	2):	3248	
points:	42	mins	
RM3	(Section	4:	
Region	3):	2628	
points:	32	mins	 X	
15.00079	 HGD	 19/08/16	 19/08/16	 X	 X	 25/08/16	
RM1	(Section	1:	
Region	1):	15827	
points:	188	mins	
RM2	(Section	1:	
Region	2):	
18200	points:	
212	mins	 X	 X	
	120	
15.19299
_1	 BE	 22/08/16	 22/08/16	 22/08/16	 X	 26/08/16	
RM1	(Section	3:	
Region	1):	3200	
points:	42	mins	
RM2	(Section	2:	
Region	2):	2886	
points:	40	mins	
RM3	(Section	4:	
Region	3):	1628	
points:	22	mins	 X	
15.17268	 AC	 25/08/16	 25/08/16	 X	 X	 27/09/16	
RM1	(Section	1:	
Region	1):	16074	
points:	192	mins	
RM2	(Section	1:	
Region	2):	5475	
points:	68	mins	 X	 X	
15.11932	 LGD	 25/08/16	 25/08/16	 25/08/16	 X	 06/09/16	
RM1	(Section	1:	
Region	1):	2346	
points:	33	mins)		
RM2	(Section	1:	
Region	2):	5600	
points:	72	mins	 X	 X	
15.05026	 BE	 25/08/16	 25/08/16	 25/08/16	 X	 30/09/16	 X	
RM1	(Section	2:	
Region	2):	9047	
points:	112	mins	
RM2	(Section	2:	
Region	3):	6634	
points:	85	mins	 X	
14.35789	 HGD	 25/08/16	 25/08/16	 25/08/16	 X	 06/09/16	
RM1	(Section	1:	
Region	1):	3087	
points:	40	mins	
RM2	(Section	2:	
Region	2):	1995	
points:	28	mins	
RM3	(Section	2:	
Region	3):	3139	
points:	40	mins	 X	
15.18519	 AC	 25/08/16	 X	 X	 X	
Slide	
broken	 X	 X	 X	 X	
15.08465
_2	 LGD	 25/08/16	 25/08/16	
Slide	
broken	 X	
Slide	
broken	 X	 X	 X	 X	
15.21473
_2	 BE	 25/08/16	 X	 X	 X	 26/09/16	
RM1	(Section	1:	
Region	1):	4717	
points:	62	mins	 X	 X	 X	
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14.35738	 HGD	 25/08/16	 25/08/16	 25/08/16	 X	 06/09/16	
RM1	(Section	1:	
Region	1):	1024	
points:	15	mins	
RM2	(Section	2:	
Region	2):	3268	
points:	44	mins	
RM3	(Section	3:	
Region	3):	1295	
points:	18	mins	 X	
15.15382	 NSq	 26/09/16	 26/09/16	 X	 X	 28/09/16	
RM1	(Section	1:	
Region	2):	2079	
points:	26	mins	
RM2	(Section	2:	
Region	2):	1150	
points:	16	mins	 X	 X	
16.24149	 NSq	 06/09/16	 06/09/16	 06/09/16	 06/09/16	 28/09/16	
RM1	(Section	1:	
Region	1):	4346	
points:	52	mins	
RM2	(Section	1:	
Region	2):	1530	
points:	22	mins	 X	 X	
16.13136	 NSq	 06/09/16	 06/09/16	 06/09/16	 06/09/16	 29/09/16	
RM1	(Section	1:	
Region	1):	1829	
points:	26	mins	
RM2	(Section	3:	
Region	2):	3822	
points:	50	mins	
RM3	(Section	4:	
Region	3):	2867	
points:	38	mins	 X	
14.25714
_2	 NSq	 06/09/16	 06/09/16	 06/09/16	 06/09/16	 29/09/16	
RM1	(Section	1:	
Region	1):	3102	
points:	39	mins	
RM2	(Section	2:	
Region	2):	2310	
points:	30	mins	 X	
RM3	(Section	2:	
Region	4):	1323	
points:	17	mins	
16.24074	 NSq	 26/09/16	 26/09/16	 26/09/16	 X	 28/09/16	
RM1	(Section	1:	
Region	1):	13568	
points:	164	mins	 X	 X	 X	
16.2339	 NSq	 26/09/16	 X	 X	 X	 29/09/16	
RM1	(Section	1:	
Region	1):	8844	
points:	105	mins	 X	 X	 X	
16.23855	 NSq	 26/09/16	 26/09/16	 26/09/16	 26/09/16	 Slide	 X	 X	 X	 X	
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broken	
15.8037	 NSq	 26/09/16	 26/09/16	 X	 X	 29/09/16	
RM1	(Section	1:	
Region	1):	3256	
points:	40	mins	 X	 X	 X	
16.23626	 NSq	 06/09/16	 06/09/16	 06/09/16	 06/09/16	 26/09/16	
RM1	(Section1:	
Region	1):	4876	
points:	65	mins	
RM2	(Section	2:	
Region	2):	4000	
points:	53	mins	
RM3	(Section	3:	
Region	3):	2688	
points:	32	mins	 X	
16.23342	 NSq	 06/09/16	 06/09/16	 06/09/16	 06/09/16	 29/09/16	 X	 X	
RM1	(Section	2:	
Region	3):	3626	
points:	48	mins	
RM2	(Section	2:	
Region	4):	3496	
points:	44	mins	
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Appendix III 
Autofluorescent Results 
Normal Squamous Tissue 
 
476nm    488nm              496nm 
 
Barrett’s oesophagus without Dysplasia 
 
476nm    488nm              496nm 
 
Barrett’s oesophagus with Low Grade Dysplasia 
 
476nm    488nm              496nm 
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Barrett’s oesophagus with High Grade Dysplasia 
 
476nm    488nm              496nm 
 
Oesophageal Adenocarcinoma 
 
476nm    488nm              496nm 
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Appendix IV 
Biochemical Peak Assignment 
 Wavenumber 
(cm-1) 
Reference 
Glycogen 470 Hutchings et al 2010 
484-90 Hutchings et al 2010, Almond et al 
2013 
852-5 Shetty et al 2006, Hutchings et al 
2010 
933-7 Shetty et al 2006, Almond et al 
2013 
944 Hutchings et al 2010 
1036 Hutchings et al 2010 
1048 Shetty et al 2006 
1086-8 Hutchings et al 2010, Almond et al 
2013 
1128 Almond et al 2013 
1135 Hutchings et al 2010 
1133-8 Shetty et al 2006, Hutchings et al 
2010 
1467 Hutchings et al 2010 
DNA 719-20 Shetty et al 2006 
748-55 Shetty et al 2006 
781-5 Shetty et al 2006, Hutchings et al 
2010, Almond et al 2013 
885 Almond et al 2013 
1334-5 Almond et al 2013, Bergholt et al 
2014 
1576-9 Hutchings et al 2010, Bergholt et 
al 2014 
1663 Shetty et al 2006 
Nucleic Acids 1018-21 Almond et al 2013 
1173 REF 62 
1360 Almond et al 2013 
1511 Almond et al 2013 
Protein 820 Shetty et al 2006 
852-5 Hutchings et al 2010 
884 Shetty et al 2006 
936-40 Hutchings et al 2010, Bergholt et 
al 2014 
1036 Hutchings et al 2010 
1223 Shetty et al 2006 
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1261 Hutchings et al 2010 
1265 (Amide 
III) 
Bergholt et al 2014 
1278 Shetty et al 2006 
1312 Hutchings et al 2010 
1453 Hutchings et al 2010 
1655-9 (Amide 
I) 
Hutchings et al 2010, Bergholt et 
al 2014 
1663 Shetty et al 2006 
Phenylalanine 1001-4 Hutchings et al 2010, Bergholt et 
al 2014 
1031 McManus et al 2012 
Lipids 968 Dukor et al 2002 
1078 Bergholt et al 2014 
1302 Bergholt et al 2014 
1745 Bergholt et al 2014 
Lactic Acid 750 Shetty et al 2006 
918 Shetty et al 2006 
Glucose 842 Rehman et al 1995 
Porphyrins 1618 Bergholt et al 2014 
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Appendix V 
Posters 
 
Towards an understanding of the biochemical changes of dysplasia.          
Upchurch E, Old OJ, Lloyd GR, Isabelle M, Shepherd N, Stone N, Kendall C 
and Barr H.                                                                    
SPEC: International Spectroscopy Conference: Montreal, Canada, June 2016. 
 
Developments in Infrared Spectroscopy of colorectal pathology.               
Upchurch E, Old OJ, Griggs R, Woods J, Lloyd GR, Isabelle M, Shepherd N, 
Cook T, Nallala J, Barr H, Stone N and Kendall C.                                                                                                                                                  
Faraday Discussions: Advances in Vibrational Spectroscopy.  Cambridge, 
England.   March 2016.   
 
 
 
 
 
 
 
 
 
FTIR	  Classifica-on	  of	  Colorectal	  Pathology	  	  
 
Sample	  collec-on	  &	  prepara-on:	  
§ 	  Colorectal	  *ssue	  biopsies	  were	  snap	  frozen	  at	  colonoscopy.	  
§ 10μm	  thick	  *ssue	  sec*ons	  microtomed	  onto	  CaF2	  slides	  for	  FTIR.	  
§ 	  Con*guous	  H+E	  sec*ons	  reviewed	  by	  specialist	  GI	  pathologist	  &	  
iden*fied	  as	  normal,	  hyperplas*c,	  adenoma,	  cancer	  or	  ulcera*ve	  
coli*s.	  
Infrared	  spectroscopy:	  
§ 	   Spectral	  maps	   of	   samples	   were	  measured	   using	   Perkin	   Elmer	  
Spotlight	  400	  Spectrum	  One	  infrared	  imaging	  system	  (figure	  1)	  
§  	   Spectra	   were	   selected	   from	   areas	   of	   epithelium	   for	   analysis	  
using	   ‘in	   house’	   developed	   soSware.	   Mean	   spectra	   for	   each	  
pathology	  group	  are	  shown	  in	  figure	  2.	  
§ 	  Epithelial	  spectra	  were	  classified	  according	  to	  source	  pathology	  
type	  using	  a	  mathema*cal	  model	  (Principal	  Components	  analysis	  
with	   Linear	   Discriminant	   Analysis	   and	   Leave	   One	   Out	   Cross	  
Valida*on);	  	  sensi*vi*es	  91.6-­‐100%	  and	  specifici*es	  97.7-­‐99.9%.	  	  
Fig. 1: PE	  FTIR	  Spectrometer 	  	  	  	  	  	  	  	  	  Fig. 2: Mean FTIR	  
	  
	  
 
 
. 
 
 
 
 
Fig. 3: Linear	  discriminant	  score	  plots	  showing	  good	  visual	  discrimina*on	  between	  
spectra.	  Normal	  (blue),	  hyperplas*c	  polyp	  (red),	  adenoma	  (green),	  adenocarcinoma	  
(yellow)	  and	  ulcera*ve	  coli*s	  (cyan).	   
	  Developments	  in	  infrared	  spectroscopy	  of	  colorectal	  pathology	  
Emma	  Upchurch*1,2,4,	  Rebecca	  Griggs1,2,4,	  James	  J.	  Wood1,	  2,	  Gavin	  R.	  Lloyd2,	  Mar*n	  Isabelle2,	  Neil	  A.	  
Shepherd3,	  Tim	  A.	  Cook1,	  Jayakrupakar	  Nallala4,	  Nick	  Stone4	  and	  Catherine	  A.	  Kendall2	  
j	  
*emma.upchurch.glos.nhs.uk	  
	  
Introduc-on	  
Colorectal	   cancer	   is	   the	   second	   most	   common	   cause	   of	   cancer	  
death	   in	   the	   UK	   and	   accounts	   for	   13%	   of	   all	   new	   cancer	   cases	  
each	   year.	   Most	   cancers	   arise	   from	   pre-­‐exis*ng	   adenomatous	  
polyps.	  Histopathology	  provides	  the	  gold	  standard	  assessment	  of	  
colonoscopic	  biopsies,	  however	  improved	  tools	  are	  sought.	  
 
Infrared	   spectroscopy	   (FTIR)	   can	   be	   used	   to	   map	   biochemical	  
concentra*ons	  across	  a	  *ssue	   sec*on	  and	  discriminate	  between	  
disease	  states.	  FTIR	  may	  therefore	  aid	  the	  diagnosing	  pathologist	  
and	  	  lead	  to	  automated	  histopathological	  processing.	  
Conclusions	  
Infrared	   spectral	   imaging	   demonstrates	   the	   ability	   to	   map	   *ssue	  
sec*ons	   at	   high	   resolu*on,	   providing	   biochemical	   informa*on	   that	  
correlates	  with	  disease	  state	  and	  suitability	  for	  the	  automated	  analysis	  
of	  specimens.	  
	  
The	  exact	  nature	  of	  the	  biochemical	  change	  that	  results	  in	  the	  spectral	  
picture	   has	   not	   been	   delineated.	   	   It	   is	   hypothesised	   that	   the	   level	   of	  
apoptosis	   changes	   with	   dysplasia	   and,	   thus,	   apopto*c	   breakdown	  
products	  may	  themselves	  have	  a	  dis*nc*ve	  auofluorescent	  or	  spectral	  
signature	  that	  can	  be	  used	  in	  diagnosis.	  	  
	  
Melanosis	   coli,	   a	   benign	   condi*on	   of	   the	   colon,	   is	   characterised	   by	  
epithelial	   cell	   apoptosis.	   	   Using	   this	   *ssue	   as	   a	   template	   may,	   thus,	  
enable	   the	   iden*fica*on	   of	   apopto*c	   breakdown	   products	   and	  
determine	  their	  presence	  in	  colonic	  and	  oesophageal	  *ssue.	  	  	  
High	  Resolu-on	  Imaging	  of	  Colorectal	  disease	  
 
Sample	  collec-on	  &	  prepara-on:	  
§  	   65	   blocks	   of	   archive	   formalin	   fixed	   paraffin	   embedded	   (FFPE)	  
colorectal	  *ssue	  was	  microtomed	  onto	  CaF2	  slides	  (10μm	  thick)	  for	  FTIR	  
imaging.	  
§  	   Con*guous	   sec*ons	   were	   stained	   with	   Haematoxylin	   &	   Eosin	   for	  
review	  by	  a	   specialist	  GI	  pathologist	  &	   iden*fied	  as	  normal,	  dysplasia,	  
polyp	  cancer,	  cancer	  or	  epithelial	  misplacement.	  
	  
Infrared	  spectroscopy:	  
§  	   Spectral	   maps	   of	   samples	   were	   measured	   using	   Agilent	   620	   FTIR	  
imaging	  system.in transmission mode with 1.1 micron resolution (figure	  
4).	  
§ 	  Spectra	  were	  selected	  from	  areas	  of	  epithelium	  for	  analysis	  using	  ‘in	  
house’	  developed	  soSware.	  Mean	  spectra	  for	  each	  pathology	  group	  are	  
shown	  in	  figure.	  
§ 	  Principal	  Component	  Analysis	  with	  Linear	  Discriminant	  Analysis	  of	  the	  
spectral	   peaks	  was	   performed	   to	   elucidate	   spectral	   differences	   across	  
the	  dataset.	  
	  
 
 
 
 
 
  Fig. 4: Agilent	  high-­‐res	  FTIR	  Spectrometer	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 Developments in infrared spectroscopy of colorectal pathology: 
Towards an understanding of the biochemical changes of dysplasia 
E Upchurch*1,2,4, O Old1,2,4, R Griggs1,2,4, J Woods1, 2, G Lloyd2, M Isabelle2, N Shepherd3, T Cook1, J Nallala4, H Barr, N Stone4 and C Kendall2 
j 
*emma.upchurch.glos.nhs.uk 
Introduction 
Colorectal cancer is the 2nd most common cause of cancer death in the 
UK, accounting for over 16000 deaths in 2012.  Each year approximately 
41000 cases are diagnosed [1].  When diagnosed at an early stage >90% of 
patients survive for at least 5 years.  This drops to <10% when diagnosed 
at a late stage.  Diagnosing early changes representing disease is, 
therefore, of paramount importance.   
Conclusions 
Infrared spectral imaging demonstrates the ability to map tissue sections at 
high resolution, providing biochemical information that correlates with 
disease state.  The exact nature of the biochemical change that results in 
the spectral picture for each pathology has not been delineated.   
 
As colorectal cancer progresses from adenomatous changes, through 
dysplasia and finally to adenocarcinoma, and that this progression is 
characterised by increasing levels of apoptosis, it may be that a portion of 
the spectral changes are caused by the changes of apoptosis or by the 
products formed by apoptosis. 
 
Melanosis coli, due to the high volume of lipofuscin, provides an ideal 
model for characterising and investigating both the pigment and apoptosis.  
High resolution infra red has been shown to differentiate between tissues 
that, even to an experienced Histopathologist, are visually unable to be 
distinguished from each other.  It may be that this modality is able to detect 
differences in the melanosis coli tissue which is due to apoptosis and that, 
once identified, can be seen in and used to aid differentiation of different 
colorectal pathologies. 
High Resolution Imaging 
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Development of Colorectal Carcinoma 
The majority of colorectal carcinomas develop through a well established 
pathway of adenoma to carcinoma (Figure 1) [2].  Genetic alternations 
affecting the regulation of the cell cycle occur as the cells progress along 
this pathway.  Apoptosis, the programmed death of a cell, generally 
increases as cells move along this pathway and become more abnormal. 
Figure 1: Diagrammatical Representation of the  
pathway of adenoma - carcinoma 
Classification of Colorectal Pathology 
High resolution imaging using the 
Agilent 620 FTIR imaging system with a 
pixel resolution of 1.1 microns was able 
to discriminate between colorectal 
cancer and colonic epithelial 
misplacement (Figure 4), a benign 
pathology of the intestine that mimics 
invasive carcinoma, causing significant 
diagnostic difficulties [3].  An average 
sensitivity of 75% and specificity of 82% 
was found.  
Epithelial spectra were classified according to source pathology type using 
a mathematical model (Principle Components Analysis with Linear 
Discriminant Analysis and Leave One Out Cross Validation) (Figure 3) with 
sensitivites of 91.6-100% and specificities of 97.7-99.9%. 
Snap frozen colorectal tissue 
biopsies were measured using a 
Perkin Elmer Spotlight 400 
Spectrum One infrared imaging 
system.  Spectral maps for each 
pathology group (normal tissue, 
hyperproliferative, adenoma, 
carcinoma and ulcerative colitis) 
were measured.  The mean spectra 
are shown in Figure 2. 
Figure 2: Mean FTIR spectra 
Figure 3: Linear discriminant score plots showing good visual discrimination between spectra.  Normal (blue), hyperplastic polyp 
(red), adenoma (green), adenocarcinoma (yellow) and ulcerative colitis (cyan) 
Figure 4: LDA Histogram clustering of Two 
Group Model.  Purple = Epithelial 
Displacement: Black = Carcinoma 
Can we identify apoptosis? 
Infra red imaging has been able to distinguish between different pathology 
types.  High resolution imaging can detect subtle changes in tissues that, 
visually, pathologists find difficult to differentiate.  Could the biochemical 
changes that occur in dysplasia, i.e.: apoptosis, be detectable with infra red 
imaging and, thus, enable earlier diagnosis if used clinically? 
Melanosis coli is a benign condition 
of the colon, characterised by 
increased apoptosis of the epithelial 
cells.  The apoptotic cell fragments 
fuse with lysosomes after their 
phagocytosis by macrophages, 
resulting in the formation of lipofuscin 
[4].  Lipofuscin, a breakdown product 
of apoptosis, causes the classical 
pigmentation of the colon. 
All tissues produce autofluorescence when illuminated.  Dysplastic 
epithelial cells were found to be a source of autofluorescence [5].   
Lipofuscin may be the source of the autofluorescence seen in dysplastic 
cells  and may represent dysregulated waste disposal. 
Melanosis Coli as a model 
Figure 5: Macroscopic appearance of  
melanosis coli 
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Abstract
The incidence of Barrett’s oesophagus and oesophageal adenocarcinoma is increasing in Western countries. The outcome for patients with oesophageal cancer is 
extremely poor with only 15.1% of patients surviving for 5 years. The dismal outcome is largely due to late diagnosis which eliminates many patients from effective 
treatment.
Oesophageal adenocarcinoma is often preceded by the development of dysplasia in a segment of Barrett’s oesophagus. With the current surveillance strategies, it 
is extremely difficult to not only visualise areas of dysplasia, but also to accurately identify their morphological and architectural changes during histopathological 
diagnosis. Consensus statements recommend mucosal resection for dysplastic change in the oesophagus, thereby, preventing the development of adenocarcinoma. 
This strategy requires improved diagnostic tools that can reliably distinguish patients with dysplasia.  
Years of research have looked at a variety of different modalities that may aid with the current dilemma of difficulties in diagnosing dysplasia. This review looks at the 
modalities under development and analyses their advantages and the part they may well play in the future. It also looks at the future avenues that could be explored 
to aid in the understanding of the disease and to improve the outcomes.
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Introduction
The recent increase in the incidence of Barrett’s oesophagus and 
oesophageal adenocarcinoma, especially in Western countries, has 
fuelled the sharp rise in the number of studies attempting to understand 
this disease as well as the development of improved diagnostic 
modalities that can detect its very early stages and even predict those at 
greatest risk of disease progression.
Current diagnostic techniques and advancements in surgery with 
a move to a minimally invasive approach have failed to impact on 
the mortality rates for oesophageal adenocarcinoma with the 5 year 
survival floundering at 15.1%, making this the fifth leading cause of 
cancer-related death in men worldwide [1]. The paramount focus 
must, therefore, be on the improved detection and diagnosis of the 
early changes of disease that will facilitate early treatment and will, 
therefore, revolutionize the mortality statistics.
Barrett’s oesophagus
Barrett’s oesophagus, originally described in 1950 [2], is an 
acquired condition, characterised by the replacement of normal 
squamous epithelium by columnar epithelium in a process termed 
metaplasia. It is a premalignant condition that predisposes to the 
development of oesophageal adenocarcinoma, although the overall risk 
is small with the conversion rate of oesophageal adenocarcinoma from 
Barrett’s oesophagus being 0.5% per year [3]. It has been established that 
adenocarcinoma develops through a multi-step morphological pathway, 
characterised by increasing grades of dysplasia [4], and it is the presence 
and grade of dysplasia that is currently the only marker that is able to 
delineate those at a higher risk of progression to adenocarcinoma. 
This is, however, not a perfect method. The natural history of high 
grade dysplasia remains debatable with certain factors correlated with a 
higher risk of progression, including central obesity, length of Barrett’s 
segment, insulin resistance and serum levels of leptin [5]. The natural 
course of low grade dysplasia is more hotly contested with some 
evidence indicating that this can regress, although this may be related 
to initial inaccurate diagnosis [6]. Persistent low grade dysplasia was, 
however, associated with disease progression [7]. 
Dysplasia
The recognition of dysplasia is extremely complex. The major 
difficulty is our ability to detect and biopsy the areas with dysplasia. 
Although metaplasia is apparent macroscopically at endoscopy, areas 
of dysplasia are not always identifiable. The current protocol is, thus, 
for random biopsies from each quadrant of the oesophagus at every 
1-2 cm interval in a macroscopically columnar lined area, known as 
the Seattle Protocol. Even if properly adhered to, significant pathology 
can be missed; 40% of resections undertaken for presumed high grade 
dysplasia had an occult malignancy detected during histological 
analysis which had not been identified on the preoperative diagnostic 
endoscopy [8,9]. Additional studies indicate that 34% of early stage 
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oesophageal cancers (both squamous and adenocarcinoma) had not 
been recognised in preceding endoscopies [10].   
The problem does not end there. Even if areas with dysplasia are 
randomly selected for biopsy, there can be considerable difficulty 
in determining the degree of abnormality present. Dysplasia is 
characterised by multiple morphological changes and it is often the 
degree of the abnormalities that determines not only if dysplasia 
is present, but also its grade (Figure 1). The criteria for a diagnosis 
of low grade dysplasia includes preserved nuclear polarity, nuclear 
heterogenicity and margination, few mitoses and decreased numbers of 
transition to adjacent glandular epithelium [11]. Architectural changes 
should be absent or minimal. 
With a complex array of changes, it is hardly surprising that there 
is a high degree of intra- and inter-observer variability [12-14] in 
assigning a grade to these patients. The assessment is highly subjective 
and dependent on experience. It is, however, vitally important as the 
diagnosis of low grade dysplasia documents a watershed transition in 
the course of the disease and has significant management implications.
Parallel to the morphological changes seen in dysplasia, genetic 
alterations occur which alter gene expression and, subsequently, the 
regulation of the cell cycle. There is evidence, for example, that p16 
hypermethylation is an early predictor of progression in Barrett’s 
oesophagus, especially in low grade dysplasia [15]. Extensive evidence 
shows that p53 overexpression is seen in both cancerous and high 
grade dysplasia and is, thus, predictive of progression [16]. This could 
be an excellent predictive tool when its overexpression is detected by 
immunohistochemistry [17]. Due to the complexity of the control of 
the cell cycle and the amount of genetic alterations that can occur, it 
is likely that mutations will vary between patients and there may not 
be a single trigger that will be able to explain, nor predict, progression, 
but rather an accumulation of changes that will ultimately push the cell 
towards carcinoma. 
Dysplasia is, nevertheless, despite its problems, the best method 
that we currently have at our disposal to identify risk of progression 
to adenocarcinoma and, thus, to identify patients who would benefit 
from early, minimally invasive endoscopic intervention. Consensus 
statements generated through a Delphi process [3,18] recommend 
that endoscopic ablation or resection is undertaken in the presence of 
established dysplastic degeneration, making the accurate assessment of 
dysplasia a vital process. This logically leads to improved outcomes as a 
cohort of patients will be able to avoid the development of oesophageal 
adenocarcinoma and the major undertaking of an oesophagectomy. 
Identifying dysplasia
Endoscopic surveillance and biopsy is at present the mainstay for 
identifying dysplasia in Barrett’s oesophagus. Endoscopic screening for 
Barrett’s oesophagus is, at present, being suggested for men aged 60 
years with prolonged (>10 years) reflux symptoms [3] as their risk of 
progression to dysplasia and adenocarcinoma is greatest. Population 
based screening is not recommended due to the low rate of conversion 
of Barrett’s oesophagus to adenocarcinoma [19]. Controversy does, 
however, remain as to the frequency of surveillance endoscopy and 
which patients require more intensive surveillance and in whom it 
can be stopped. A large RCT is currently underway to help solve this 
dilemma [20]. 
Surveillance has been shown to be beneficial as surveillance leads 
to diagnosis of oesophageal adenocarcinoma at an earlier stage and, 
hence, leads to improved survival [21]. The outcomes were better when 
compared to patients diagnosed outside of a screening programme and 
dramatically better than those who had already become symptomatic 
[22]. 
The main quandary is how to bring forward the diagnosis 
of dysplasia to allow earlier, and ultimately minimally invasive 
endoscopic intervention. Even if there is a genetic breakthrough which 
is able to identify a higher risk cohort, visualisation of the oesophagus 
with targeted biopsy of abnormal areas alongside a higher degree of 
assurance in dysplastic staging will still be required. A number of 
optical techniques have been and are still being investigated for these 
purposes. They offer the potential of detecting changes very early in 
the cancerous process, at the microstructural and molecular level, far 
earlier than the morphological changes that are needed for detection 
by traditional endoscopy. They offer additional information to 
differentiate dysplastic from non-dysplastic tissue and high grade from 
low grade dysplasia.  
Optical diagnostic techniques, which are being used and are under 
development, are high resolution endoscopy, chromoendoscopy, 
narrow band imaging, optical coherence tomography, autofluorescence, 
immunophotodiagnostic endoscopy, confocal fluorescence 
microendoscopy, light scattering spectroscopy, Raman spectroscopy 
and infrared spectroscopy. No single modality has surged ahead and 
is able to satisfy all difficulties being faced and it is, thus, increasingly 
likely that a combination of techniques will be required to enable early 
disease detection and to reverse the dismal outcomes of oesophageal 
adenocarcinoma.
Optical techniques
High resolution endoscopy (HRE)
Traditional endoscopes are able to generate a 300,000 pixel image. 
High resolution endoscopes are able to generate images with greater 
than 1,000,000 pixels. Unsurprisingly, high resolution endoscopes 
have been shown to have a higher sensitivity than standard white light 
endoscopy for the detection of Barrett’s oesophagus [23, 24], although 
the majority of evidence focuses on their use by expert endoscopists. 
The performance of and experience of the endoscopist contributes 
significantly to the detection of neoplasia, with mean inspection time 
per cm of Barrett’s oesophagus having a significant impact [25]. The 
improved sensitivity is, by no means, perfect with only 79% of dysplasia 
detected [23], and with a substantial inter-observer variability identified 
[23,26]. Consensus guidelines have, nevertheless, recommended its use 
in expert centres [3] as it does go some way to improving the detection 
of abnormal areas. Figure 1. Focal area of high grade dysplasia in an endoscopic resection specimen.
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Chromoendoscopy
High resolution endoscopy has, in some studies, obtained better 
results when used in conjunction with chromoendoscopy [27] although 
this is not consistent [26]. Chromoendoscopy describes the exogenous 
administration of specialised dyes, including Lugols solution and 
methylene blue, onto the mucosal surface. They are typically sprayed 
onto the mucosal surface via a specifically designed catheter at the 
time of endoscopy. The stains enhance the detection of subtle mucosal 
irregularities that may otherwise be invisible [28].
Lugol’s solution interacts with glycogen within minutes of its 
application in normal squamous epithelium resulting in a brown / 
black discoloration. In contrast, it does not stain columnar epithelium 
and, thus, can be useful in distinguishing squamous from columnar 
epithelium [28]. It has been shown to be effective in identifying early 
squamous cell cancer in the oesophagus and has been used for this 
application by Japanese endoscopists in patients who have previously 
had a diagnosis of head or neck cancer [29].
Methylene blue stains the intestinal metaplasia that defines 
Barrett’s oesophagus and has an almost 100% correlation with Barrett’s 
epithelium [28]. Despite highlighting areas of Barrett’s, the staining 
does not appear to aid the identification of areas of dysplasia. Acetic 
acid is another dye which enhances surface topography and has been 
shown, in some studies, to be superior to white light endoscopy in the 
localisation of dysplasia in Barrett’s oesophagus [30]. 
Chromoendoscopy seems to be a sensible solution to improve the 
diagnostic yield of dysplasia, even if it is used as a temporary measure 
whilst other, better technologies are developed. The practise, however, 
has not been universally adopted primarily due to difficulties with spray 
application, time required for spray application and with operator 
subjectivity meaning that it is still far from ideal. 
Narrow band imaging
Narrow band imaging enhances the resolution of the mucosal 
surface, aiding visualisation of surface irregularities as well as alterations 
in the vascular patterns. The mucosa is illuminated with both blue and 
green light wavelengths. The different wavelengths penetrate the tissue 
to different degrees resulting in increased resolution. Narrow band blue 
light displays the superficial capillary networks, due to its increased 
absorption by haemoglobin [31] and the alterations in vascular pattern 
that is seen in disease can be identified. 
Initial reviews showed high sensitivities for distinguishing gastric 
mucosa from intestinal metaplasia [32] and subsequent work with 
further magnification demonstrated a high accuracy in identifying 
high grade dysplasia [32]. As with the other modalities discussed thus 
far, however, there is a high level of inter-observer variability in the 
detection of mucosal irregularities and, although this modality would 
be easy to integrate into standard endoscopy practises, its use is limited. 
14% of endoscopists referring patients to a tertiary centre for further 
assessment of Barrett’s oesophagus had used narrow band imaging [3].
Optical coherence tomography
Optical coherence tomography (OCT) is an imaging system 
analogous to ultrasonography in that it uses electromagnetic waves 
to form images based on the detection of reflected light, rather than 
reflected sound waves [33]. OCT systems have resolutions of 10-25 µm, 
which enables the identification of microscopic features, including villi, 
glands, lymphatic aggregates and blood vessels [28]. 
Multiple studies have described the in vivo use of OCT as a screening 
tool for Barrett’s oesophagus with the ability to distinguish between the 
appearances of squamous mucosa, gastric cardia, Barrett’s oesophagus 
and adenocarcinoma [38-42]. The sensitivity for the differentiation 
between high grade dysplasia and adenocarcinoma was, however, only 
83% with a specificity of 75% [42], with similar, if not worse results, in 
a subsequent study [43]. 
The identification of dysplasia, particularly high grade dysplasia, is 
the ultimate goal and the results thus far for OCT are, in the majority, 
not good enough, although a recent review found excellent diagnostic 
sensitivity and specificity for the detection of Barrett’s oesophagus, 
although not necessarily of dysplasia [44]. This is likely to be linked 
to the subjective interpretation by the endoscopists, especially as this 
modality requires interpretation of histopathological changes. Its 
benefit does, however, lie in the fact that it provides cross-sectional 
imaging that permits assessment of the depth of invasion and can 
determine for which patients mucosal resection is a suitable option [34].
The speeds and modes of operation prohibit acquisition of data 
over large segments of the GI tract [35]. Spectrally encoded confocal 
endomicroscopy uses a different grating and a wavelength swept 
laser to image tissues at very high speeds [36]. In vivo experiments on 
anaesthetised living swine suggested that this technology could rapidly 
(in 2.1 minutes) provide large (5 cm length) contiguous images of the 
oesophagus [35]. The technology had some technical flaws; however, it 
is an important step towards the illustrious wide-field scanning that is 
desperately required.
A novel approach has been the development of a swallowed tethered 
capsule endomicroscopy device which has been shown to image large 
portions of the oesophagus with agreement of 94% to manual tissue 
classification [37]. This form of technology could provide screening 
data, but patients would need further investigation, likely to be an 
endoscopy, to obtain tissue or to perform endomucosal resection.  
Autofluorescence
All tissues produce autofluorescence when illuminated by ultra-
violet (<400 nm) or short visible light (400-550 nm). The molecules 
responsible for this are termed fluorophores and the resultant 
autofluorescent signal is dependent on the concentration and 
distribution of the fluorophores. Normal, metaplastic and dysplastic 
tissue will have different autofluorescent spectra as malignant 
transformation alters the type, concentration and microdistribution of 
the constituent fluorophores [45]. 
Tissue autofluorescence can be performed relatively simply with 
the ability to sample wide areas of the mucosal surface. Different 
wavelengths penetrate and effectively interrogate the tissue to different 
depths, resulting in an image which provides clues as to the tissue 
topography and vasculature [46]. 
Studies using a variety of systems have had confounding results 
with some improving detection of dysplasia [47], and others being 
no better than traditional white light endoscopy [24,48]. A combined 
video endoscope system with both white light and autofluorescence did 
improve the detection of new areas of dysplasia [49], but was hampered 
by the inability to accurately distinguish inflamed tissue with that of 
dysplasia.
It may be overly hopeful to think that differences in autofluorescence 
patterns are specific enough to distinguish between low grade 
dysplasia, high grade dysplasia and adenocarcinoma. Alterations in 
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autofluorescence would, however, direct the endoscopist to areas of 
interest which would be further assessed with a different diagnostic 
modality and/or biopsied. What would be ideal is a marker of dysplasia 
that has a unique fluorescent signal that would objectively identify the 
areas of the oesophagus that require further evaluation. No markers 
have, thus far, been identified; however, it may be that a molecular 
marker of the processes that are involved in dysplastic formation, such 
as apoptosis or cellular proliferation, can be found and that they have a 
unique autofluorescent signal. 
Lipofuscin could be a candidate for this role (DaCosta; personal 
communication). Work looking at the colonic mucosa has shown that 
dysplastic epithelial cells had increased red autofluorescence intensity 
when compared to normal and hyperplastic cells and that this increase 
was due to the presence of large numbers of highly autofluorescent 
granules which were shown to be lysosomes [50]. Lipofuscin forms 
due to iron catalysed oxidation and polymerisation of protein and lipid 
residues [51]. These residues are cell fragments which are the result of 
apoptosis of epithelial cells. 
If lipofuscin is able to be easily detected and enables differentiation 
between non-dysplastic and dysplastic tissue, and/or between different 
levels of dysplasia, or indeed if there are alternative markers that 
can do this, this would increase our ability to perform quick wide 
field scanning of the entire oesophagus and identify areas requiring 
magnified investigation. 
Immunophotodiagnostic endoscopy
In a similar approach, studies have looked at combining 
chromogenic or fluorescent dyes with monoclonal antibodies that are 
specific for tumour-related antigens. The antibody would bind with the 
antigen and then emit fluorescence which is detectable and identify 
abnormal areas of the oesophagus. The clinical application of this has, 
thus far, had limited success which may be due to the lack of specific 
markers or the sub-optimal contrast differentiation between tissue 
types [46].
A glimmer of hope is lectins. Cell surface lectins are altered in the 
progression from Barrett’s oesophagus to adenocarcinoma causing 
changes in binding patterns which can be identified [53]. This modality 
is highly attractive and as our understanding of the molecular basis of 
dysplasia and adenocarcinoma increases, further dysplasia associated 
markers may well be discovered.
Confocal fluorescence microendoscopy
Confocal fluorescence microendoscopy is an extension of 
autofluorescence. It images endogenous and exogenous fluorophores 
within the cells of the tissue sections [21] and provides a histological 
image of the tissue [52]. In ex vivo samples, dysplastic and non-dysplastic 
Barrett’s oesophagus fluoresced mainly in the green spectrum with the 
main contribution from the mucosal layer. High grade dysplasia was 
able to be differentiated from that of non dysplastic Barrett’s based on 
the assessment of the microstructural tissue changes [52]. This suggests 
that Barrett’s oesophagus can be detected by mucosal autofluorescence 
[31], but the further delineation of dysplastic tissue requires the 
histological component of this modality which is a subjective measure.
Spectroscopy
Spectroscopy offers the ability to detect subtle biochemical changes 
in tissues and, thus, aids the differentiation of various tissue types, 
including that of dysplastic tissue. There is a substantial volume of 
work in the literature that confirms the ability of different forms of 
spectroscopy to differentiate between pathology states in a wide range 
of organ systems, including the oesophagus. Despite many years 
of evidence, however, there has been no move of spectroscopy into 
routine clinical practise.
Light scattering spectroscopy: Light scattering spectroscopy, also 
known as elastic scattering spectroscopy, provides microstructural 
information about tissue based on the reflectance of scattered white 
light. The backscattered light from epithelial nuclei can identify nuclear 
enlargement and crowding and this can be used to detect dysplasia with 
sensitivities and specificities of >90% [54]. Subsequent studies have 
obtained reasonable results and have also been able to differentiate 
high risk sites from inflammation with sensitivities and specificities of 
79% [55].
The main disadvantage of this tool, as with other methods 
of spectroscopy, is that it is unable to sample a large volume of the 
oesophagus. Other forms of spectroscopy provide greater information 
regarding tissue composition and, thus, it seems unlikely that light 
scattering spectroscopy will become a main stream tool to aid our 
identification of dysplasia. 
Raman spectroscopy: Compared to the other spectroscopic 
techniques under investigation, Raman spectroscopy provides the 
most detailed information about the molecular composition of tissue. 
It relies on the inelastic scattering of monochromatic light, where the 
scattered photon’s energy is altered by interaction with the molecular 
bonds present and results in a change in frequency. This information 
is extracted and enables the molecular composition of a tissue to be 
determined (Figure 2) [46].
The ability of Raman spectroscopy to discriminate between different 
pathology groups in a variety of ex vivo tissue groups has been well 
documented. In the oesophagus, in an analysis of snap-frozen biopsy 
samples, Raman analysis was able to discriminate between 8 different 
pathology groups, including subtypes of Barrett’s oesophagus [56]. 
Fibre optic probes for Raman analysis via a needle probe or endoscope 
can enable tissue access for in vivo analysis [57]. 
From the turn of the century, a number of groups have trialled in 
vivo Raman probes. Work in 2011 demonstrated the identification of 
cancer in the oesophagus with a sensitivity of 91% and a specificity of 
94% and, importantly, with an acquisition time of 0.4-0.5 seconds [58]. 
Dysplastic change was, however, not differentiated. 
Despite rapid spectral acquisition times, a major limitation of 
Raman probe measurement is that only a small volume of mucosa 
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Figure 2. Examples of Raman spectra measured from a variety of human molecular 
constituents. Characteristic Raman peaks are seen for each substance at reproducible 
positions.
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can be interrogated at one time. This prohibits its use as a wide field 
scanning modality, but would make it an ideal instrument for point 
measurements to aid in vivo diagnosis. Raman probes can, and have 
been, used in conjunction with other modalities which are able to 
scan wide areas of the oesophagus to overcome this barrier and this is 
discussed later. The narrow field imaging of Raman would, however, 
be well suited to other in vivo applications, such as real time targeted 
therapy during endomucosal resection to establish resection margin 
clearance [59], although it would need to be able to distinguish areas of 
dysplasia as well as adenocarcinoma.
Rather than replacing the gold standard of histopathology for 
diagnosis, Raman spectroscopy could be utilised in the laboratory for 
the analysis of ex vivo samples to aid diagnosis, particularly when there 
is a lack of consensus regarding the presence and/or grade of dysplasia. 
Rapid mapping of tissue sections using Raman has the potential to be 
used as an automated histopathology tool. It has been shown that 2 mm 
diameter sections can be mapped over a time scale of 30-90 minutes, 
and that this was sufficient to discriminate pathology [60]. This would 
provide an additional tool for the pathologist when analysing biopsy 
samples. Current work is focused on investigating system transferability 
when using Raman to map oesophageal tissue sections to facilitate this 
function [61]. 
Fourier-transform infra-red spectroscopy: Infrared spectroscopy 
exploits the feature that tissue absorbs light at characteristic wavelengths 
which are determined by the vibrational motions of covalently bonded 
atoms. FTIR is able to collate a rapid molecular fingerprint of tissue 
with information regarding different tissue constitutes such as DNA 
and glycogen. The pattern of the spectra generated is sensitive to small 
changes in multiple tissue constituents and, therefore, is different 
for the different pathologies [62]. For example, increased DNA and 
glycoprotein content predicts the presence of dysplasia in Barrett’s 
oesophagus and this is consistent with histopathology [63].
The development of adenocarcinoma follows a well established 
pattern which begins prior to any morphological changes. Gene 
mutation is the primary event, followed by changes in the biomolecules 
of the tissue. FTIR has the potential to detect these changes and 
potentially identify changes prior to those described as precancerous, 
i.e.,: at the earliest stage of dysplastic change. As with Raman, however, 
this is not currently a method whereby the entire oesophagus can be 
screened with FTIR to identify these areas. An additional hindrance 
of IR is the strong influence of water with peaks overlapping with 
the Amide I band of proteins, affecting the diagnostic ability of this 
technique [64]. Fibre-optic evanescent wave spectroscopy (FEWS)-
FTIR with endoscope compatible fibre-optic silver halide probes has 
been shown to be feasible, although the development of in vivo tissue 
drying is likely to improve results [65]. 
The role of FTIR is, therefore, likely to be complimentary to Raman 
in aiding histopathological diagnosis of biopsied material. 
The way ahead
An ideal diagnostic model to identify dysplasia in the oesophagus 
would enable real time scanning of a vast area of mucosa, ideally the 
entire oesophagus. It would be able to accurately identify areas of 
low grade dysplasia, high grade dysplasia and adenocarcinoma and 
differentiate these from active inflammation and other pathologies 
with a high degree of specificity. It would be easy to set up and use and 
be cost effective. Unfortunately it does not exist.
What then is the solution? A multi-modal approach is needed 
to tackle the two predominant problems that face the diagnosis of 
dysplasia in Barrett’s oesophagus. 
A wide field detection is required that is able to assess the whole 
oesophagus and identify areas requiring more specific review. 
Autofluorescence would be simple and easy to employ and if a marker 
of dysplasia could be identified then this would make this modality 
the principal choice. A narrow field modality would then be utilised 
at the same endoscopy to further delineate these areas. The narrow 
field modalities, predominantly those of Raman and FTIR, provide 
additional and complimentary information to that of histopathology. 
Using all modalities in conjunction will provide the greatest 
information regarding the disease state of the tissue, increasing the 
accuracy of diagnosis and providing detailed information regarding the 
cancerous changes that take place. It will only be with complimentary 
working with pathology, rather than an attempt to replace them, that 
we will develop the greatest understanding of the changes that occur in 
cancerous change in the oesophagus. 
Evidence is starting to filter in of the benefit of a multimodal 
approach. For example, the combination of Raman spectroscopy 
and optical coherence tomography has been shown to be superior 
to either modality in isolation at discriminating between colonic 
adenocarcinoma and normal colon [66]. A dual probe combining 
fluorescence and Raman spectroscopy was shown to have good 
correlation with histopathology when used for ex vivo melanocytic 
lesions [67] and a recent study using the same two modalities in the 
same probe demonstrated the potential of this technology to be used in 
vivo [68]. The combination of autofluorescence and Raman has taken 
an early lead in the ideal modality combination as the two provide 
complimentary information. 
Conclusion
There is still a long way to go. Each modality needs to be perfected 
and translated into clinical care and then the ideal combination needs 
to be selected. This may, however, not be the same for every patient and 
the advantages of each may alter depending on the patient. Nevertheless, 
the incidence of both Barrett’s oesophagus and adenocarcinoma are 
climbing and the requirement for new and improved diagnostic tools 
is greater than ever. 
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Abstract
The principles and techniques that have long been es-
tablished in the world of Physics are beginning to merge 
with the field of clinical medicine. Optical and vibrational 
spectroscopy techniques provide biochemical and mo-
lecular information. This information can be used to dif-
ferentiate between different types of tissue and, thus, aid 
diagnosis, augmenting the methods already in routine 
clinical practise.
This chapter explains the underlying principles of op-
tical and vibrational spectroscopy and the current research 
into some of the areas where these techniques are facilitat-
ing our understanding and management of disease.
Introduction: Optical and Vibrational 
Spectroscopy
When light interacts with a material, multiple pro-
cesses can occur; reflection, transmission, scattering, ab-
sorption, fluorescence or vibration. These processes take 
place when the incidental radiation induces changes in 
the energy level of the material. The change in energy can 
be detected and can provide valuable information regard-
ing the underlying material.
Vibrational spectroscopy, alongside autofluorescence, 
provides information regarding the biochemical compo-
sition of a tissue in a non destructive manner by produc-
ing spectra based on the interaction of the light with the 
tissue. Chemometric analysis of the spectrum can char-
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acterise and classify the tissue based on the information 
obtained.
This information is less subjective and additional to 
that gained by histopathological review and, thus, these 
techniques are being developed and evaluated for their 
use in clinical diagnostics, both for ex vivo tissue and bio-
logical samples and for in vivo, real time diagnosis.
Raman Spectroscopy
Molecules are made up of atoms that are held together 
by chemical bonds. Each chemical bond has a character-
istic vibrational energy. When illuminated by electro-
magnetic radiation, usually from a laser light source, the 
bonds vibrate as the molecule enters a virtual energy state. 
A photon, from the light source itself, is absorbed by the 
material, exciting an electron into a higher virtual energy 
level (Figure 1). As the electron decays back to a lower 
energy level, it emits a scattered photon. If the electron de-
cays back to the same starting energy level, this is a form 
of elastic scattering, also known as Rayleigh scattering 
(Figure 2).
Figure 1: Feynman diagram of scattering between two electrons by 
emission of a virtual photon.
Figure 2: Stokes and Anti-Stokes Shift.
When the incident photon interacts with the electric 
dipole of the molecule, the excited electron can decay back 
to a different energy level from that of its starting position. 
This is known as inelastic scattering, and the difference 
in energy level between the incident (non-scattered) pho-
tons and the scattered photons corresponds to the energy 
of the molecular vibration. This inelastic scattering of light 
was predicted by Adolf Smekal in 1923 [1], however, it was 
not observed in practise until 5 years later, where it was 
named after one of its discoverers, Sir Chandrasekhara 
Venkata Raman [2]. 
Two forms of Raman scattering exist, depending on 
the final energy level of the electron. If the final energy 
level of the electron is more energetic than the original 
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state, the inelastically scattered photon will be shifted to 
a lower frequency. This shift is known as a Stokes shift. 
If, however, the final vibrational state is less energetic, the 
photon will be shifted to a higher frequency, known as an 
anti-Stokes shift (Figure 2).
The detection of the scattered photons, therefore, pro-
vides a unique spectrum of Raman peaks based on the 
bonds present within the sample and is, thus, a molecu-
lar fingerprint of the tissue sample (Figure 3). A wealth 
of information regarding the chemical bonds associated 
with DNA, RNA, proteins, lipids, other biomolecules and 
even a single cell can be interpreted. The intensity of the 
scatter is directly proportional to the concentration of re-
sponsible molecules within the specimen and, therefore, 
also provides a quantitative measure.
Figure 3: Example of a Raman Spectrum [3].
The use of visible or near infra-red light results in very 
weak Raman signals from the –OH bond present in water 
molecules and, hence, water contributes minimally to the 
resultant spectra [4]. This is a significant advantage as it 
means that fresh tissue, either ex vivo or in vivo, with no 
prior preparation is able to be analysed without interfer-
ence from the water. Raman spectroscopy, nevertheless, 
faces other difficulties. Only a fraction of the photons are 
inelastically scattered (1/106-109) resulting in an inherent-
ly weak signal [5]. This is further compounded by ambi-
ent light which must be removed to reduce unwanted and 
distracting spectral contributions [5].
Several advanced Raman based techniques have been 
developed which produce a stronger signal. Resonance 
Raman and Resonance hyper Raman spectroscopy do this 
by adjusting the energy of the incoming laser. Coherent 
anti-Stokes Raman spectroscopy (CARS) employs multi-
ple photons, whereas, surface enhanced Raman spectros-
copy (SERS) uses specially prepared metal surfaces to en-
hance the signal. 
An additional disadvantage of Raman is that it is only 
able to penetrate a few hundred microns into the tissue 
[6]. Spatially offset Raman spectroscopy (SORS) uses 
the principle that photons migrate to measure spectra 
from surface areas at distances from the excitation point. 
A scaled subtraction of the spectra from spatially offset 
points enables the production of pure spectra from the in-
dividual layers of the sample [7]. The advancement of this 
and other Raman techniques are overcoming the disad-
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vantages, however, as the majority of research is based on 
the traditional Raman techniques, this chapter will focus 
on this work.
Fourier Transform Infrared Spectroscopy 
(FTIR)
Infrared spectroscopy is one of the most widely used 
and important analytical methods employed in science. 
Infrared radiation was initially discovered in 1800 by Sir 
William Herschel. It was, however, not until the commer-
cially driven IR spectrometers of the 1970s that the tech-
nique became so broadly applied. 
When a beam of infrared radiation is passed through 
a tissue sample, each chemical bond within the molecule 
will vibrate. These vibrations occur in a variety of ways; 
symmetrical stretching, antisymmetrical stretching, scis-
soring, rocking, wagging and twisting (Figure 4). When 
the frequency of the infrared radiation is the same as that 
of the vibrational frequency of the chemical bond, the di-
pole moment of the molecule alters, albeit only temporar-
ily. This transition results from the absorption of a photon.
By measuring the transmitted light, the amount of 
energy absorbed at each frequency (or wavelength) can 
be determined and an absorbance spectrum is generated. 
The complexity of this spectrum depends on the complex-
ity of the molecule as the more complex a molecule, the 
more bonds and, therefore, more peaks the spectra will 
have (Figure 5).
Figure 4: Schematic Diagram of some of the vibrations that molecular 
bonds undergo when excited.
Figure 5: Infrared Spectrum of Ethanol (CH3CH2OH).
Fourier Transform Infrared (FTIR) spectroscopy 
(Figure 6) uses an interferometer to guide infrared light 
prior to its transmission through the sample. A moving 
mirror inside the interferometer alters the distribution of 
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infrared light, allowing the simultaneous collection of in-
formation from multiple frequencies. Not only does this 
speed up the process, but it also reduces the signal-to-
noise ratio. Virtually all modern infrared spectrometers 
are FTIR.
Figure 6: Schematic Representation of FTIR Spectroscopy 
(Courtesy: Jasco, UK).
Despite the advantages of both speed of acquisition 
and the requirement of only a small amount of sample, 
FTIR has a major limitation. Water is highly absorbent 
in the mid infrared range (4000 – 400cm-1), the range at 
which most other vibrations occur. As the majority of bio-
logical tissue has high water content, this affects the ability 
to gain meaningful data from in vivo measurements.
Although its use with fresh tissue is limited due to 
the presence of water, FTIR is ideal for use with paraffin-
embedded tissue samples as the ability to correct for the 
absorption of paraffin has been determined and validated 
[8]. These preparations are routinely used in histopathol-
ogy for Haematoxylin and Eosin (H&E) staining and im-
munohistochemistry and, thus, this technique could be 
used as an adjunct in the laboratory without additional 
sample preparation. 
Infrared spectra can be hampered by distortion from 
resonant Mie scattering and reflectance [9]. This can be 
reduced by using Attenuated Total Reflectance (ATR) 
spectroscopy. In ATR spectroscopy, the sample is placed 
in contact with a sensing element (IR transmission crys-
tal) which affects the angle of light, producing an evanes-
cent standing wave [10]. An evanescent wave is an oscil-
lating electric or magnetic field which does not propagate 
as an electromagnetic wave, but instead concentrates its 
energy in the vicinity of the source. This enables higher 
spatial resolution as well as the ability to control the sam-
ple penetration depth, however, it does require that con-
tact exists between the sample and the probe, introducing 
the opportunity for contamination.
As with other technologies, there is a drive to produce 
real time, in vivo measurements. Fibre-optic evanescent 
wave spectroscopy (FEWS)-FTIR with endoscope com-
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patible fibre-optic silver halide probes have been shown 
to be feasible [11], however, the technology is not, as yet, 
ready for routine clinical use and further advances are re-
quired, particularly in relation to reference data and the 
selection of suitable tips that enable use with current en-
doscopes.
Autofluorescence
All tissues produce autofluorescence when illuminat-
ed by ultraviolet (<400nm) or short visible (400-550nm) 
light. Fluorophores, the constituent biomolecules of the 
tissue, emit longer wavelengths when illuminated and 
are, thus, responsible for the resultant fluorescence [12]. 
The majority of fluorophores are found in the submucosa 
layer of the tissue, with collagen and elastin producing 
highly green fluorescent signals. A weaker contribution is 
produced by the mucosal components of epithelium and 
lamina propria.
Figure 7: Autofluorescent image of the intestine of a mouse.
Different disease processes in tissues will produce dif-
ferent autofluorescent patterns as the type, concentration 
and microdistribution of the fluorophores will also alter 
[13, 14]. For example, the ratio of fluorescence intensity of 
tryptophan to that of NADH changes in cancerous tissue 
[15].
Tissue autofluorescence has the ability to sample wide 
areas of mucosal surface in a short space of time. Confocal 
fluorescence microendoscopy is an extension of this pro-
cess, imaging endogenous and exogenous fluorophores 
within the cells of tissue sections [16], providing a detailed 
histological image of the tissue [17]. This may enable the 
detection of primary changes in cells which may be the 
initial change in the disease process.
Clinical Applications
Cancer Diagnostics
Cancer is responsible for an enormous burden of dis-
ease with 14.1 million cases diagnosed worldwide in 2012, 
and 8.2 million deaths in the same year [18]. Despite an 
extraordinary amount of effort and financial outlay, the 
eradication of, or even the control of advanced disease has 
failed to materialise [19].
The classical model of the clonal evolution of cancer 
cells, originally proposed by Nowell in a landmark paper 
in 1976, suggests that neoplasms arise from a single cell 
of origin. Tumour progression is the result of acquired 
genetic variability within the original clone which allows 
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the sequential selection of more aggressive sublines [20]. 
Cancer cells follow a Gompertzian model of replication 
with an early, almost exponential growth rate, followed 
by a slower growth rate which finally reaches a plateau as 
tumours grow larger in size. The majority of the growth, 
as shown in figure 8, occurs when the tumour is clinically 
undetectable.
Figure 8: Gompertzian Model of Tumour growth.
Although cancer therapy has had its successes, in real-
ity, very few advanced or metastatic malignancies can be 
eradicated or even effectively controlled. The accumula-
tion of genetic change that occurs over time as the original 
clone replicates, provides opportunities for at least some of 
the cancer cells to evade the provided therapy, to survive 
and to continue to replicate. Early detection and interven-
tion of precancerous changes prior to the advanced stages 
of disease would alleviate the need to outwit the cancer 
cells, and reduce the morbidity and mortality burden of 
cancer. 
Cancer diagnostics utilises a variety of imaging mo-
dalities dependent on the presentation of the patient and 
tumour location. The gold standard for diagnosis is histo-
pathological tissue diagnosis which requires direct access 
to and biopsy of the tumour or its draining lymph node 
(if there is spread to the lymphatic system). Histopatholo-
gists use morphological and architectural information, of-
ten in combination with, immunohistochemical staining, 
to interpret the sample. In some cases, this is extremely 
difficult and there can be significant inter-observer vari-
ability in the analysis of the appearances. This can delay, 
or even alter, management decisions. In addition, histo-
pathological diagnosis requires the changes to be mor-
phological visible and, thus, may eliminate the window of 
opportunity for earlier diagnosis where changes are not 
macroscopically visible.
Spectroscopic analysis provides information on the 
biochemical constituents of the tissue and could, therefore, 
identify changes that predate morphological alterations. 
Automated classification systems could be developed for 
use in the laboratory in conjunction with histopathology 
to enable earlier and less subjective detection of cancer-
ous and precancerous changes. The development of fibre-
optic probes, in addition, has paved the way for in vivo 
measurements with the added benefits of real time diag-
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nosis, thus, helping to identify potentially abnormal areas 
at the time of imaging. 
Research has looked at the application of these tech-
nologies in a variety of different cancers. This chapter will 
focus on developments in cancers of the GI tract (oesoph-
agus, stomach and colorectum), and the brain. Work on 
breast, cervical, lung, bone, prostate, head and neck and 
skin cancer will not be covered here.
Oesophageal Carcinoma
The incidence of oesophageal adenocarcinoma is 
increasing in Western countries with no concurrent im-
provement in survival figures [18]. Oesophageal ad-
enocarcinoma is often preceded by Barrett’s oesophagus 
which is the metaplastic replacement of normal squamous 
epithelium by columnar epithelium. The development of 
dysplasia within Barrett’s oesophagus is the best marker 
for progression to adenocarcinoma and current guidelines 
[21, 22] indicate that treatment, in the form of endoscopic 
resection and complete ablation, should occur in the pres-
ence of high grade dysplasia.
Dysplasia in Barrett’s oesophagus is difficult to iden-
tify. Macroscopically it appears identical to non-dysplastic 
Barrett’s oesophagus. The current biopsy protocol, the 
Seattle regimen, takes four quadrant biopsies every 2 cm 
and can easily miss areas of dysplasia. Even if an area of 
dysplasia is selected for biopsy, there exists a significant 
amount of inter-observer variability, even among special-
ised GI Histopathologists, in its diagnosis [23-25].
Alternative modalities to aid the identification and 
classification of dysplasia in Barrett’s oesophagus are 
highly sought after to both prevent and improve the out-
comes for those with oesophageal carcinoma.
Raman Spectroscopy in the Oesophagus
The ability of Raman spectroscopy to discriminate 
between different pathology groups in the oesophagus 
has been well documented. In an analysis of snap-frozen 
biopsy samples, Raman analysis was able to discriminate 
between 8 different pathology groups, including subtypes 
of Barrett’s oesophagus [26]. 
The next stage is the development of an in vivo Raman 
probe and this has been trialled from the turn of the cen-
tury. Work in 2011 demonstrated that the identification of 
cancer in the oesophagus could occur with a sensitivity of 
91% and a specificity of 94% and, importantly, with an ac-
quisition time of 0.4-0.5 seconds [27]. Dysplastic change 
was, however, not differentiated in this study. This work 
followed earlier studies with a variety of probes [28-32] 
which had different sensitivities for pathology detection 
and different acquisition times. The development of a va-
riety of probes will, undoubtedly, help to further the ad-
vancement in technology and enable the development of 
a probe which can be used routinely in clinical practise. 
Rather than replacing the gold standard of histopa-
thology for diagnosis, Raman spectroscopy could be uti-
lised in the laboratory to aid analysis of the specimens. 
Rapid mapping of tissue sections using Raman has the 
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potential to be used as an automated histopathology tool. 
It has been shown that 2mm diameter sections can be 
mapped over a time scale of 30-90 minutes, and that this 
was sufficient to discriminate between pathologies [33]. 
This would provide an additional tool for the pathologist 
when analysing and interpreting biopsy samples. 
FTIR in the Oesophagus
The development of adenocarcinoma follows a well 
established pattern which begins prior to any morpho-
logical changes. Gene mutation is the primary event, fol-
lowed by changes in the biomolecules of the tissue. FTIR 
has the potential to detect these changes and potentially 
identify changes prior to those traditionally described as 
precancerous, i.e.: at the earliest stage of dysplastic change. 
It has been demonstrated that DNA, protein, glycoprotein 
and glycogen account for absorption in the 950-1800 cm-1 
region and that changes here are able to identify dysplasia 
in fresh oesophageal samples with a high sensitivity and 
specificity [34].
A hindrance of IR is the strong influence of water with 
peaks overlapping with the Amide I band of proteins, af-
fecting the diagnostic ability of this technique [35]. This 
has slowed the ability to develop in vivo probes, how-
ever, fibre-optic evanescent wave spectroscopy (FEWS)-
FTIR with endoscope compatible fibre-optic silver halide 
probes has been shown to be feasible [11].
Autofluorescence in the Oesophagus
Studies using a variety of autofluorescent systems have 
had confounding results with some improving the detec-
tion of dysplasia [36], and others being no better than 
traditional white light endoscopy [37]. A combined video 
endoscope system with both white light and autofluores-
cence did improve the detection of new areas of dysplasia 
[38], but was hampered by the inability to accurately dis-
tinguish inflamed tissue with that of dysplasia. An obvi-
ous advantage is, however, the ability to image a wide field 
and, thus, examine the entire oesophagus, something that 
is impossible to do with Raman or FTIR spectroscopy in 
isolation. Its use could be as a ‘red flag’ technique to high-
light suspicious areas prior to a more detailed vibrational 
spectroscopy analysis.
Gastric Carcinoma
Gastric cancer is the 4th commonest worldwide can-
cer, although incidences vary significantly [18]. In the 
UK, it accounts for only 2% of all new cases of cancer (ap-
proximately 7100 new cases / annum), whereas in the Far 
East, the incidence is as much as 4 times higher [39]. In 
Japan there are 31.1 new cases / 100000 population, 41.4 
in South Korea, 29.9 in China and 34.0 in Mongolia [39]. 
Survival rates for gastric cancer, akin to its incidence, 
vary widely with a 15% overall survival in the UK [18]. 
As with all cancers, in those with early disease, survival 
can be increased. Survival rates of 90% are seen in special-
ist centres in Japan in patients with submucosal disease 
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[40]. Due to the high incidence, Japan introduced a Na-
tional Screening programme in the 1960’s. This combines 
barium double-contrast radiography with endoscopy in 
those with detected abnormalities. Despite the exemplary 
survival rates seen in Japan, it is unclear how much of an 
impact the screening programme itself has had [41].
With or without screening, the ability to accurately 
detect precancerous changes in the stomach, in a similar 
vain to that of detecting dysplasia in Barrett’s Oesophagus, 
is the primary factor in enabling early treatment and, thus, 
improving the survival rate.
Raman Spectroscopy in the Stomach
Following on from work demonstrating significant 
differences in Raman spectra between normal and dys-
plastic gastric tissue, development of an in vivo Raman 
probe has moved this technology closer to clinical appli-
cation.
The first in vivo Raman spectroscopy study of gastric 
dysplasia and normal tissue was reported by Huang et al 
in 2010 [42] with a specificity and sensitivity of 96.3% 
and 94.4% respectively. The first in vivo study comparing 
gastric cancer to normal tissue was published in the same 
year [43] with equally good results.
The distinction between intestinal and diffuse types 
of gastric cancer is important as it affects the treatment 
options for the patient. Differences in the subtypes have 
been demonstrated in the spectral regions that relate to 
proteins, nucleic acids and lipids and have enabled the 
differentiation based on their spectra with high predictive 
accuracies [44]. These results were repeated in work from 
different research groups [45].
The first results from a real time in vivo system were 
published in 2012 [46] (previous in vivo work had saved 
spectra with analysis at a later time) with a total of 2748 
spectra from 308 patients analysed with a processing time 
of 0.5 seconds. Diagnostic accuracies in the 80-90% range 
were demonstrated for the identification of gastric cancer. 
Recent work by Wang et al [47] with a real time probe 
combining both fingerprint (800-1800 cm-1) and high 
wavenumber (2800-3600 cm-1) spectra provided diagnos-
tic sensitivities of 96.1%, 81.8% and 88.2% and specifici-
ties of 86.7%, 95.3% and 95.6% for normal, dysplastic and 
cancerous tissue.
The demonstration of real time in vivo diagnosis is a 
vital development that is required if this technology is to 
be used during endoscopic resection and endoscopic sub-
muosal dissection. Raman spectroscopy could be utilised 
to ensure all abnormal tissue is resected with adequate 
margins and subsequently be used to reassess the resec-
tion area for recurrence. The results demonstrated in the 
stomach are a significant step forward, however, there is 
still a long way to go before this technology becomes a 
routine adjunct in clinical practise.
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FTIR Spectroscopy in the Stomach
There has been a reduced focus on the use of FTIR 
in the stomach, presumably due to the leaps made in the 
real time in vivo measurement that has occurred with Ra-
man spectroscopy. FTIR is also abe to differentiate normal 
from cancerous tissue and can differentiate these tissues 
from superficial gastritis and atrophic gastritis, although 
the sensitivity for atrophic gastritis was only 60% in some 
studies [48].
It has been speculated that the serum of patients with 
gastric cancer differs from that of healthy controls [49]. In 
one study, FTIR has shown this difference to be detectable 
based on serum RNA/DNA ratios. Raman spectroscopy 
has also demonstrated a difference with increases seen in 
nucleic acid, collagen, phospholipid and phenylalanine 
content and decreases in amino acid and saccharide con-
tent in patients with cancer [50]. Whether this is repeat-
able and specific remains to be seen, however, if it is, it 
could provide a useful screening test using these technolo-
gies in an ex vivo manner.
Autofluorescence in the Stomach
Autofluorescence has been researched in the stom-
ach, as in the rest of the GI tract, with conflicting results. 
Although highly sensitive (96.4%), this technology had a 
very low specificity (49.1%) for the detection of early gas-
tric neoplasms [51]. This was primarily due to the abnor-
mal fluorescence of a large proportion of benign lesions. 
In addition, inflammatory processes in the stomach, 
such as gastritis, can produce changes in the fluorescence 
leading to difficulties in the differentiation of the two pa-
thologies. Despite this, however, autofluorescence has 
been shown to detect 25% of lesions that are missed by 
white light endoscopy [52]. The combination of autofluo-
rescence with Raman has been evaluated for the identi-
fication of cancer from normal tissue and found to have 
an accuracy of 92.2% [53]. If utilised, it is likely that auto-
fluorescence will be used in combination, such as this, as 
opposed to a single modality.
Colorectal Carcinoma
Colorectal cancer is the third commonest cancer 
worldwide. It is widely accepted that the adenoma – carci-
noma sequence represents the progression by which most, 
if not all, colorectal cancers arise [54]. If adenomas are de-
tected at endoscopy, this offers an opportunity for early 
diagnosis and endoscopic resection prior to established 
cancer arising. There are, however, a number of challenges 
involved in the identification and classification of polyps.
The miss rates for small (<1cm) adenomas can be in 
the order of 25-50% [55, 56]. Although the significance of 
missing small adenomas is unclear, that of missing large 
adenomas (>10mm) and carcinomas is apparent and oc-
curs in 5.8% and 5.4% of cases respectively [57]. This is 
partly related to the quality of the colonoscopy, including 
the preparation of the bowel and the endoscopist’s tech-
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nique, however, it is felt that some lesions are missed, pre-
dominantly in the right colon, because they are flat and 
relatively subtle [56]. Disappointingly, at present, high 
definition white light endoscopy has shown only a modest 
improvement [58] and narrow band imaging conflicting 
results [59, 60].
In addition to the problems faced in lesion detection, 
there can be difficulty in assigning pathology. The ability 
to differentiate between hyperproliferative and dysplastic 
change in adenomas can be challenging. Determining the 
nature of the polyp accurately has significant implications 
for both immediate management and future surveillance. 
Diminutive polyps (<5mm) rarely harbour advanced dis-
ease and if this could be assured in vivo, without biopsy, 
this would reduce an already overburdened histopathol-
ogy service and reserve their expertise for other areas. 
There is currently a debate regarding not sending these 
polyps for histology with a ‘resect and destroy’ policy. In 
all polyps, a very important question after determining 
its nature, is the resection base; what is left behind in the 
patient. The detection of precancerous lesions is further 
complicated in areas of underlying inflammatory bowel 
disease where the ability to discriminate between patholo-
gies is trickier.
Raman spectroscopy in the Colon and Rectum
Initial studies analysing colorectal tissue were found 
to have sensitivities of over 90% when differentiating nor-
mal mucosa from metaplastic and adenomatous polyps 
and from adenocarcinomas [61, 62]. The real push, as 
with other areas of the GI tract, has been towards the de-
velopment of an in vivo probe. As with other endoscopic 
probes, the probe has a number of requirements: it needs 
to fit through the accessory channel of a colonoscope 
(typically 2.8-3.2mm diameter), it needs to withstand the 
manipulation and articulation that the colonoscope needs 
to go through to reach the caecum and it must be biocom-
patible and be able to withstand the decontamination and 
disinfection processes. Alongside perfecting the technol-
ogy of spectroscopy, these requirements add further intri-
cacies to the development process.
Results from the first in vivo probe, the ‘Visionex’ 
probe were published in 2003 [63]. In vivo spectra from 10 
adenomas and 9 hyperplastic polyps were obtained with 
an estimated depth of 500µm with an acquisition time of 5 
seconds (which is a reasonable length of time for contact 
with a peristalsing colonic mucosa to be maintained). The 
two pathologies were discriminated with a sensitivity of 
100% and specificity of 95%. 
Recent developments with the use of high wave num-
ber Raman has resulted in a reduction in acquisition time 
without a loss in diagnostic accuracy. Short et al [64] used 
wavenumbers of 2050-3100 cm-1 to differentiate between 
normal tissue and tubular adenoma with a 1 second ac-
quisition time. A simultaneous FP (fingerprint) and HW 
(high wavenumber) Raman endoscopic technique was 
shown to be able to characterise mucosa from different 
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areas of the colon with only a 0.5 second acquisition time 
[65]. This probe was able to selectively target the epithe-
lial lining which is associated with the early changes of 
carcinogenesis and would suggest promising results in the 
ability to differentiate disease pathologies. 
As well as in vivo analysis of tissues, Raman spectros-
copy could be used as an adjunctive tool for histopatholo-
gists to use when analysing biopsy specimens. Rapid Ra-
man mapping of snap frozen sections with subsequent 
chemometric analysis has demonstrated the ability to 
identify subtle histological features of colonic polyps [66]. 
This method could ultimately be utilised as an automated 
sample analysis to add to the information gained from 
histopathologists, or as a first line measure to identify nor-
mal and benign tissue, thus, freeing up pathologists time 
to focus on uncertain or malignant samples.
FTIR Spectroscopy in the Colon and Rectum
Initial work using FTIR in colorectal cancer was pub-
lished over 25 years ago when Rigas et al demonstrated 
a difference in IR spectra between normal and cancerous 
fresh colonic tissue [67]. This has been repeatedly demon-
strated in further studies, including in vivo work during 
surgical resection [68]. 
The greatest difficulty in diagnosis is, however, dis-
tinguishing adenomatous tissue with varying grades of 
dysplasia as well as inflammatory and hyperproliferative 
tissue. Studies have proven that these different pathologies 
are able to be differentiated based on their IR spectra [69] 
with increases in the lipid/protein ratio with higher grades 
of dysplasia. The change in ratio is presumed to be sec-
ondary to the higher cell turnover and subsequent change 
in DNA levels that occur with dysplasia and malignancy. 
Later experiments included inflammatory diseases in the 
samples and maintained a high predictive accuracy (sen-
sitivity of 91.6-100% and specificity of 97.7-99.9%) [70].
High resolution IR mapping has been able to detect 
subtle biochemical changes in tissue and has, thus, been 
shown to differentiate the benign condition of epithelial 
misplacement from carcinoma [71]. This differentiation 
has proved to be problematic to histopathologists based 
on similar morphological appearances. The ability to be 
able to distinguish subtle differences may pave the way for 
the detection of earlier changes in the cancerous pathway.
Autofluorescence in the Colon and Rectum
Diminutive polyps (<5mm) that occur in the colon 
rarely harbour advanced disease. It has, thus, been sug-
gested that, as opposed to resection and routine histo-
pathological diagnosis, these lesions are diagnosed at the 
time of colonoscopy based on their macroscopic charac-
teristics [72, 73]. In addition, hyperplastic polyps, which 
are believed to be without neoplastic potential, could be 
diagnosed at the time of endoscopy and prevent the ad-
ditional time, cost and potential side effects that polyp re-
moval would carry.
 Autofluorescence could be a simple technique used 
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in colonoscopy to aid the identification of and differentia-
tion of colonic polyps. The results are, however, conflict-
ing with some showing differentiation with an accuracy 
greater than that of white light endoscopy, whilst others 
reporting low specificity [74]. 
The detection of dysplasia in inflammatory bowel 
disease is particularly important. The reason for this is 
twofold. Firstly the incidence of colorectal cancer in this 
cohort of patients can be as high as 18% after 30 years of 
disease [75], and secondly the underlying inflammation 
makes identification of underlying dysplasia problematic 
with the two often being mistaken. Autofluorescence has 
been shown to identify additional areas of dysplasia in pa-
tients with quiescent Ulcerative Colitis, areas that white 
light endoscopy had missed [76]. In active disease, how-
ever, its role is shakier as autofluorescence has, similarly 
to other areas of the GI tract, been unable to differentiate 
active inflammation from dysplasia. It may be that a dual 
system of modalities is needed in this cohort, with auto-
fluorescence being used to identify active inflammation or 
dysplasia and vibrational spectroscopy confirming which 
disease process is taking place.
Intracranial Tumours
Intracranial tumours encompass a broad range of 
pathological entities, ranging from benign to high-grade 
lesions. Multiple cells of origin exist, including mesin-
gothelial cells, glial cells, pituitary cells and metastatic de-
posits, resulting in a range of tumours with different natu-
ral histories, management decisions and outcomes.
A combination of imaging techniques alongside sur-
gical biopsy or excision is used for accurate diagnosis. The 
mainstay of treatment, where possible, is surgical excision. 
The need to accurately delineate the excision border to en-
sure complete surgical excision whilst preventing unnec-
essary neurological deficit is unmet with current imaging 
modalities.
Raman Spectroscopy in the Cranium
Raman probes, using the high wavenumber spectral 
region of 2400 – 3800 cm-1, are able to differentiate and 
characterise ex-vivo porcine brain tissue [77]. The transi-
tion of normal brain tissue to neoplastic tissue is connect-
ed to a unique change in the composition and concentra-
tion of lipids [78]. Changes in the main protein bands as 
well as reductions in the phosphate-to-carbohydrate ratio 
are seen with increasing grade of glioma [79], indicating 
that different grades of tumour, as well as tissue type are 
able to be identified.
One of the major difficulties faced in the excision 
of brain tumours is ensuring that all tumour is removed 
without compromising normal, functioning tissue. In 
vivo Raman probes are under investigation [80] to aid the 
detection of intracerebral tumours by brain surface map-
ping and also to map the exact edges of the tumour. This 
technique has been tested with promising results in vivo 
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in mice to image undetectable tumour margins [80] and, 
thus, aid complete surgical excision. 
FTIR Spectroscopy in the Cranium
Research using FTIR to aid identification and charac-
terisation of brain tumours has furthered the understand-
ing of the changes that occur with this transition and oth-
er intracranial disease processes. As well as the changes in 
the composition of lipids seen with Raman spectroscopy, 
the secondary structure of fibrillar and non-fibrillar col-
lagens was found to be different in solid and diffuse brain 
tumours [81]. Ongoing research work is investigating the 
structure of proteins in Parkinson’s Disease [82] and the 
role of ischaemia in cerebral pathologies [83]. Using FTIR 
to further the understanding of the changes that occur 
may enable to development of new and novel treatments 
for a variety of pathologies.
Non-Cancer Diagnostics
Multiple pathologies, not limited to cancer, lead to 
chemical and structural changes, resulting in character-
istic vibrational spectra. These can be used as a marker of 
the disease to aid diagnostics as well as the understanding 
of the disease. Vibrational spectroscopy in prion disease, 
kidney stones, diabetes and osteoarthritis as well as ath-
erosclerosis is being actively investigated. I will discuss 
research in atherosclerosis as an example.
Atherosclerosis
Cardiovascular disease is the leading cause of mortal-
ity in the Western world causing 31% of all deaths [84]. 
Atherosclerosis, the process that leads to cardiovascular 
disease, describes the chronic, often asymptomatic, devel-
opment of plaques which narrow the lumen of the arteries 
resulting in a reduction in blood flow. The rupture of these 
vulnerable atherosclerotic plaques can occur after years of 
indolent development and accounts for the majority of 
clinically significant cardiovascular events.
Atherosclerosis is a lipoprotein driven disease cul-
minating in plaque formation via a process of intimal 
inflammation, necrosis, fibrosis and calcification. The 
plaque consists of three distinct components; the ath-
eroma (meaning ‘lump of gruel’), composed mainly of 
macrophages; cholesterol crystals; and calcium. The exact 
composition of the plaque is directly related to its stability 
and, hence, the likelihood of rupture. Being able to deter-
mine which plaques are unstable will aid the identification 
of patients who will benefit from aggressive treatment and, 
thus, improve the outcomes from cardiovascular disease.
Raman Spectroscopy in Atherosclerosis
Spectroscopic techniques are able to study the distinct 
chemical changes that occur during atherosclerosis and 
provide vital data regarding the composition of the plaque 
that cannot be detected with current imaging technolo-
gies. Current technologies are able to detect plaques and 
stenotic lesions but, at present, no technique has been able 
to identify which are vulnerable plaques.
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Following on from work on ex vivo samples, recent 
developments in Raman optical fibre probe technology 
has allowed for the first real time in vivo characterisation 
of atherosclerotic plaques. The probe was utilised during 
carotid endarterectomy and femoral artery bypass surgery 
and demonstrated the potential to identify vulnerable 
plaques with a sensitivity and specificity of 79 and 85% 
[85]. These results were similar to those obtained using 
fluorescence spectroscopy in an in vivo rabbit model [86]. 
IR Spectroscopy in Atherosclerosis
The plaque most likely to rupture is the thin-capped 
fibroatheroma with high inflammatory and lipid content. 
Near infra-red spectroscopy has been shown to identify 
the histological features of plaque vulnerability in human 
aortic plaques obtained at autopsy. A 90% sensitivity and 
specificity for the identification of lipid rich plaques as 
well as the presence of inflammatory cells was detected by 
this method [87]. 
An intravascular near infra-red spectroscopy system 
for the detection of lipid core coronary plaques demon-
strated in the SPECTACL Study [88] the feasibility of 
the invasive detection of coronary lipid core proteins, al-
though the initial results had an unacceptably high rate of 
failure to gain adequate interpretation. If these limitations 
can be overcome, this technology, either in isolation or 
with other vibrational modalities, could be used to aid the 
decision making in which plaques require intensive and 
immediate management. In addition, understanding why 
plaques are vulnerable may improve our ability to stabi-
lise, or even prevent their occurrence.
Biofluids
Biofluids, such as blood and urine, are advantageous 
for diagnostic tests as they are non-invasive and allow 
multiple sampling when compared to the often small tis-
sue volumes obtained from biopsies. Unfortunately, how-
ever, biomolecules of interest are not always present in 
a sufficient concentration to allow measurement. Drop 
coated deposition Raman spectroscopy (DCDRS) precon-
centrates the proteins to enable subsequent analysis [89], 
thus, overcoming this potential drawback.
Malaria
Although malaria has virtually disappeared from Eu-
rope and the USA, it remains a major problem in tropical 
countries where it causes 300-500 million cases and 2-3 
million deaths per year. It is said to have caused ‘the great-
est harm to the greatest number’ of all infectious diseases 
(Sir Frank Macfarlane Burnet). 
Malaria is transmitted to humans by the Anopheles 
mosquito where the organisms are injected into the hu-
man bloodstream, invading both liver and red blood cells, 
resulting in their structural and morphological alteration 
which impairs their circulation. Malaria is diagnosed in 
the laboratory by microscopic examination of a Giemsa-
stained smear of peripheral blood. Early diagnosis is im-
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portant for enabling effective treatment, whilst avoiding 
the unnecessary and expensive use of anti-malarials when 
not required.
The study of red blood cells by Raman spectroscopy 
has been extensively undertaken. More recently, the anal-
ysis of plasma as an alternative to blood smears has been 
evaluated. Raman spectroscopy was able to monitor the 
changes in plasma that occur during Plasmodium infec-
tion in mice. On the first day after infection, changes in 
the Raman bands that correspond to haemoglobin and 
hemozoin were seen, whereas, changes in the membranes 
of erythrocytes that are detected by blood films are detect-
able at around day 4 [90].
The ability to identify and diagnose malaria in asymp-
tomatic carriers and in patients with low parasitaemia 
would appear to be advantageous. FTIR microscopy us-
ing a Focal Plane Array (FPA) imaging detector is able 
to diagnose malaria parasites at a single cell level using 
a standard glass microscope slide [91]. It seems highly 
improbable that vibrational spectroscopy will find a place 
in the diagnosis of malaria in the clinics and rural hospi-
tals of developing countries where the disease is endemic. 
The technology and the understanding of the disease may, 
nevertheless, aid and advance the development of addi-
tional treatments and the illustrious malaria vaccination.
The Inflammatory Response
A large number of medical conditions, including but 
not restricted to infectious disease, cause inflammation. 
Monitoring of the C-reactive protein (CRP) in blood sam-
ples is used as a sensitive, but non-specific biomarker of 
inflammation. CRP is an acute phase protein of hepatic 
origin. Its role in inflammation is to activate the comple-
ment system. This enhances the ability of both antibodies 
and phagocytic cells to clear microbes and damaged cells.
In some cases, it is difficult to differentiate between in-
fectious and non-infectious causes of inflammation. This 
differentiation can have a significant impact on the man-
agement of the patient. Procalcitonin (PCT), the peptide 
precursor of the hormone calcitonin, rises in response to 
a proinflammatory stimulus of bacterial origin. It does not 
rise significantly with viral or non-infectious inflamma-
tion and, thus, can be used to aid in the identification of 
bacterial infections. It can, however, take over 24 hours for 
a definitive result.
Raman spectroscopy has, in small studies, been 
shown to differentiate inflammation due to infectious to 
that of non-infectious causes with an accuracy of 80% 
[92]. If shown to be repeatable in large scale studies, this 
modality could be used as an adjunct in the laboratory 
in selected cases to aid patient management, particularly 
with regard to the accurate and appropriate administra-
tion of antibiotics.
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Summary
The field of clinical medicine needs to utilise the prin-
ciples and technologies that exist in other areas of science 
to further the understanding of disease processes, to facil-
itate earlier diagnosis and, thus, to improve the manage-
ment and outcome of patients. This chapter exemplifies 
how the world of Physics is helping to provide answers 
to questions which are currently unanswered in medicine 
and has shown the broad areas that have been and are 
continuing to be investigated.
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